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ABSTRACT  
Mass spectrometry imaging (MSI) is a multiplex methodology that has the 
capability to map molecular distributions within biological tissues via an 
unlabelled approach. The ability of MSI to detect a drug, its active metabolites 
and the molecular changes to treatment has demonstrated value for pre-clinical 
efficacy and toxicity studies in the pharmaceutical industry. Parallel to the 
developments in MSI, three-dimensional (3D) cell cultures have emerged as 
biologically relevant models for pre-clinical therapeutic research in part as an 
attempt to address the economic and societal issues of the use of animals in 
science. The combination of MSI with 3D cell culture models has previously been 
shown to provide an elegant method for small molecule drug analysis; however, 
with recent progress in the development of biopharmaceuticals there are 
increasing demands for advancements in this field. 
Within this thesis, a multimodal MSI approach to analyse a novel aggregated 3D 
cell culture model for the use in pre-clinical biopharmaceutical testing was 
developed. Firstly, three “aggregoid” models of cancer were established: two 
osteosarcoma (MG63 and SAOS-2) and a HCC827 lung adenocarcinoma. 
Multimodal MSI techniques: DESI, LA-ICP and IMC were employed for a detailed 
characterisation of the endogenous metabolite, protein and metal content within 
the tumour models. These methods determined molecular heterogeneity and 
identified the biological functions that contributed to the phenotypical proliferative 
and hypoxic microenvironments. Metabolic similarities between the 
osteosarcoma aggregoid models and clinical tissue was also observed.  
The use of multivariate statistics in combination with DESI-MSI analysis of the 
aggregoid models enabled mapping of metabolic responses to three biologic 
treatments and revealed potential mechanistic drug resistance. In addition, use 
of the multimodal MSI strategy was successful in the detection of a 
biopharmaceutical (cetuximab) within the HCC827 aggregoid. A bottom-up 
MALDI-MSI proteomics approach enabled the preliminary detection of cetuximab 
via its unique proteotypic peptides. A complementary targeted approach of metal-
labelled cetuximab detection by LA-ICP-MSI was also successfully employed.  
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The aim of pre-clinical studies is to determine the safety and efficacy of a drug 
before it is tested in humans at the clinical stage. The essential information 
obtained from drug development research includes the delivery and biological 
effect of a therapeutic, the cellular response to treatment, and its toxicity. 
Untargeted analytical techniques are highly desired for the bioanalysis of drugs. 
The current principal technique used in drug development is liquid 
chromatography (LC) coupled with tandem mass spectrometry (MS/MS) as it can 
offer a combination of high sensitivity and specificity for a dynamic range of 
analytes, in addition to the quantitative capabilities that are of considerable 
interest in the pharmaceutical industry (Rönquist-Nii & Edlund, 2005; Xu et al., 
2007; Punt et al., 2019). Whilst LC-MS/MS is of significant relevance in pre-
clinical studies, the measurement of a drug is typically achieved through the 
analysis of blood plasma or tissue homogenates. The limitation of analysing such 
biological samples is the loss of valuable spatial information. The ability to 
visualise endogenous and exogenous molecules within tissues can provide vital 
information of how a therapeutic penetrates, distributes, and metabolises, in 
addition to observing the biological responses to the treatment. The analysis of 
blood plasma or tissue homogenates is therefore an inaccurate representation of 
drug concentrations within organs or specific regions of tissues. 
Traditional methodologies employed in pharmaceutical research to spatially 
localise drugs and endogenous molecules within tissue samples or in vivo include 
immunofluorescence microscopy (Hess, Girirajan, & Mason, 2006), positron 
emission tomography (PET) (Piel, Vernaleken, & Rösch, 2014), magnetic 
resonance imaging (MRI) (Chen et al., 2015) or quantitative whole-body 
autoradiography (qWBA) (Solon & Kraus, 2001). A drawback of these 
techniques, however, is the targeted nature of the methods that requires prior 
knowledge about the analyte of interest for which fluorescent tags or radiolabels 
are needed, and thus the number of molecules that can be visualised 
simultaneously is restricted. In addition, the conjugation of probes onto drugs can 
affect their ability to reach its target or alter its biological effect, and therefore 
could misrepresent its true therapeutic nature (Liu et al., 2018). The analysis of 
drugs using probes has also limited use within human subjects and can add 
3 
 
complications when comparing between pre-clinical and clinical results (Krohn et 
al., 2007).  
On the other hand, mass spectrometry imaging (MSI) is an established analytical 
technique that has the capability to localise thousands of analytes simultaneously 
in an untargeted manner. MSI allows the visualisation of molecules in situ in two- 
and more recently three- dimensions without the use of labels or probes 
(Goodwin, Takats & Bunch, 2020). The benefits of MSI in drug development 
studies are the capabilities to detect the drug, its active metabolites and molecular 
changes in response to the treatment without prior knowledge (Swales et al., 
2019). It is also significant in terms of understanding the complex cellular 
environments within a biological sample through the detection of heterogeneous 
distributions of molecular species which can facilitate the identification of disease 
biomarkers (Buchberger et al., 2018). A diverse range of MSI techniques have 
demonstrated the ability to spatially resolve endogenous molecules including 
small molecules such as metabolites (Ly et al., 2015; Tucker et al., 2019), and 
lipids (Angel et al., 2012; Henderson et al., 2020), as well as larger molecules 
such as peptides (Guenther et al., 2011; Ly et al., 2019) and proteins (Stoeckli et 
al., 2001; Quanico et al., 2013), in addition to exogenous compounds and drugs 
in biological tissue (Trim et al., 2008; Nilssoni et al., 2015; Dexter et al., 2019). 
Recent developments have also expanded the capabilities of quantifying analytes 
of interest in situ (Vismeh et al., 2012; Pirman et al., 2013; Swales et al., 2018; 
Sammour et al., 2019; Handler et al., 2021). The continuous advancements of 
MSI, including the high sensitivity and specificity of analyte detection as well as 
the increasing spatial resolution, have rapidly progressed the technique in drug 
development and has gained a credible reputation within the pharmaceutical 
industry.  
1.2 Mass spectrometry imaging 
Imaging mass spectrometers are composed of three main components: an 
ionisation source which generates charged ions from the tissue sample; a mass 
analyser that separates the ions based on their mass to charge (m/z); and an ion 
detector that measures the relative abundance of the selected ions. The basic 
principle of MSI is the movement of the ionisation beam rastering across a tissue 
sample in the x, y direction. At each point across the tissue, chemical species are 
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ionised and desorbed, which are subsequently extracted into the mass 
spectrometer. The ions are then sorted by a mass analyser prior to a detector 
measuring the relevant abundance of the ions of interest. Software is used to 
reconstruct an image in which each pixel contains a mass spectrum that 
represents the ions detected from that specific point in the tissue. An image can 
be generated for any specific m/z value detected showing the distribution of that 
species and its relative abundance within the region of interest (ROI), similar to 








Figure 1.1 Basic principles of MSI. (Above image) The main components of an 
imaging mass spectrometer from the sample inlet to the ionisation source where 
ions are formed. The mass analyser separates the ions based on m/z values 
where they are measured by the detector and the data system generates the 
image from the measurable signal. (Below image) The fundamentals of MSI: an 
ionisation source rastering across a tissue section, producing ions which are 
detected by the mass spectrometer, generating a mass spectrum at each position 
of the tissue. Below figure from Porta Siegel et al., (2018). 
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The MSI workflow in pre-clinical research is generalised into sample preparation, 
data acquisition and data analysis. An overview of an undefined MSI workflow is 
shown in Figure 1.2, however following a specific workflow is determined by 
differing parameters. A major variant that effects the MSI workflow is the 
ionisation technique. Many different ionisation techniques have been developed 
and utilised in drug development and this has been previously reviewed (Swales 
et al., 2019; Xiao et al., 2020). Table 1.1 highlights some of the main ionisation 
modalities used in MSI and the attributes of the techniques that influence their 
use in different imaging applications. The aim of this introduction is to focus on 
the MSI workflows in relation to the four modalities used in this thesis, these 
include: matrix-assisted laser desorption ionisation (MALDI), desorption 
electrospray ionisation (DESI), laser ablation inductively coupled plasma (LA-
ICP) and imaging mass cytometry (IMC). The specific considerations of sample 








Figure 1.2 An overview of a generic MSI workflow showing the key steps involved from extracting the tumour biopsy to 
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1.2.1 Sample preparation 
Sample preparation is an important factor of the workflow as the collection and 
handling of a sample can have a significant influence on the quality of the data 
acquired. Robust sample preparation protocols have been established for 
application across MSI methods and have been previously reviewed (Goodwin, 
2012). The basic sample preparation workflow starts from the collection of a 
sample, such as a tumour biopsy from a patient or animal. The sample is then 
stabilised typically through snap freezing (i.e., in liquid nitrogen), which is then 
stored at - 80°C until use. In addition, the use of a fixative (e.g., formalin) in 
imaging studies has also been reported (Ly et al., 2019), although can limit the 
nature of the study to peptide detection. The purpose of stabilising tissue is to 
maintain the sample integrity and minimise degradation of molecules. Samples 
can be embedded using materials such as gelatin to assist handling of smaller 
fragile tissues or to decrease sample preparation time by embedding several 
samples in one mould. In the case of frozen samples, tissues are then 
cryosectioned at subfreezing temperatures (- 15 to - 25°C) typically at a thickness 
between 10-20 µm, with 12 µm a typical thickness used for MSI (Stoeckli et al., 
2001). Sections are thaw mounted onto compatible slides such as glass 
microscope slides or indium tin oxide (ITO) slides depending on the instrument 
used for analysis. Frozen tissue sections are then typically stored at - 80°C until 
use. Prior to analysis, slides are generally desiccated using freeze-dry techniques 
to remove moisture in order to minimise molecular degradation and 
delocalisation.  
1.2.2 Data acquisition  
1.2.2.1 Imaging modalities 
The ionisation method chosen for analysis can affect the imaging workflow by the 
requirement for additional sample processing steps. In this thesis, four ionisation 
techniques have been employed: MALDI, DESI, LA-ICP and its variant, IMC. The 
specific steps for the analysis of analytes by these methods are discussed. Figure 





1.2.2.1.1  MALDI-MSI 
In this thesis, MALDI-MSI has been employed for the detection of abundant 
endogenous lipid species to assess the success of the experiment and 
exogenous biotherapeutics with the development of a bottom-up proteomics 
workflow. For the detection of lipids by MALDI, samples are prepared with matrix 
prior to acquisition, which is discussed later within this section. To detect protein-
originated peptides following a bottom-up proteomics approach however, 
additional sample preparation steps are necessary. Firstly, to enhance the 
detection of peptides samples can be washed with organic solvents such as 
ethanol and chloroform to remove salts and lipid species that cause ion 
suppression of peptide signal due to their high abundance in tissues. A variety of 
sample washing protocols have been assessed to increase the sensitivity of 
peptide imaging studies (Schwartz, Reyzer, & Caprioli, 2003; Lemaire et al., 
2006; Seeley et al., 2008). In a bottom-up proteomics workflow, proteins undergo 
enzymolysis to generate peptides by on-tissue digestion in a humid environment. 
Typically, an enzyme such as trypsin is used to cleave proteins into their 
constituent peptides at the lysine or arginine amino acid sites. The approach 
Figure 1.3 A schematic of the MALDI, DESI, LA-ICP and IMC interfaces. 




enables the identification of intact proteins (> 40 kDa) through the detection of 
proteotypic peptides of a lower mass range (< 4 kDa) which are more ionisable 
and therefore easier to measure. A comprehensive study comparing multiple on-
tissue digestion protocols with MALDI-MSI has been previously reported (Diehl 
et al., 2015). 
The detection of analytes including both lipids and peptides is highly dependent 
on the selected matrix that is applied to the sample. The MALDI matrix must be 
capable of absorbing the photon energy emitted by the UV light of the laser at an 
appropriate wavelength (i.e., 355 nm for a Nd:YAG laser) to promote the 
desorption and ionisation of analytes. The basic requirements for a matrix are to 
be stable under a vacuum, accept or donate a proton to the analytes during 
ionisation, have a similar solubility in solvents as the analytes and the ability to 
crystalise. Typical matrices used in MALDI-MSI experiments for the detection of 
lipids and peptides are α-cyano-4-hydroxycinnamic acid (α-CHCA) or 2,5-
dihydroxybenzoic acid (DHB) in positive mode. However, other matrices including 
9-aminoacridine (9AA) and 1,5-diaminoapthalene (DAN) have been used for the 
extraction of lipids in negative mode, in addition to sinapinic acid (SA) for the 
detection of proteins in positive mode. The solvent to dissolve the matrix can also 
have impact on analyte extraction. Typically, solvents such as acetonitrile, 
methanol or ethanol are mixed with small concentrations of an organic acid 
(commonly trifluoroacetic acid (TFA), 0.1-1% v/v) in water to dissolve both 
hydrophobic and water-soluble molecules in solution. The concentration of 
organic solvent and acid, in addition to the matrix concentration are generally 
optimised for different analytes of interest.  
The application of matrix is also an important parameter in MALDI-MSI analysis. 
It is fundamental that the matrix is applied homogenously to minimise variation in 
analyte signal across the sample. In addition, the crystal size of the matrix can 
have great influence on the spatial resolution of the image. The most conventional 
method of matrix deposition is by spray-coat, typically using commercial systems 
including HTX TM Sprayer™ or SunChrom’s SunCollect™ MALDI Sprayer. 
These automated systems have enabled a rapid and reproducible method of 
applying matrix (Djidja et al., 2010; Barré et al., 2019; Hermann et al., 2020). 
Alternatively, micro-spotting techniques, such as the Portrait™ 360 acoustic 




array creating matrix spots 100-200 µm apart (Aerni, Cornett & Caproli, 2006). 
However, the micro-spotting method can hinder the spatial resolution capabilities 
of MSI analysis. Aside from these ‘wet’ matrix applications, ‘dry’ methods are also 
heavily employed in MALDI-MSI studies (Hankin, Barkely & Murphy, 2007; Angel 
et al., 2012; Handler et al., 2021). Sublimination offers a way of generating sub-
micron sized crystals applied homogenously across the tissue which gives the 
opportunity to generate images of high spatial resolution. The advantage of using 
a dry technique also minimises the possibility of analyte delocalisation which 
commonly occurs in the presence of a solvent in the matrix. The signal intensity 
of analytes by sublimination can be relatively low due to the lack of solvent which 
normally facilitates the extraction of analytes.  
After analysis, post-preparation of MALDI samples is possible due to the ‘soft’ 
ionisation nature of the technique. Most commonly, samples are prepared for 
histology staining after MSI analysis. An additional step of removing matrix using 
a solvent such as 100% ethanol prior to the staining process is required. The 
benefits of post-preparation such as histology staining the same section allows 
co-registration with the MALDI image to correlate molecular distributions with 
morphological ROIs.  
1.2.2.1.2  DESI-MSI 
The use of DESI in the MSI workflow generally requires relatively limited to no 
sample preparation, according to the application or the nature of the biological 
sample. Due to the ambient conditions of the technique, whole living tissue 
samples can be imaged directly, however DESI is generally restricted to flat and 
regular surfaces therefore in the case of animal organs or tissues, cryosections 
are still most commonly analysed. The use of DESI-MSI in this thesis was for the 
detection of metabolites in tissue cryosections which were analysed directly 
without sample preparation. Due to the use of a specific nebulising solvent (i.e., 
95% methanol/water, v/v) for the ionisation of analytes there is minimal 
destructive sampling. This is beneficial, since it permits further analysis by mass 
spectrometric methods such as MALDI-MSI and IMC, or other visualisation 





1.2.2.1.3  LA-ICP-MSI 
Similar to DESI, no additional sample preparation is required for LA-ICP-MSI 
analysis. Tissue sections can be analysed directly in the laser ablation chamber 
under atmospheric pressure. Using LA-ICP-MSI, the sample is near to fully 
ablated using a high energy 213 nm Nd:YAG laser and therefore post-preparation 
analysis of tissue sections is normally not possible. Typically, optical images of 
the sections are taken prior to analysis or serial sections are used for histological 
staining.  
1.2.2.1.4  IMC 
Analysing samples by IMC is a novel approach that requires tissue sections to 
undergo immunostaining with rare lanthanide metal-labelled antibodies prior to 
laser ablation. The detection of proteins and protein-modifications are achieved 
through measuring the relative abundance of the metal isotopes. Unlike the 
conventional MSI techniques that are commonly performed in an untargeted 
manner, IMC requires some prior knowledge of the protein content within the 
biological sample. Compared to traditional immunostaining methods, however, 
IMC has the capability to analyse up to 50 specific markers simultaneously within 
a single tissue section (Chang et al., 2017). A limitation of IMC is the added time 
needed to prepare the sample for analysis. Established protocols generally 
require two days due to the overnight incubation of the antibody cocktail on the 
tissues to ensure significant antibody binding to the protein targets. Though, due 
to the nature of the staining protocol, samples can be prepared in advance and 
left at room temperature for months before analysis. Therefore, bulk staining 
samples in earlier preparations can reduce the workflow time in future IMC 
analysis. IMC also fully ablates the tissue and therefore optical images prior to 
acquisition or staining of serial sections is used to correspond to IMC data.  
1.2.3 Data processing 
After imaging acquisition, data processing and analysis is the next fundamental 
part of the MSI workflow in order to generate the images and interrogate the data. 
The data generated from MSI experiments results in large data files that are 
typically > 10 GB in size for one image, with some nearing 100 GB. Analysing 
such complex files thus requires a multitude of image processing steps including 




a representative image of the peak of interest. Software packages typically 
generate an image based on the relative abundance of the analyte of interest by 
combining the spatial coordinates with the spectral data acquired. Data 
processing platforms have been developed by various instrument vendors. 
Previously the aim of using their specific software was to process the unique file 
type created by the vendor, however this created limitations on multimodal 
imaging workflows and hindered collaborative studies by being unable to share 
data across research groups. The MSI community have since introduced imzML 
as a common file format that can be used universally across most software 
packages, at least in the case for MALDI and DESI data (Römpp et al., 2010; 
Schramm et al., 2012). A review summarising the software tools that support the 
imzML file format currently used in MSI has been previously discussed (Russo et 
al., 2020).  
Developments in software packages have made them more versatile and they 
now contain additional data processing options to enable improved data mining. 
For example, the non-commercial software package SpectralAnalysis provides 
statistical capabilities such as multivariate analysis (MVA) (e.g., Principal 
component analysis (PCA) and partial-least squares (PLS)) which have allowed 
interpretation of complex datasets with the prospective of biomarker discovery 
and treatment assessment (Dexter et al., 2016; Race et al., 2016). In addition, 
specific quantitation software packages (e.g., msIQuant) have progressed the 
application of MSI in drug quantitation studies by providing a tool to calculate 
unknown amounts of an analyte through generating mean relative abundances 
of calibrants to produce calibration curves (Källback et al., 2016). A powerful MSI 
software tool, SCiLS™ Lab offers additional data processing capabilities that 
support untargeted data analysis including spectral spatial segmentation, 
discriminative receiving operating characteristics (ROC) analysis, 3D image 
construction and tissue classification of data sets based on training data allowing 
for further data mining than most software packages (Krasny et al., 2015; Mallah 
et al., 2018; Ly et al., 2019). The software also facilitates the option to import 
complementary optical images such as histological or immunofluorescent 
staining of the same or serial tissue section after analysis. This enables the MSI 




methods in order to differentiate and correlate analytes to heterogeneous regions 
within complex tissues. 
In the case of processing data obtained from LA-ICP-MSI and IMC 
instrumentation, common data analysis platforms used for MALDI or DESI cannot 
typically support their specific file types. Alternatively, the development of LA-
ICP-MSI specific software, such as Igor Pro Iolite Software, has been required, 
which specialises in time-resolved data reduction with the capabilities of baseline 
subtraction and normalisation to reference materials in addition to the ability to 
perform quantitative analysis (Paton et al., 2011). Nevertheless, advancements 
in software packages such as ProteoWizard (Chambers et al., 2012) have 
demonstrated an indispensable tool for converting LA-ICP-MSI Excel generated 
file types (xlsx) to the mzML format for the versatile use in most MSI processing 
programs. A review evaluating the software platforms used to analyse LA-ICP-
MSI data has been recently published (Weiskirchen et al., 2019). 
For vendor specific IMC data files (generated in the proprietary mcd format), 
producing the images is performed by the MCD Viewer software developed by 
Fluidigm®. This open-source platform allows for the visualisation of the protein 
markers to produce quality images for publication; however, it is limited to a 
viewing tool only. Alternatively, in-depth processing of IMC data requires 
specialist software that is typically commercialised and expensive. For example, 
advanced imaging software that was initially developed for histological analysis 
can also support the IMC raw data files. HALO® from Indica Laboratories enables 
single-cell segmentation allowing for tissue classification and quantification of 
positive staining within tissues, which can be performed on large data groups 
through training data sets.  
1.3 Pre-clinical disease models studied by MSI 
The use of animals in research has become prominent for drug development due 
to their complex biological environment within a whole organism that provides an 
advanced in vivo representation, modelling specific aspects of human diseases. 
Animals have been considered the ‘gold standard’ model system in some 
research for the evaluation of new therapeutic approaches in cancer and disease 
biology (Hooijmans, Leenaars & Ritskes-Hoitinga, 2010). The combination of MSI 




al., 2008; Trim et al., 2008; Vismeh et al., 2012; Takai, Tanaka, & Saji, 2014; 
Swales et al., 2014), with the first MS images of pharmaceutical detection 
achieved in mouse tumour and rat brain tissues in 2003 by MALDI-MSI (Reyzer 
et al., 2003). For MALDI-MSI, robust methods of handling and preparing animal 
specimens have been established, from freezing and sectioning tissues to matrix 
application (Swales et al., 2018; Huizing et al., 2019; Dannhorn et al., 2020). 
Therefore, MALDI-MSI is highly validated for pharmaceutical analysis. 
Continuous developments in other MSI modalities, such as the detection of a 
wide molecular coverage from DESI-MSI, are also expanding the capabilities of 
pharmaceutical analysis (Dexter et al., 2019). The value of animal studies as an 
appropriate model to predict human responses has been challenged (Mignini & 
Khan, 2006). It is strongly argued that the failure of animal models to replicate 
human conditions contributes to the failure of the majority of therapeutics at 
clinical trials (Seok et al., 2013; Ugarte et al., 2018). Further challenges are also 
raised regarding the regulatory, economic, and societal issues with the use of 
animal models involved (Russo et al., 2018). 
Alternatively, a conventional technique routinely used for in vitro research is two-
dimensional (2D) cell cultures. The simplicity and low-cost maintenance of 
monolayer culture is an appealing strategy in biological studies to achieve 
reproducible high throughput analysis. The applications of SIMS-MSI with 2D cell 
cultures has been a leading approach to study pharmaceutical development 
(Passarelli et al., 2015; Vanbellingen et al., 2016). The submicron resolution and 
nanometre depth of the technique can enable a three-dimensional imaging 
capability to localise and quantify molecules at single-cell level (Gilmore, 2013). 
However, the sensitivity and matrix effects of SIMS have impacted its progression 
in drug efficacy and toxicity studies (Passarelli & Ewing, 2013). Advancements in 
the spatial resolution capabilities of MALDI, which can provide higher mass 
resolution across a larger mass range, has demonstrated the ability to profile 
individual cells of cancer cell lines (Schober et al., 2012; Zavalin et al., 2012). 
Though due to the low volume of material and small quantity of analytes in 2D 
cultures, the application in pharmaceutical analysis is limited (Comi et al., 2017). 
Alternatively, the recent developments in IMC has also improved the level of 
detail of detecting protein expressions at single-cell resolution in drug treated cell 




A major criticism of 2D cell cultures in pharmaceutical research, however, is the 
inability of monolayer cells to reproduce the complexity and heterogeneity of 
human tissues (Duval et al., 2017). Two-dimensional cell cultures form a 
monolayer growth, which can influence the interactions between cells and impact 
components such as the extracellular matrix (ECM) formation, cell signalling, and 
gene and protein expression that are all vital in drug analysis. The monolayer 
growth thus alters the function within cell cultures and can result in drug 
behaviours and responses that do not truly represent the outcome of the in vivo 
environment. Consequently, 2D cell culture experiments often cannot accurately 
predict drug reactions in a tissue environment, and therefore exhibit substantial 
limitations for such research (Kapałczyńska et al., 2018). 
There is high demand for alternative biological models that accurately replicate 
the in vivo environment and responds to the societal requirements to impact on 
the 3Rs – reduction, replacement and refinement – for the use of animal in 
research (Russo et al., 2018). Three-dimensional (3D) cell cultures are an 
advanced system that bridges the gap between 2D cultures and animal models, 
by having the cheap and high-throughput qualities from 2D cell cultures whilst 
providing the cellular and molecular complexity of animal models. Growing cells 
in 3D enhances the organisation and intricacy of cellular cultures so that they 
more closely mimic the in vivo microenvironment of primary tissues. These 3D 
models promote levels of cell differentiation and tissue organisation, which 
replicate typical tumour characteristics of gene and protein expression, nutrient 
diffusion, and cell-cell and cell-matrix interactions (Edmondson et al., 2014). A 
variety of 3D culture models have been developed to meet the biological 
requirements for specific research including drug analysis (Reynolds et al., 2017), 
patient-derived treatment (Huang et al., 2015), and biological crosstalk 
(Maschmeyer et al., 2015). These models include tumour spheroids, organoids, 
and microfluidic systems or 'organ-on-a-chip'. Each model varies in their levels of 
complexity and yet requires relatively low maintenance to achieve representative 
in vivo qualities. With the additional advantages of low cost and high throughput, 
the use of 3D models is appealing for early stage drug research and development 
prior to in vivo studies.  
Studies which combine MSI with 3D cell culture models are currently of 




reported extensive applications in MSI analysis of 3D cultures for pre-clinical drug 
efficacy and toxicity research. The detection of endogenous molecules including 
metabolites, lipids and proteins have characterised the tumoral phenotypes of the 
3D models. Drug distribution studies have localised therapeutics and their active 
metabolites, in addition to the cellular response to treatment within specific 
substructural regions. In addition, developments in MSI have also demonstrated 
quantitative analysis of drugs in 3D cultures. The current literature in these areas 
is discussed in detail within this thesis and are summarised in Table 1.3.  
1.4 Application of MSI with 3D cell culture models  
1.4.1 Tumour spheroids 
Tumour spheroids have become invaluable tools for in vitro research due to their 
ability to replicate the important aspects of the in vivo microenvironment. First 
developed in 1971 by Robert Sutherland, these tumour models were initially 
formed to resemble cancer nodules seen in animal and human carcinomas 
(Sutherland, McCredie & Rodger, 1971). Spheroids blend the flexibility of cell 
culture systems with the ability to assume complex cellular architecture. They 
display a gradient of oxygen and nutrients that can be divided into three regions: 
a necrotic core, which experiences a high rate of apoptosis due to the extremely 
poor delivery of oxygen and nutrients; a non-proliferative region, where the cells 
display a state of dormancy as a result of hypoxia; and a proliferative edge with 
an abundant supply of nutrients, which accelerates tumour growth (Figure 1.4). 
These phenotypical microenvironments have a subsequent effect on the 
endogenous molecules within the spheroid and thus the distribution of such 
species can determine molecular processes significantly affected by hypoxic 




Figure 1.4 A basic diagram showing the phenotypical regions of a necrotic 







Figure 1.5 Spheroid characteristics from the effects of oxygen and nutrient 
gradients. Combination of analytical images of spheroid sections obtained by 
different technologies including autoradiography, the TUNEL assay, 
bioluminescence imaging and probing with oxygen microelectrodes. These 
techniques enable the concentric arrangement of cell proliferation, viability, the 
microenvironment in tumour spheroids to be understood. Figure from 




The creation of spheroids can be achieved by a variety of means, either as an 
independent culture or co-culture with different cell lines. Most conventionally, 
tumour spheroids are developed through the aggregation of cells from an 
independent culture via attachment prevention techniques. This is a simple 
method to produce highly reproducible spheroids relatively fast and at low costs 
which benefit high throughput drug analysis. Such methods include the use of 
attachment prevention surfaces such as commercial ultra-low attachment (ULA) 
plates or matrix coatings like agarose, or the suspension of cells within a droplet 
of liquid termed ‘hanging-drop’ (Timmins & Nielsen, 2007; Bartosh et al., 2010). 
In each technique, cells accumulate together and are forced to interact forming a 
single spheroid, otherwise known as a multicellular tumour spheroid (MCTS). 
Some cell lines, however, are unable to form robust spheroid cultures using these 
methods and different techniques can influence experimental outcome from the 
same cell line (Nagelkerke et al., 2013; Bresciani et al., 2019).  
Alternatively, the use of natural or synthetic scaffolds or culturing with embedding 
gels may be incorporated into the model. Such scaffolds can bring external ECM 
properties to facilitate the structure of a cellular environment and develop cell-
matrix interactions found in vivo. Typical materials used include basement 
membranes (i.e., Matrigel), collagen, alginate or cellulose, which are derived from 
natural ECM components (Ma et al., 2003; Fischbach et al., 2007). Synthetic 
materials such as biopolymer hydrogels can also be tailored to mimic a specific 
environment for different applications (Li, Yunfeng & Kumacheva, 2018). Using 
scaffolds allows a single-cell suspension to proliferate into isogenic spheroid 
populations to enable a more natural development of cultures that resemble in 
vivo properties. The development of spheroids in this manner, however, can be 
time consuming and the diameter of the cultures are generally smaller than 
MCTS, which with the spatial resolution capabilities of MSI could present 
challenges to generate an image with sufficient data points in order to observe 
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Table 1.2 Comparison of tumour spheroid types. (Adapted from Palubeckaite, 
2018). 
 
1.4.1.1 Characterisation of tumour spheroids by MSI 
The Hummon group were the first to publish work describing the combination of 
MSI with spheroids and have continued leading research utilising spheroid 
cultures with MSI for drug analysis. Their initial study used colon carcinoma 
MCTS from the HCT 116 cell line and adapted previous MALDI-MSI protocols for 
imaging tissue sections, to examine the protein distribution within spheroids (Li 
& Hummon, 2011). To assist the handling of tumour spheroids, the group 
embedded the samples within gelatin prior to flash freezing and cryosectioned 
tissues at a thickness of 10 µm. A protocol describing the workflow of tumour 
spheroids with MALDI-MSI was published by the group and included the 
development of the MCTS, sample handling, matrix application and data 
acquisition (Ahlf Wheatcraft, Liu, & Hummon, 2014). From the study, protein 
images of the sectioned spheroids were obtained in positive mode at a spatial 
resolution of 75 µm (~13 pixels across a typical MCTS). MALDI-MSI was able to 
detect species within specific regions of a spheroid; with the majority of peaks 
distributed across the section, and a specific unidentified peak at m/z 12,828 
localised predominantly within the central necrotic region. The individual peaks 
detected were not identified directly from the MSI data. For protein identification, 




species, including Histone H4 and cytochrome c, by MALDI profiling and nanoLC-
MS/MS, correlating the m/z values to the MSI ion maps. The detection of protein 
species localised within specific regions of the spheroid identified phenotypic 
differences that corresponded to the tumour microenvironment, highlighting the 
hypoxic gradient. The initial MALDI-MSI study of MCTS therefore enabled an 
understanding of the heterogeneity of protein distributions within the model.  
The characterisation of tumour spheroid models has since been explored with 
MALDI techniques that provide higher mass accuracy and resolving power 
capabilities for more definitive identifications of molecular species. Hiraide et al., 
(2016) utilised AP-MALDI-MSI to characterise lipids throughout HCT 116 and 
DLD-1 MCTS. The group used an MS/MS imaging approach to identify m/z 885.5 
as an arachidonic acid containing phospholipid PI 38:4 specifically accumulated 
in the outer edge of the colorectal cancer models. It was suggested this 
phospholipid was associated with the migration of cancer cells, which thus 
identified the species as a potential biomarker for metastatic colorectal cancer. In 
addition, Tucker et al., (2019) employed Fourier-transform ion cyclotron 
resonance (FT-ICR)-MALDI-MSI for an untargeted approach to identify 
metabolites in MCF-7 breast cancer spheroids at 50 µm spatial resolution. The 
localisation of metabolites involved in the adenosine triphosphate (ATP) 
metabolism, which is fundamental for energy production, determined the oxygen 
gradient across the spheroid; correlating higher ATP levels with higher 
proliferative activity in the outer region compared to the central region. The group 
mapped the ion images of key metabolites to distinct biochemical processes 
including glycolysis and the hexosamine biosynthetic pathways to improve the 
understanding of the molecular microenvironment. 
In addition, similarities in metabolic signatures including the glutamine, fatty acid 
and phospholipid metabolism pathways were recently identified between KYSE-
30 oesophageal cancer spheroids and clinical patient tissue samples determined 
by MALDI-MSI at a greater spatial resolution (12 µm) (Zang et al., 2021). The 
corresponding detection of metabolites to in vivo demonstrated the spheroid 
model as an accurate representative of cancer metabolism. As demonstrated by 
these studies, characterising the spatial localisation of key endogenous 




the cellular functions in tumours and can benefit the discovery of biomarkers for 
drug targeting to improve biological outcome.  
1.4.1.2 Analysis of therapeutics in tumour spheroids 
The combination of spheroids with MSI has further progressed for drug 
developmental research. Liu, Weaver, & Hummon (2013) investigated the 
efficacy of drug penetration by analysing the spatial distribution of irinotecan, an 
anticancer drug and topoisomerase I inhibitor, over a time-dependent course 
within HCT 116 colon carcinoma MCTS. Using MALDI-MSI irinotecan (m/z 587.3) 
was observed within the necrotic core only after 12 h of incubation. At 24 h, 
appreciably higher levels of the parent drug were observed within the central 
hypoxic region and necrotic core, and higher levels of irinotecan metabolites 
including the cytotoxic SN-38 (m/z 393.1) and SN-38 glucuronide (m/z 569.2) 
were located within the outer region. This study reported that a higher enzymatic 
activity localised in the proliferative outer layer of the MCTS. The data was 
validated by nanoLC-MS/MS; however quantitative analysis was not conducted. 
Rather, an additional study of a simpler and more accurate experimental method 
to analyse individual cells from spheroid cultures with spatial specificity by serial 
trypsinisation was published (Liu & Hummon, 2015). The group followed a novel 
method initially demonstrated by McMahon et al., (2012) of short trypsin 
treatments to sequentially remove cells from the outside of the spheroid in 
concentric radial layers and compared the process to like ‘peeling an onion’. The 
concentrations of irinotecan and SN-38 were detected by nanoLC-MS/MS in a 
time-dependent manner showing the movement of the parent drug from the outer 
region to the core over 72 h, as the cytotoxic metabolite was quantifiable after 12 
h and was more abundant in the outer and middle regions than the core at 72 h. 
Using a combination of advanced analytical techniques, the Hummon group 
therefore successfully demonstrated the quantification and localisation a parent 
drug and its metabolites, determining regions of metabolic activity within a 
spheroid model.  
A similar approach employing the ambient technique, single-probe MSI 
determined the influence of a series of time- and concentration-dependent 
irinotecan treatments on metabolite distributions in HCT 116 MCTS (Tian et al., 
2019). The group used advanced MVA methods to identify significant changes in 




(m/z 732.5) of the treated 3D cultures compared to the control, in addition to five 
times lower abundance of PC 34:2 (m/z 758.6) specifically in the inner region of 
the treated spheroids. These studies therefore demonstrated the analysis of 
therapeutically treated spheroids by different ionisable imaging modalities to 
study drug metabolism and cellular response.  
The Hummon group has further exploited the MSI-spheroid technique to study 
the penetration of a range of drugs including platinum-based (Liu & Hummon, 
2016), epigenetic-targeting (Lukowski, Weaver, & Hummon, 2017) and liposomal 
delivery (Feist et al., 2017). LaBonia et al., (2018) recently investigated the 
penetration of a combinational drug, FOLFIRI (folinic acid, 5-fluorouracil and 
irinotecan), within HCT 116 MCTS by an innovative 3D printed dosing platform to 
mimic the dynamic flow of chemotherapeutics used in vivo. Similar to the previous 
study, high levels of cytotoxic metabolites within the outer proliferative region 
were observed, as parent drugs, irinotecan and folinic acid, were localised within 
the necrotic core. Further analysis determined the proteomic changes to 
treatment with FOLFIRI by iTRAQ proteomic analysis acquired on a nano-ultra-
performance (UP)LC-MS/MS system. Tryptic peptides labelled with iTRAQ tags 
allowed for identification of proteins in addition to quantitative fold changes 
between treated and untreated samples; however, the spatial resolution within 
the MCTS by this method was lost. Nonetheless, the study provided evidence 
that MALDI-MSI can detect clinically approved combination therapeutics treated 
through a representative drug administration route and the active metabolites 
within the different regions of the spheroid, alongside detecting the proteomic 
response to treatment using complementary quantitative analysis. Not only does 
this further support the proposition that spheroids display differing metabolically 
active regions within the tumour microenvironments, but it also gives valuable 
insights into the cellular behaviour in response to drug treatment, which could 
help predict clinical outcome. 
Another demonstration of the diverse applications for drug distribution analysis 
within spheroid cultures is the evaluation of metal-based drugs by LA-ICP-MSI. 
Although the literature is limited, there has been some interest regarding the 
localisation of platinum-based drugs and hypoxia-responsive cobalt complexes 
(Theiner et al., 2017; O'Neill et al., 2017). For example, LA-ICP-MSI analysis of 




distributions between HCT 116 colon carcinoma and CH1-PA-1 ovarian 
teratocarcinoma spheroid models (Theiner et al., 2016). The study demonstrated 
high sensitivity with achievable spatial resolution (10 µm laser spot size) for 
detecting platinum within the periphery and necrotic regions of the spheroid 
models.  
From small molecule chemotherapy to immunotherapy, the Hummon group 
studied HT 29 and DLD-1 colon cancer spheroid cultures to observe the 
distribution of the monoclonal antibody, cetuximab by MALDI-MSI. In order to 
achieve this a direct on-tissue reduction with dithiothreitol (DTT) followed by 
alkylation was developed by Liu et al., (2018). In this method, a protein is reduced 
to break the disulphide bonds and alkylated to prevent re-formation by modifying 
the cysteine residues. Cetuximab was detected using a signal arising from the 
light chain variable domain at m/z 23,412.5. The group observed a difference in 
the distribution of the light chain domain between the two spheroid models; at 72 
h cetuximab was primarily localised within the core of the HT 29 spheroids, 
whereas in the DLD-1 spheroids it was detected in the outer region. It was 
confirmed by immunofluorescent staining that this was due to the different 
expression levels of the antibody target, epidermal growth factor receptor (EGFR) 
in both cell lines. The light chain domain of cetuximab was also detected within 
colorectal-tumour organoids at 72 h; however, information about the distribution 
of the antibody within the organoid section was not given. In addition, the study 
examined the treatment response by detecting higher intensity signals of ATP 
(m/z 506.0) in the core of the HT 29 spheroids, indicating an increase in apoptosis 
in the presence of cetuximab. Overall, the study provided proof-of-concept that 
MALDI-MSI has the capabilities to detect the presence of a complex 
biopharmaceutical (~150 kDa) within an emerging 3D in vitro model, the tumour 
spheroid, and analyse the cellular response to treatment.  
1.4.1.3 Considerations of tumour spheroid analysis by MSI 
It is clear from the literature discussed in section 1.4.1 that the combination of 
spheroids with MSI is a powerful tool to investigate the biological behaviour of 
replicate in vitro tissues and study the efficacy of therapeutic drugs. Although 
there are a range of applications demonstrated, there are still gaps within the 
literature. MALDI-MSI has demonstrated great potential with tumour spheroids 




imaging modalities could further expand the opportunities in drug analysis with 
tumour spheroids, such as by detecting a larger amount of metabolite information 
for biomarker identification or the detection of metal-based drugs as 
demonstrated by DESI and LA-ICP methods, respectively (Theiner et al., 2016; 
Robison et al., 2020).  
The main spheroid culture investigated by MSI has been MCTS of colon cancer 
cell lines. Although recent reports of MSI with other models of cancer (i.e., breast 
and ovarian cancer) have been published, there is still a need to expand the 
research for range of in vitro cancer models. This is primarily to demonstrate 
heterogeneity of spatially resolved molecules between cancer types and 
determine their independent response to treatment. Within this thesis, two cancer 
types have been studied: lung adenocarcinoma and osteosarcoma. Lung 
adenocarcinoma is one of the most common cancers effecting 1 in 15 people in 
the UK. The low patient outcome (< 15% at 5 years) has been linked to the 
aggressiveness of the cancer leading to inconsistent patient results and high 
resistance to therapeutics (Molinier et al., 2020). On the other hand, 
osteosarcoma is a rare bone disease more prevalent within adolescents, 
however the survival rate is relatively low at < 50% at 5 years (Stiller et al.,2018). 
This low rate is again due to a poor understanding of the cancer and thus there 
is a lack of an effective treatment. Both cancer types have an unmet clinical need, 
with many of the therapeutics that have initially passed the pre-clinical studies 
failing at the clinical stage. The development of representative 3D cultures of both 
cancer types therefore has the potential to progress research towards finding 
effective therapies. 
As previously mentioned, there are various types of spheroids models, such as 
those made within a biomimetic hydrogel scaffold, which act to recapitulate the 
behaviour of a native ECM giving an extra dimension to the spheroid model. A 
MSI experiment with these spheroid types could potentially provide additional 
information of drug behaviour and biological crosstalk within the ECM, which is 
essential for certain tissue types that grow within a filamentous structure in vivo. 
Furthermore, spheroids of co-cultured cell lines would provide an extra level of 
complexity and induce cell-cell interactions between different cellular phenotypes 





It is argued that spheroid cultures are unable to fully recapitulate the 
morphological, phenotypic and genetic heterogeneity of in vivo tumours (Liu et 
al., 2018). This is in-part due to the spherical shape they adopt, which does not 
necessarily capture the complex phenotypical structures observed in patient 
tumours, thus impacting how the drug behaves and penetrates the system. In 
addition to this, spheroids of certain cancer cell lines can be difficult to grow large 
in size (< 100 µm) and prove challenging for MSI to generate an image with 
sufficient raster spots to observe the sub structure, as well as the low quantity of 
material available to analyse (David et al., 2018). Although, continuous 
developments in MSI spatial and mass resolution are demonstrating achievable 
efforts to overcome this challenge. Nevertheless, it is an understandable 
requirement to use more advanced models that can be grown large enough to 
study the spatial distribution of molecules. Moreover, MSI analysis of tumour 
spheroids alongside clinical tissue has shown great impact for the application of 
3D cultures in pre-clinical research (Zang et al., 2021). The similarities in 
metabolic signatures between spheroids and in vivo tissue supports the 
development of a representative in vitro model of cancer. With the considerations 
of enhancing the tumour spheroid model, this thesis aimed to address an 
alternative method of culturing 3D spheroids by the use of a natural scaffold 
followed by aggregation in attempt to increase the complexity of the spheroid 
model for a closer representation of in vivo. A detailed explanation of the model 
is described in Chapter 2. 
1.4.2 Organoids 
Derived from patient stem cells or biopsies, organoids are small-scale constructs 
that adopt the morphological structures of in vivo tumours and organs. Like 
spheroids, these self-organised systems allow for the study of biological 
processes including cell behaviour, tissue repair and drug response. As 
organoids are derived from patients, these systems hold the potential to assist in 
the prediction of drug response in a personalised manner. The first reported 
organoid structure dates back to 1975 by Rheinwald & Green, who cultivated a 
living skin replacement from epidermal keratinocytes which was later used to treat 
burn patients (Rheinwald & Green, 1975). Although organoids first received 
interest back in the 1970s, within the last decade the 3D models have witnessed 




successfully commercialised by several businesses for experimental use. These 
include: a human reconstructed epidermis (HRE) and a 3D differentiated 
epidermis cultures derived from human keratinocytes known as EpiSkin (Episkin, 
Lyon, France) and EpiDerm (Mattek, Ashland, USA), as well as full thickness 
living skin equivalents (LSE) that is T-skin (Episkin, Lyon, France) and Labskin 
(Labskin U.K. Ltd, York, U.K.).  
The development of alternative organoid cultures have been used in a range of 
studies to investigate healthy and diseased organs or the behaviours of primary 
tumours to drug treatment. For example, Dye et al., (2015) generated lung 
organoids from human pluripotent stem cells and observed their remarkable 
similarities to human foetal lungs, thus stating it an excellent model for human 
lung development, maturation and disease studies. In addition, a study 
conducted by Crespo et al., (2017) developed colonic organoids to observe the 
blocking effects of a chemotherapeutic, geneticin in hyperproliferation, which has 
been associated with colon cancer in vivo.  
1.4.2.1 MSI analysis of LSE models 
The combination of human skin models and MALDI-MSI has been extensively 
utilised to study the drug absorption into the different layers of the skin. The 
benefits of using the skin models with MALDI-MSI analysis, is that the skin can 
be treated similarly to animal tissues in terms of sample preparation and imaging 
acquisition. The earliest work of the MALDI-MSI approach was conducted by 
Avery et al., (2011), who examined the absorption of an antidepressant drug, 
imipramine into a model of the human epidermis, ‘Straticell’. A considerable 
difference in the intensities of imipramine at 2 h and 8 h was observed, with higher 
signals of the drug in the epidermis at 8 h. No quantifiable data analysis was 
conducted to achieve a significant concentration; however, this is partly due to 
the lack of quantitative methodologies for MALDI-MSI data at the time the study 
was conducted. The study stated some data remained inconclusive and 
additional experimentation is required to determine biotransformation of the drug. 
Avery et al., (2011) however, clearly understood the potential capabilities of 
MALDI-MSI to determine drug penetration..  
Since this work, a comprehensive study has characterised the endogenous lipid 




species including phosphatidylcholine (PC), sphingolipids (SM) and 
lysphosphatidylcholine (LPC) (Mitchell et al., 2015). Using MVA (PCA), changes 
in the lipid localisations of PC 32:1 (m/z 732.6) and PC 38:0 (m/z 759.6) over a 
time-dependent course were observed; from initial detection of the PC species 
solely within the epidermis to a homogenous distribution throughout the skin 
sections after 24 h. The changes in distribution were associated with cell 
differentiation in the dermis and epidermis of the skin model. The data obtained 
from this study was further used to determine the effects of a topical treatment in 
order to differentiate between the pharmacodynamic effects arising from the 
compounds and the normal processes of cellular differentiation in the LSE model. 
Mitchell et al., (2016) determined the lipid changes in response to emollient 
creams. Both emollient treatments were detectable by ions characteristic to each 
cream, in addition to the detection of endogenous lipid species previously 
observed within the Labskin model. After 24 h of treatment, differences in PC 
32:1 (m/z 732.6) and PC 36:1 (m/z 758.6) distributions were observed; both 
species were abundant solely within the epidermis of the untreated skin, 
compared to their distribution within  the dermis and throughout the treated skin. 
This was an interesting study to show the effects of treatment on the spatial 
localisation of lipid species and can be used to determine the metabolic changes 
in response to topical therapeutics, as well as the simultaneous detection of the 
emollients.  
A following study by Harvey et al., (2016) examined the absorption of the drug, 
acitretin in a psoriasis induced Labskin model. It was demonstrated by MALDI-
MSI acitretin penetrated the epidermis at 24 h then further infiltrated the dermal 
layer of the skin after 48 h. To confirm the location of the drug in the LSE model 
a sodiated sphingomyelin at m/z 725.4, which correlated to the epidermis, was 
detected. This time-dependent approach allowed for the evaluation of the drug’s 
penetration and stability properties within a living tissue. In this study, MALDI-MSI 
successfully demonstrated the capabilities of analysing drug delivery, whilst also 
identifying specific regions of a complex organoid skin equivalent model.  
The use of MSI to study skin has been further developed to achieve absolute 
quantification. A study conducted by Russo et al., (2018) developed a quantitative 
MSI (QMSI) approach to determine the amount of an antifungal agent, terbinafine 




micro-spotting methodology to achieve precise and uniform analytical and 
internal standards at nanolitre volumes solely within the epidermal layer, in order 
to mimic the cell-type ionisation response in treated tissues. Increasing 
concentrations of the internal standard were successfully detected at m/z 148 by 
MALDI-MSI to generate a calibration curve. Signals from the ROIs observed from 
endogenous species that defined the epidermis (PC at m/z 184) and stratum 
corneum (m/z 264) were employed to ensure that the drug calibration signals 
extracted were true to the specified region. In addition, the study evaluated the 
performance of the penetration enhancer Dimethyl Isosorbide (DMI) added to the 
delivery formulation. QMSI detected an increase in concentration of terbinafine 
with an increase in percentage of DMI within the epidermis of the LSE. Validation 
analysis observed no statistical significance between the values from QMSI and 
the values from the ‘gold standard’ LC-MS/MS, thus proving MALDI-MSI as a 
powerful quantitative method. This study demonstrated the potential impact 
QMSI with tissue engineered models will have on drug development, as by 
determining the amount of drug present within a tissue, information of its 
pharmacological activity can be obtained.  
1.4.2.2 MS imaging of tumour organoids 
The combination of MSI with tumour organoids is a relatively new approach. The 
development of tumour organoids, also known as cancer tissue originating 
spheroids (CTOS), is a similar process to generating tumour spheroids. 
Generally, patient derived cells are cultured in hydrogels such as basement 
membrane extract (BME), which are made with native ECM components and 
growth factors. CTOS are similar in size to tumour spheroids, and therefore 
require embedding medium, such as gelatin, to assist sample handling prior to 
preparation for MSI analysis following conventional protocols. More conventional 
imaging techniques such as fluorescence microscopy have mainly been used to 
observe these tumour models (Shah, Heaster, & Skala, 2017). However, efforts 
using MSI strategies to analyse CTOS have been reported, either in combination 
with fluorescent microscopy to detect the penetration of small molecule drugs that 
are inherently non-fluorescent (Bergmann et al., 2018), or the development of 





Liu et al., (2018) reported the use of MALDI-MSI with patient derived colorectal 
tumour organoids to observe the drug distribution of irinotecan in a time-
dependant dosage. MALDI-MSI detected high intensities of irinotecan at m/z 
587.3 and its metabolites SN-38 (m/z 393.1) and SN-38 glucuronide (m/z 569.2) 
distributed heterogeneously within the CTOS at 24 h of dosage. It was stated that 
this was possibly due to the various cell types including ISCs, differentiated 
enterocytes, goblet cells, entero-endocrine cells and Paneth cells that form the 
organoid model, which could have metabolised irinotecan differently. Thus, it 
demonstrated the benefits of utilising organoids over single-cell type spheroids to 
understand the metabolism of therapeutics within a structure comprised of many 
cell-types. The study also employed a QMSI approach to determine the amount 
of irinotecan present in the CTOS compared to its metabolites at a higher dosage 
at 72 h, observing lower signal of SN-38 and indicating less conversion of the 
active metabolite from irinotecan. This approach proved a valuable insight in the 
capabilities of QMSI to determine drug efficacy and potential chemo-resistance 
in patient derived CTOS, which in turn could predict clinical outcome that is 
specific to the patient.  
1.4.2.3 Considerations of MSI organoid analysis  
Alternative organoid cultures that mimic in vivo tissues other than skin or 
colorectal tumours have yet to be studied by MSI. Various challenges of cell 
culturing or MSI ionisation may be within optimisation; however, there is progress 
towards the development of the MSI-organoid approach. For example, a study 
conducted by David et al., (2018) developed a method to study tumour explants 
of breast cancer xenografts. This was to overcome the issues of being unable to 
grow large enough breast cancer spheroids for spatial distributional analysis. The 
group developed xenografts in mice, to which the tumours were harvested and 
divided into explants of desired size and then treated in vitro. Following this, the 
tumours were embedded in gelatin and prepared following conventional protocols 
for MSI analysis. MALDI-MSI spatially localised the distribution of macrocyclic 
peptides and small molecule treatments including cyclosporin A and tamoxifen in 
the ex vivo mice organoids. Although the group utilised mouse tissue, the idea 
was to demonstrate the ability to extract biopsies and detect the uptake of 
therapeutics for a promising analytical method to examine patient specific 




The reported use of MSI techniques other than MALDI-MSI is limited for organoid 
cultures. This is most likely due to the analysis of organoids with MSI being a 
relatively new concept, especially in terms of CTOS. However, as the literature 
has demonstrated with the analysis of tumour spheroids, the ability to analyse 
organoids by other MS imaging techniques has potential. The growth of CTOS 
are typically reduced due to being primary cultures compared to the fast growth 
of MCTS from immortalised cell lines. The size of certain CTOS and the spatial 
capabilities of MSI may therefore limit spatial distribution studies. Though, in 
terms of larger cultures such as the LSE model similar approaches for the MSI 
analysis of animal tissues can be applied. Overall based on the current success, 
imaging complex organoid cultures has demonstrated the ability to spatially 
locate and quantify drugs. This emerging technique could be extremely valuable, 
and it will be interesting to see where organoid imaging can take drug 
developmental research further.  
Recent developments of cutting-edge technology have enabled further 
advancements with organoid cultures. Three-dimensional bioprinting enables 
automated fabrication of highly complex multicellular tissues by combining cells, 
growth factors, and biomimetic materials. This technology has revolutionised 
tissue engineering due to its versatile processing capabilities to recapitulate 
important structural features of functional organs, which in the long-term could be 
considered for transplantable tissue in regenerative medicine (Akizuki et al., 
2018). Bioprinting also has the potential to be used for personalised medicine for 
cancer treatment. For example, Zhao et al., (2012) constructed an in vitro cervical 
cancer model by the fabrication of HeLa cells with hydrogel-based materials, 
observing a significant difference in chemo-resistance to the anti-cancer drug, 
paclitaxel, compared to 2D cell culture. Evaluation of anti-cancer treatment using 
3D bioprinting is still a relatively new concept, in addition analysis by MSI has not 
been exploited so far. However, the potential to analyse more complex models of 
in vivo tissue is an exciting avenue for research and could in future be used as a 
valuable in vitro tool for pre-clinical drug development. 
1.4.3 Microfluidic systems 
Technically microfluidic systems mostly contain 2D cell cultures, the complex 
structure is designed to recreate the multiscale architecture and tissue-tissue 




‘organ-on-a-chip’ the purpose of this system is not to build a whole living organ 
within a representative native environment, but rather to synthesise minimal 
functional units that recapitulate tissue and organ level processes. The benefits 
of using the microfluidic system facilitates the generation of microscale 
dimensions and volumes that are similar to those typically found in biological 
systems (Chiu et al., 2017). The microfluidic device can be designed in multiple 
ways depending on the complexity of the tissue that is modelled. The basic 
concept of the system is that the cells are plated within patterns on a chip that is 
coated with biocompatible materials such as polymer substrates. These materials 
allow for the passage of nutrients from the microchannels that provide a 
continuous flow of fluid. Unlike 2D cell cultures and 3D models, including 
spheroids and organoids, which are typically grown and treated sitting within a 
well of media. The continuous flow allows for the manipulation of the chemical 
gradients for cell survival and function over a long time period in addition to 
enabling treatment of drugs in a more representative manner such as 
recapitulating the oral or IV injection administration route. In more complex 
designs, numerous microchannels are connected by different porous membranes 
for different cell types. This constructs the interfaces between different tissue 
types to recreate a model of the human body. The many attributes of microfluidic 
systems identify this method of culture as one of the most advanced 3D tissue 
engineered models. 
1.4.3.1 MSI potential with microfluidic systems 
An extensive range of research has already utilised these microfluidic systems 
with mass spectrometry techniques in pharmacological studies. Santbergen et 
al., (2020) designed an on-line UPLC-MS technique coupled to a ‘gut-on-a-chip’ 
model fabricated with a co-culture of colonic adenocarcinoma cell lines, Caco-2 
and HT29-MTX. The dynamic system had switching valves to switch between the 
apical and basolateral sides of the in vitro model, allowing for permeability 
analysis of the oral drugs, verapamil and granisetron. Qualitative and quantitative 
analysis of the anti-cancer drug, genistein was demonstrated by Chen et al., 
(2012) developing a stable isotope labelling assisted microfluidic chip (SIL-chip)-
ESI-MS platform. The device cultivated MCF-7 breast cancer cells with the 




subsequently calculated the concentration of the eluting drug to determine 
genistein absorption.  
Typically, imaging organ-on-chip cultures is performed by either fluorescence or 
optical microscopy. Microfluidic devices may be amenable to MSI, however there 
is no literature to date that has utilised this approach. This simply could be due to 
the fact the microfluidic system is much more complex and lacks accessibility to 
image these cells. In addition, the sample size of the cultures in a microfluidic 
system is very small. This is a limitation for multiple reasons, including the inability 
to reproduce the spatial heterogeneity found in larger 3D models, such as tumour 
spheroids and organoids. In addition to the spatial resolution challenges of MSI; 
although, the developments in spatial resolution technology hold potential. 
Ambient MSI methods such as DESI or LESA may be better suited with 
microfluidic devices, as for MALDI required sample preparations and the laser 
desorption technique could impact the biological composition.  
An unconventional approach, however, has interfaced a microfluidic device with 
MALDI-MSI. Jo et al., (2007) stimulated neurons cultured onto a microfluidic 
system and collected the neuronal release on a functionalised surface that is 
compatible for direct MALDI-MSI analysis. An estimated amount of 
neuropeptides released including acidic peptide and α-BCP, was calculated by 
imaging the distance the peptides flowed through the measured channels of the 
functionalised surface. The group further adapted the MALDI-MSI method to 
achieve improved accuracy and precision (Zhong et al., 2012). This method 
utilised the abilities of MALDI-MSI to image the spatial distribution of the peptides 
as a measurement tool. Although the study did not directly analyse the spatial 
integrity of the neurons in culture, the group demonstrated the MSI method as a 
novel approach to examined biological behaviour.  
As demonstrated by the extensive range of studies, conducted to date, MSI has 
proven strength in the investigation of pharmacological activity in 3D cell culture 
models. With the expanding surge of microfluidic systems for the study of 
therapeutics and the biological response, it can be contemplated that there is a 
high possibility the MSI-microfluidics approach will be exploited within the 
foreseeable future. This is especially true when the recent advances in 
microfluidics to further enhance the complexity of the 3D culture systems are 




have been engineered to combine the complexity of microfluidic devices with ex 
vivo tissues, spheroids and organoids, rather than 2D cell cultures, to replicate 
the in vivo microenvironments for patient-derived cultures (Yu & Choudhury, 
2019). A similar concept of a macrofluidics system with spheroids was previously 
discussed, used as a 3D printed dosing platform device to treat HCT 116 MCTS 
with FOLFIRI (LaBonia et al., 2018). Alternatively, Spencer et al., (2020) reported 
the preliminary work of a developed macrofluidics device cultivating an ex vivo 
small intestine tissue on a Quasi Vivo 600 Liquid-Liquid Interphase in vitro system 
to model the GI tract and the oral-drug administration route. After treatment, the 
ex vivo tissue was removed from the fluidics system, snap frozen and cryo-
sectioned prior to preparing the sample with matrix by sublimation. MALDI-MSI 
analysis was able to detect regions of lymphatic tissue, known as Peyer’s patches 
(m/z 389), identifying substructures within the small intestine. The sodium adduct 
of the oral drug, atorvastatin (m/z 581) within the apical side of tissue after a 6 h 
incubation was localised outside of the Peyer’s patches and indicated an 
absorption by passive diffusion. Not only did this demonstrate advanced 
manipulation of ex vivo tissue, but it also allowed for even more accurate drug 
analysis than previously mentioned 3D models, such as spheroids or organoid 
cultures by MALDI-MSI. These advancements in 3D culture models can offer an 
ideal testing platform in drug developmental studies, which also hold potential to 
















Spheroid Aggregation MALDI  75 µm Detected specific regional distributions 
of proteins across spheroids and 
highlighted a central necrotic region. 
Proteins Histone H4 and cytochrome c 
identified, validated by LC MS/MS. 





Spheroid Aggregation MALDI  75 µm Drug penetration of irinotecan mapped 
over a 72 h time-dependent course, 
moving from outer region of spheroid 
into the core. Detection of drug 
metabolites within spheroid validated 
by nanoLC-MS/MS.  





Spheroid Aggregation MALDI Not reported Combination of confocal Raman 
microscopy and MALDI-MSI to 
determine structure of spheroids by 








Spheroid Aggregation MALDI  Not reported Spheroid-MSI workflow protocol. 
Includes the culture, preparation and 
analysis of spheroid samples by 
MALDI-MSI.   
Hiraide et al., 
(2016) 










AP-MALDI 5 µm (laser   
spot size) 
Tandem MS identified specific lipid 
species arachidonic acid containing PI 
38:4 within the outer region in spheroid 
culture. Phospholipid associated with 







Spheroid Aggregation MALDI  
 
75 µm Localisation of platinum-based drugs 
and their metabolites displayed 







spheroids. On-tissue chemical 
derivatization. UPLC-MS/MS 
quantification.   











10 µm (laser 
spot size) 
Analysis of platinum-based compounds 
including satraplatin, showed 
heterogeneous distributions between 
the two spheroid models. Platinum was 
detected in the periphery and necrotic 






Spheroid Aggregation MALDI  75 µm Demonstrated doxorubicin-encased 
liposome delivery into spheroids. 
Detection of doxorubicin and active 
metabolites throughout spheroid at 72 
h.  





Spheroid Aggregation MALDI  75 µm Proteomic imaging of histone peptides 
and their post-translational 
modifications determined the response 
to epigenetic drug within serial sections 
of spheroids, generating samples from 
core, the mid and external areas. 




Spheroid Aggregation  LA-ICP-
MSI 
25 µm (laser 
spot size) 
Multimodal analysis employing LA-ICP-
MSI and MRI to study hypoxia 
responsive cobalt complexes, detecting 
Co(II)TPAx in the core of the spheroid 
sections.  







5 µm (laser 
spot size) 
Analysis of metal-based cancer drugs 
in spheroids determined hypoxic, non-







within the spheroid based on platinum 






Spheroid Aggregation MALDI 75 µm Proteomic changes from a dynamic 
flow dosing with FOLFIRI treatment 
investigated and quantified by iTRAQ 
analysis. Heterogeneous distribution of 
drugs and active metabolites 
throughout spheroid.  



















type 2  
MALDI 70 µm  On-tissue reduction and alkylation 
method to detect time-dependent 
penetration and distribution of 
monoclonal antibody, Cetuximab. 
Different localisations of immuno-drug 
determined between two cell lines. 
Detection in organoid cultures also 
demonstrated.  




Spheroid Aggregation FT-ICR 
MALDI 
50 µm Untargeted metabolite mapping in 
spheroids identified proliferative and 
hypoxic regions via ATP metabolism 
pathway. Ion images mapped onto 
biological pathways including 
glycolysis. 






Spheroid Aggregation MALDI 50 µm On-tissue digestion workflow 
embedded spheroids in Matrigel prior 
to FFPE. Co-localised proteotypic 
peptides within the outer layer and 
necrotic region of spheroids.  
Machálková 
et al., (2019) 
HT-29 colon 
carcinoma 
Spheroid Aggregation MALDI 50 µm Multimodal co-registration of MALDI 
and IHC images of perifosine treated 







MALDI analysis and protein 
expressions in IHC identified 
proliferative and hypoxic regions. 





Spheroid Aggregation MALDI 50 µm Multimodal approach of spheroid 
analysis:  Perifosine drug detection by 
MALDI; Identification of proliferative 
and apoptotic cells by laser scanning 
confocal fluorescence microscopy 
(LSCM).  







Not reported Spatially resolved metabolic profiles in 
spheroids treated with irinotecan. MVA 
determined the drug effected 
abundances in metabolites in different 
regions of spheroids.  
Palubeckaitė 















Local apoptotic and necrotic regions 
identified by metabolite distributions. 
Changes in metabolic activity in 
doxorubicin treated cultures and 
localisation of drug detected by FTICR. 




Spheroid Aggregation MALDI 50 µm Metabolic changes in response to 
environmental contaminant BPS 
identified in phenotypic regions of 






Spheroid Aggregation DESI 50 µm Spatial mapping of lipids identified 
metastatic potential metabolites in the 






















6 µm (laser 
spot size) 
Characterization of a novel aggregated 
spheroid model by multimodal MSI 
techniques detecting metabolites, 
proteins and metals determined 
phenotypic regions of the tumour 
microenvironment. Identified 
proliferative outer region and hypoxic 
core of aggregoid and presented a 3D 
reconstruction. 





Spheroid Aggregation MALDI 12 µm Spatial resolved metabolomics defined 
phenotypic regions within spheroids, 
ion images mapped onto biological 
pathways. Similarities of metabolic 
signatures identified between clinical 
tissue and spheroids. 












MALDI 150 µm Demonstrated a MALDI-MSI method of 
an artificial skin model analysis by 
detection of imipramine absorption.  
Francese et 
al., (2013) 
Healthy LSE Skin organoid Evocutis 
“LabSkin” 
MALDI 50 µm The evaluation of curcumin as a matrix 
for MALDI across different applications, 
lung tissue, artificial skin and 
fingermark. Lipid imaging identified 
epidermis and dermis regions within 
the LSE. Detection of acitretin 







Mitchell et al., 
(2015) 




50 µm Characterisation of lipid changes in a 
time-dependent course by MALDI-MSI 
were associated with processes of 
cellular differentiation across the 
epidermis and dermis of the skin. 
Mitchell et al., 
(2016) 




50 µm MALDI-MSI detected emollient creams 
within the skin model and determined 
changes in lipid distributions in 
response to treatment. The lipids that 
defined the epidermis in the untreated 
were localised throughout the treated 
skin sections.  




Skin organoid Innovenn 
“Labskin” 
MALDI 100 μm Absorption of acitretin within psoriatic 
LSE by MALDI-MSI determined a 
larger depth of penetration in psoriatic 
model compared to healthy LSE.  
Russo et al., 
(2018) 
Healthy LSE Skin organoid Innovenn 
“Labskin” 
MALDI 60 μm Quantitation of terbinafine 
hydrochloride absorption into 
epidermal region of LSE by MALDI-
MSI. Regions of LSE identified by 
detection of abundant lipid species. 
Penetration enhancer DMI increased 














MALDI Not reported Development of a BBB organoid 
platform for drug analysis by 
fluorescent microscopy and MALDI-









dabrafenib permeability with BBB 
organoids.  









MALDI 35 μm  Heterogeneous distribution of 
irinotecan and its active metabolites 
within organoid cultures demonstrated 
metabolic variability in complex tissue 
samples.  








MALDI Not reported Ex vivo method of visualising peptides 
and small molecules in breast cancer 
tumour explants as an alternative to 
spheroid cultures. Detection of small 
molecule drug (4-hydroxytamoxifen) 
and peptide drug (cyclosporin A) as 
proof-of-concept. 
Lewis et al., 
(2018) 
Healthy LSE Skin organoid Innovenn 
“Labskin” 
MALDI 75 μm Examined the skin barrier repair/wound 
healing process through identification 









MALDI  75 μm 
  
Method development of organoid 
cultures into gelatin microarrays for 
high-throughput MSI analysis. 
Organized array of organoids in the 
same z-axis for multi-sample imaging.  














MALDI 100 μm to 
200 μm 
Characterised released neuropeptides 
from stimulated neurons by potassium 

























MALDI 100 μm to 
200 μm 
Quantification of released 
neuropeptides from stimulated neurons 
by potassium chloride solution. 
Measured the length of peptides 














MALDI Not reported Detection of metabolites identified 
substructures within small intestine 
tissue including the lymphatic tissue. 
Detection of atorvastatin sodium 
adduct within apical side of tissue 
demonstrating passive diffusion of 
drug. 




1.5 Future perspectives 
MSI has demonstrated significant value for the use in pre-clinical drug efficacy 
and toxicity studies. Parallel to the developments in MSI, 3D cell culture models 
have established robust in vitro tools that accurately represent the 
microenvironments of biological tissues and disease in humans. The multiplex 
nature of MSI has enabled the analysis of a variety of 3D models including 
spheroid and organoid cultures across applications of tumour characterisation by 
the detection of metabolites, peptides and proteins. In addition, a plethora of 
studies have evaluated the distribution of drugs and their metabolites 
simultaneously in situ, with some including quantitative capacity (Table 1.3).  
Although an extensive amount of research on the combination of MSI with 3D 
models has been reported, there are still areas of development to be made. The 
research of 3D models by MSI techniques have been limited to specific cancer 
and disease types, for instance the spheroid model of colon carcinoma. 
Henceforth, to establish the combination of 3D models with MSI as a valuable 
pre-clinical tool it is necessary to broaden the topic areas to alternative cancer 
and disease types that are just as prevalent (e.g., lung adenocarcinoma and 
osteosarcoma). The conflicting views on 3D cultures accurately representing true 
in vivo structure and functionality clearly show the need for establishing more 
complex models that include molecular heterogeneity and essential structural 
components. This is to ensure an accurate prediction of drug outcome in vivo. 
Developments in the sample preparation workflow need to keep pace to allow 
accessibility of the 3D models for MSI analysis. Furthermore, the combination of 
3D cell culture models with MALDI has been the primary imaging platform. The 
use of alternative ionisation modalities can allow for the study of a wider range of 
molecular content, expanding the opportunities in pre-clinical drug analysis for a 
variety of drugs and endogenous molecules, including the spatial resolution 
capabilities that have potential for single-cell analysis.  
In addition, MSI analysis of therapeutics within not only 3D cultures but all tissues 
have predominately focussed on the evaluation of small molecule drugs. This is 
mainly due to the effectiveness of the compounds as a treatment. However, over 
recent years progress towards the developments of complex biopharmaceuticals 
that offer high efficacy treatments with few side effects have become one of the 




literature reporting the detection of biologics in situ by MSI techniques, with only 
two studies published to date (Ait-Belkacem et al., 2014; Liu et al., 2018). This is 
mainly due to the size and complexity of the therapeutic proteins which create 
issues of low ionisation and poor sensitivity that have hindered the development 
of an established MSI workflow. It is therefore a requirement for MSI methods to 
keep with the momentum of pharmaceutical development in order to maintain its 
reputation as a valuable tool in pre-clinical drug analysis.  
1.6 Aims and objectives of this project 
The aim of this project was to develop a multimodal MSI approach to analyse a 
3D cell culture model for pre-clinical biopharmaceutical testing. In order to 
achieve this the following objectives were investigated: 
• Develop a novel 3D cell culture model of two cancer types (lung 
adenocarcinoma and osteosarcoma) and optimise the sample 
preparation workflow for universal application across MSI modalities.  
• Apply a multimodal MSI approach to characterise the lung 
adenocarcinoma model for an in-depth understanding of the tumour 
microenvironment.  
• To use the multimodal MSI approach to characterise and compare the 3D 
osteosarcoma models and investigate their molecular relevance to clinical 
osteosarcoma patient samples.  
• Employ an untargeted DESI-MSI approach to determine the metabolic 
response to biopharmaceutical treatment in the 3D cell culture models. 
• Optimise a multimodal MSI strategy to detect a biopharmaceutical in the 




CHAPTER 2. OPTIMISATION OF A 3D CELL 
CULTURE MODEL FOR MASS 





As discussed in Chapter 1.4, the combination of MSI with 3D cell culture models 
is a promising tool in early stage drug development. The ability to study the 
distribution of a parent drug and its metabolites, whilst simultaneously measuring 
the cellular metabolism within an artificially created environment expands the 
possibilities for pre-clinical research (Russo et al., 2018).  
Spheroids are the most common 3D model of cancer studied by MSI, specifically 
MCTS in combination with MALDI imaging (Chapter 1.4.1). The spheroid model 
can mimic key tumour characteristics with regards to cellular morphology and 
metabolic activity that make it a valuable tool for evaluating drug toxicity. Hypoxia 
is of particular significance due to its effects on cellular function and drug activity, 
which can give rise to drug resistance (Donovan et al., 2010; Jing et al., 2019). 
In addition, the biological and physical barriers of the periphery, such as the active 
metabolism and lessened permeability, can also prevent the delivery of a drug 
(Soo-Hyun, Hyo-Jeong, & Crispin, 2011). The spheroid model also provides a 
cost-effective and versatile method of analysing the biological processes within 
the tumour environments, with added benefits of high throughput results. These 
qualities in combination with the spatial resolution capabilities and high-speed of 
acquisition of MALDI-MSI makes this method highly desirable for drug 
development studies. 
Recent publications  have criticised MCTS because of their lack of heterogeneity 
(Liu et al., 2018; Palubeckiatė et al., 2019). This is due to the way in which the 
spheroids are formed through aggregation techniques. Aside from the phenotypic 
differences of hypoxia and proliferation that spheroids exhibit, the 3D constructs 
are seen as predominately homogenous cultures. In comparison, in vivo tumours 
are highly complex tissues that are comprised of a variety of differentiated cells 
(e.g., stromal and immune cells) within a dynamic ECM and vascularised 
environment, rather than a singular mass of cancer cells (Fong et al., 2016). As 
tumour heterogeneity is a factor contributing to drug resistance, the homogeneity 
of MCTS can negatively impact true biological behaviour and lead to therapeutic 
failure further down the line. The paradigm of modelling cancer in vitro is therefore 
seeing a shift away from spheroid cultures towards more accurate pre-clinical 
models sourced from primary cells (i.e., tumour organoids) that consist of multiple 




studying these cultures (Liu et al., 2018). The implementation of patient derived 
tumour organoids in experiments, however, is far more complex than the spheroid 
model with regards to the ethical implications, the lengthy culturing periods and 
added expenses.  
Alternatively, enhancing the complexity of the spheroid model is a more preferred 
method in drug development when aiming for high-throughput results. Such 
advancements involve the way in which the spheroid is cultured. For example, 
scaffold-based techniques provide an ECM structure to the cellular environment 
which more closely resembles the native cell-matrix interactions found in vivo. 
Scaffolds can also be adapted and tailored to mimic a specific environment for 
individual cell lines. In contrast to the aggregation method which cannot form 
robust spheroid cultures in a range of cell lines (Nagelkerke et al., 2013). 
Additionally, culturing within scaffold-based materials enforces the single cell 
suspension to proliferate in 3D, generating clonal populations through a more 
natural process. A recent study reported, 3D cell cultures promoted survival 
mechanisms in spheroid formation similar to in vivo. A marked increased levels 
of an oxidant defence transcription factor, NRF2 had significant effects on cellular 
proliferation and protection of cells within a hypoxic microenvironment (Takahashi 
et al., 2020). Thus, the results demonstrated the importance of cells proliferating 
in 3D rather than the aggregation method in order to create their own ECM 
components and promote gene expressions required for tumour survival.  
In terms of analysing such enhanced spheroid models by MSI, the literature has 
been limited to none. Potentially this is due to the ease of generating MCTS by 
the aggregation method. In addition, the size of the spheroid cultures within 
scaffolds can be limited (< 500 µm) and creates issues in terms of retrieving 
molecular information in spatial distribution studies (David et al., 2018). Some 
materials used to aid scaffold-based spheroids (e.g., PEG containing hydrogels) 
can also cause spectral interferences during analysis and therefore the choice of 
material needs careful consideration (Palubeckaite et al., 2018).  
With this in mind, a novel 3D culture model has been developed that addresses 
the limitations regarding the heterogeneity of spheroid models and their 
compatibility for quality MSI analysis. Palubeckaitė et al., (2019) generated a 
“spheroid aggregate” model through the aggregation of tumour spheres. The 




spheroids through proliferation, which are then isolated and aggregated together 
using an ultra-low attachment technique. The scaffold-based method of spheroid 
formation is clonal and creates multiple spheroids of different sizes and of genetic 
variability within a single alginate bead. The individual spheres are then 
aggregated to form a larger construct of cells of a diameter of ~ 1 mm. This is 
achieved by following a similar technique to the aggregation method utilising 
agarose coatings to prevent cells adhering to surface of well plates, enforcing the 
cells to aggregate together (Costa et al., 2014; Gong et al., 2015; Das et al., 
2017). Theoretically, the aggregation of the individual colonies creates areas 
within the spheroid aggregate that exhibit different genetic phenotypes. Thus, the 
3D model provides a more heterogeneous tissue than the typical spheroid model 
(Figure 2.1). The spheroid aggregate still displays the typical tumour 
microenvironment characteristics with proliferative and hypoxic regions 
demonstrating a viable 3D culture for pharmacological studies.  
 
  
Figure 2.1 Diagram depicting a comparison between the conventional 
MCTS model vs the spheroid aggregate model. MCTS formed through 
aggregation of a single cell suspension as the spheroid aggregate is generated 




MALDI-MSI analysis of the osteosarcoma (SAOS-2) spheroid aggregate showed 
that it was possible to detect endogenous metabolites within specific regional 
localisations (Palubeckaitė et al., 2019). The proof-of-principle study showed 
heterogenous distributions that co-localised unidentified metabolites exhibiting 
signals at m/z 281.3 within the periphery and m/z 403.1 in the necrotic core of the 
aggregate model. In addition, distributional changes of metabolites were 
observed in response to the chemotherapeutic, doxorubicin, as well as the 
detection of the drug as a protonated cation at m/z 544.2 within the SAOS-2 
aggregate. The study showed the combination of the spheroid aggregate model 
with MSI to be a promising method in studies of drug efficacy and toxicity. 
Although the model has shown to be suitable for metabolomics studies and 
chemotherapeutic applications, there is not enough evidence to demonstrate the 
full capabilities of this novel model across different MSI techniques and no data 
has yet been produced in the emerging field of biopharmaceutical applications. 
Therefore, further studies of the spheroid aggregate with MSI are of interest.  
2.2 Aims of chapter 
In the following chapter the aim was to culture additional novel 3D culture models 
using the methodology developed previously from Palubeckaitė et al., (2019). 
The objectives were to recreate the tumour microenvironment within three cancer 
cell line models, two osteosarcoma (MG63, SAOS-2) and one lung 
adenocarcinoma (HCC827) for the purpose of developing an in vitro tool in MSI 
applications for pre-clinical research in biopharmaceutical development. In order 
to conduct these experiments, optimisation of the sample preparation workflow 
for MS analysis of the 3D culture models was required. An investigation of sample 
handling and storage was performed in order to retain sample integrity and 
reduce analyte delocalisation of the 3D models. MALDI-MS profiling and imaging 
of the 3D models were employed to evaluate the technical parameters. 
2.3 Materials and methods 
2.3.1 Materials  
α-CHCA, DHB, alginic acid, aniline, calcium chloride (CaCl2), sodium 
carboxymethylcellulose (CMC), ethylenediaminetetraacetic acid (EDTA), eosin, 




polyvinylpyrrolidone (PVP), propidium iodide (PI), sodium chloride (NaCl), 
sodium citrate, TFA and xylene substitute were purchased from Sigma-Aldrich 
(Gillingham, UK). Acetonitrile (ACN), ethanol (EtOH), Hoechst 33342 and 
methanol (MeOH) were purchased from Fisher Scientific (Loughborough, UK). 
Pertex mounting medium was obtained from Leica Microsystems (Milton Keynes, 
UK). Hydroxypropyl-methylcellulose (HPMC) was purchased from Alfa Aesar 
(Thermo Fisher Scientific, Heysham, UK).  
2.3.2 2D cell culture 
Epithelial HCC827 (lung adenocarcinoma) cell line was obtained from ATCC and 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Lonza Ltd, U.K.) 
supplemented with 10% foetal bovine serum (FBS) and 1% penicillin-
streptomycin (Lonza Ltd, U.K.). Osteosarcoma cell lines, MG63 and SAOS-2 cell 
lines were obtained from ATCC and were cultured in alpha modified Eagle’s 
medium (αMEM) supplemented with 10% FBS and 1% penicillin-streptomycin. 
All cell lines were maintained in a humid atmosphere at 37°C, 5% CO2 and grown 
to 80% confluence prior to use for 2D experiments and 3D culture. Confluent cell 
lines were passaged by trypsinisation, followed by centrifugation, and 
resuspension in fresh media. Cell lines were routinely tested for mycoplasma 
every few months. 
2.3.3 3D cell culture 
The aggregated 3D cell culture models were generated based on the method of 
Palubeckaitė et al., (2019) and is described below.  
2.3.3.1 Alginate culture 
Monolayer cells were suspended in 1.2% (w/v) alginic acid in 0.15 M NaCl at an 
approximate cell density of 1 x106 cells/mL. The cell density was determined by 
Trypan blue staining (Lonza Ltd, UK) and calculated on the Countess® 
Automated Cell Counter (Thermo Fisher Scientific, U.K.). The alginic acid solution 
containing cells was extruded out of a 20-gauge needle into 10 mL 0.2 M CaCl2 
to polymerise the alginate into beads. Beads were incubated at room temperature 
(RT) for approximately 2-3 min before they washed with 0.15 M NaCl twice before 
culturing in the appropriate media. All cell lines were initially cultured up to 21 




14 days for each cell line was decided to yield spheroids of approximately 100 
µm. Beads were subjected to a media change every 72 h.  
2.3.3.2 Releasing spheroids from alginate beads 
Alginate beads were dissolved in an alginate buffer (55 mM sodium citrate, 30 
mM EDTA, 0.15M NaCl) for 10 min at 37°C after breaking up the beads in solution 
with a pipette. Approximately 30 beads were dissolved in 10 mL of buffer. The 
spheroid solution was gently centrifuged for 3 min at RT to form a pellet. The 
supernatant was removed, and the pellet was washed in the appropriate culture 
media twice, followed by centrifugation between each wash.  
2.3.3.3 Aggregoid formation 
To form tumour spheroid aggregates, the required amount of culture media was 
added to resuspend the spheroids so that there was approximately half of one 
alginate bead per well of a 1% agarose-coated 96-well plate. Spheroid 
aggregates were cultured for 7 days in the appropriate media to form aggregoids 
of an approximate diameter of 1 mm.  
2.3.3.4 Analysis of spheroid and aggregoid development 
Spheroid and aggregoid development were analysed by fluorescent staining with 
Hoechst 33342 and PI staining (10 µg/mL each) and incubated at 37°C for 30 
min. After incubation, the stain solution was replaced with fresh culture media for 
imaging analysis. Fluorescent images were obtained using either the Olympus 
IX81 Microscope (Southend-on-Sea, U.K.) where images were captured using 
Cell^F Multi-fluorescence and Imaging Software (Europa Science Ltd, 
Cambridge, U.K.), or the Cytation™ 5 Cell Imaging Multi-Mode Reader (BioTek, 
UK). 
2.3.4 Tissue processing 
2.3.4.1 Sample embedding  
To handle the aggregoid cultures a series of embedding media were tested, these 
included: (1) 10% gelatin; (2) 5% CMC; or (3) 7.5% HPMC and 2.5% PVP as 
described by Dannhorn et al., (2020). For the embedding procedure, media (1) 
and (2) were incubated at 50°C to form a liquid solution. Media (3) was pre-
conditioned on ice for 30 min before use. Prior to embedding, aggregoids were 




carefully transferred from the well into embedding media coated moulds using a 
100 µL pipette tip, which the end was cut so that the tip had a larger diameter to 
ensure the aggregoid integrity was retained. Once the aggregoid was transferred 
to the media coated moulds, excess PBS was removed to the extent possible. 
Additional embedding media was coated over the aggregoid samples before flash 
freezing in liquid nitrogen for approximately 1-2 min. Fresh frozen samples were 
stored in - 80°C prior to sectioning.  
2.3.4.2 Sectioning 
Embedded tissues were cryosectioned on a CM1950 cryostat (Leica Biosystems, 
U.K.) set to a temperature of - 24°C for the cryochamber and - 20°C for the 
sample holder. Samples were mounted onto circular cork rings with a diameter ~ 
3 cm using H2O and left for 30 min to thermally equilibrate before sectioning. 
Sections were cut at 10 µm thickness, thaw mounted onto either positively 
charged X-tra® adhesive slides (Leica Biosystems, U.K.) or onto Indium-Tin 
oxide (ITO)-coated slides (Visiontek Systems Ltd, UK) dependant on the 
instrumentation used for analysis.  
2.3.4.3 Sample storage 
To ensure aggregoid samples are stabilised and to prevent degradation of 
endogenous molecules an experimental protocol established by Swales et al., 
(2018) for optimum sample storage and preparation was followed. Briefly, 
samples were desiccated with N2 immediately after the section was adhered onto 
the glass slide. Following this, samples were vacuum packed in plastic pouches 
and stored (- 80°C), and after left to air-dry before taking out of vacuum 
conditions. A comparison of this method with the conventional storage of slides 
not desiccated or vacuum packed and stored (- 80°C) is included in section 
2.4.2.3.  
2.3.5 Optimisation of mass spectrometry imaging 
2.3.5.1 Mass spectrometric profiling of aggregoid cultures 
Profiling of the aggregoid samples and embedding media was performed by 
spotting 0.5 µL of α-CHCA (5 mg/mL) in 70% ACN:0.1% TFA with equimolar 




Mass spectra were manually acquired on a Waters MALDI HDMS Synapt G2 
mass spectrometer (Waters Corporation, U.K.) equipped with a Nd:YAG laser 
operated at 1 kHz. Instrument calibration was performed using phosphorus red 
before analysis. Spectra were acquired in positive mode, full scan sensitivity 
mode within a m/z range 100-2000 (resolution 10 000 FWHM) and a laser energy 
at 320 arbitrary units. Ion mobility function was not enabled. Data were acquired 
and converted to .txt file format using MassLynx™ software (Waters Corporation, 
UK) and analysed using mMass 3 open-source software (Strohalm et al., 2010). 
Peak picking settings were set at a signal to noise (S/N) threshold of 5, and the 
picking height was 100%. Both the absolute intensity threshold and the relative 
intensity threshold was set to 0 with baseline correction and smoothing applied. 
Identification of values were based on putative assignments using METLIN 
(http://metlin.scripps.edu), LIPID MAPS® 
(https://www.lipidmaps.org/tools/ms/LMSD_search_mass_options.php) and 
published literature.  
2.3.5.2 MALDI-MSI 
2.3.5.2.1  Matrix deposition 
All sample sections were removed from - 80°C and left to air-dry before removing 
from vacuum packaging to avoid delocalisation of the analyte and to preserve the 
integrity of the tissue. For the spray-coat method, matrix (5 mg/mL α-CHCA in 
70% ACN:0.1% TFA with equimolar amounts of aniline) was deposited onto the 
tissues using a SunCollect™ MALDI Sprayer (KR Analytical, Sandbach, UK). Ten 
layers of matrix were sprayed with a flow rate of 3 µL/min for the first layer then 
4 µL/min for the remaining layers with the sprayer nozzle positioned at a height 
of 38 mm.  
Matrix deposited by sublimation was achieved by evenly spreading 300 mg of α-
CHCA at the bottom of the Ace vacuum-sublimation apparatus (Sigma-Aldrich). 
Polylysine slides with aggregoid sections were attached to the flat top of the 
chamber using autoclave tap at either end of the slide. The flat top of the chamber 
was placed within the sublimation apparatus and sealed by vacuum at 2.5 x10-2 
Torr. The top was filled with ice-water. The apparatus was set to a temperature 
of 180°C prior to starting the sublimation process. The application of matrix was 




CHCA was achieved. This was calculated by weighing the slide before and after 
sublimation, calculating the difference (mg) and dividing by the area of the 
sublimed slide (cm2).  
2.3.5.2.2  Imaging acquisition 
Small molecule MALDI images were acquired using the Waters MALDI HDMS 
Synapt G2 mass spectrometer. Instrument calibration was performed using 
phosphorus red. Spectra were acquired in positive ion full scan sensitivity mode 
within a m/z range 100-1000 at a spatial resolution 40 µm and a laser energy set 
to 350 arbitrary units. Ion mobility function was not enabled. 
2.3.5.2.3  Data processing  
MALDI-MSI data were processed using the HDI 1.4 software tool (Waters 
Corporation, UK) to initially determine the quality of the data after acquisition. For 
more in-depth data processing, files were converted into imzML and ibd before 
being uploaded on to the SCiLS™ Lab MVS Version 2020a Core (Bruker 
Daltonics, Germany). Total ion count (TIC) normalisation was applied, the peak 
list was generated from the maximum 100 peaks per spectrum. The peak list was 
used for further data analysis including spatial segmentation and co-localisation 
of m/z images. The spatial segmentation method was performed by bisecting k-
means, with weak denoising and a correlation distance metric, working on all 
individual spectra.  
2.3.5.3 DESI-MSI 
Small molecule imaging was performed using a Q-Exactive mass spectrometer 
(Thermo Fisher Scientific Inc, Germany) operated in negative ion mode. No prior 
sample preparation was required to analyse the aggregoid cultures. The mass 
spectrometer was equipped with a custom-built automated DESI ion source. The 
mass resolution was set to 70,000 and mass spectra were collected in the mass 
range m/z 80-900 at a spatial resolution of 30 μm. The electrospray solvent was 
MeOH/water (95:5 v/v) set at a flow rate of 1 μL/min with nebulizing nitrogen used 
as gas at pressure of 2 bar. Imaging analysis was performed by combining 
individual horizontal line scans and converting into imzML format using the imzML 
converter V.1.1.4.5 (www.maldi-msi.org). The images were analysed by SCiLS 
Lab MVS Premium 3D Version 2020a (Bruker Daltonics, Germany) employing 




2.3.6 Histological analysis  
Aggregoid sections were stained with Mayer’s haematoxylin and eosin (H&E) 
solutions. After MALDI-MSI analysis, slides were washed with 100% EtOH to 
remove the presence of matrix. Sections were then rehydrated in 100% EtOH (3 
min) and 18 MΩ water (2 min) prior to staining with filtered haematoxylin (1 min). 
Tissues were then blued in running tap water (5 min) before submerging in 100% 
EtOH twice (3 min). Tissues were subsequently stained with eosin (1 min) prior 
to washing with 100% EtOH twice (3 min). Finally, tissues were submerged in 2 
changes of xylene substitute (5 min) and mounted using Pertex® mountant. For 
slides that were not used for MALDI-MSI analysis, sections were immediately 
stained with haematoxylin. An initial 4% PFA fixation step was included prior to 
the haematoxylin step for optimisation of one set of samples. Optical images were 
obtained using the Olympus BX60 microscope (Olympus, U.K.) and images 
captured using QImaging Micropublisher 5.0 RTV camera and Capture-Pro 8.0 
software (QImaging, Canada). 
2.4 Results and discussion 
2.4.1 Optimisation of an aggregated tumour spheroid model 
In this study, a novel aggregated tumour spheroid model was developed for 
multiple reasons: a) to form a larger tissue for mass spectrometry spatial 
distribution studies, and b) to create a more heterogeneous model than the 
conventional tumour spheroid suitable for early stage drug development studies. 
Three cell lines were cultured following a similar method to that described by 
Palubeckaitė et al., (2019). The cell lines included were two osteosarcoma (OS) 
cell lines, MG63 and SAOS-2, which have been previously shown to be robust 
spheroid aggregate models for the analysis by MALDI-MSI (Palubeckaite, 2018). 
Additionally, a HCC827 lung adenocarcinoma cell line was cultured following this 
protocol to further demonstrate the diversity of the 3D culture model across 
different cancer types. Initially, a single-cell suspension was cultured within an 
alginate bead over a period to examine the growth of spheroids scaffold, as 
previously demonstrated by Akeda et al., (2009) and Stock et al., (2016). 
Typically, the formation of clonal spheres takes a longer period compared to the 
aggregation method due to the development of the spheroid through single cell 




alginate bead culture was therefore assessed over a 14-day period by Hoechst 
33342/PI fluorescent staining to determine the size of the colony and the 















From day 2, images showed initial proliferation of single cells for each cell line. 
Noticeable formation of spheres, approximately 4-5 cells, were found within the 
MG63 cultures, indicating a faster rate of proliferation (Figure 2.3). By day 14, all 
three cell lines had grown a substantial amount of spheroids (~ 70%) per alginate 
bead. Both OS cell lines cultured spheroids, the majority of which had diameters 
of approximately 200 µm with the beginnings of a hypoxic/necrotic core (Figure 
2.3 and Figure 2.4).  
  
Figure 2.2 A whole alginate bead culture of SAOS-2 spheroids (day 11). 
Fluorescent image obtained by Hoechst 33342/PI staining to identify viable (blue) 




















Figure 2.3 Spheroid development of MG63 OS cell line. Fluorescent images 
obtained by Hoechst 33342/PI staining to identify viable (blue) and necrotic (red) 
regions. Spheroid formation was observed within an alginate bead culture over 





Figure 2.4 Spheroid development of SAOS-2 OS cell line. Fluorescent images 
obtained by Hoechst 33342/PI staining to identify viable (blue) and necrotic (red) 
regions. Spheroid formation was observed within an alginate bead culture over 




The HCC827 spheroids at day 14 were smaller in diameter of around 100 µm, 
with a small indication of hypoxia (Figure 2.5). The larger and faster growth of the 
OS cell lines in comparison to the lung cell line is potentially due to the 
microenvironment from which the cells originated. OS cells were derived from low 
oxygenated regions within the human body, thus are accustomed to surviving in 
hypoxic conditions. The lung cells, however, were derived from high oxygenated 
areas therefore growing the cells in alginate, where there is a decreasing gradient 
of oxygen and nutrients towards the core of the bead, will impact the growth of 
the cells. Adapting the conditions of the alginate scaffold, in which the HCC827 
cell line were cultured, could help improve the growth rate of the cells. 
Nevertheless, HCC827 cells were successfully grown to spheroids with the 
majority at the optimum diameter (> 70 µm) for the generation of large enough 
spheroid aggregates (700 – 1000 µm diameter). It was therefore decided that the 







Figure 2.5 Spheroid development of HCC827 lung adenocarcinoma cell line. 
Fluorescent images obtained by Hoechst 33342/PI staining to identify viable 
(blue) and necrotic (red) regions. Spheroid formation was observed within an 
alginate bead culture over 14 day period. Scale bar 50 µm (day 2 and 7), 100 µm 




Following the method described by Palubeckaitė et al., (2019), the spheroids 
were aggregated using agarose coated wells. The ultra-low attachment technique 
provided a non-adherent surface, forcing the spheroids to form into a single 
cluster and initiate spheroid-spheroid interaction. By documenting the growth of 
the SAOS-2 aggregates over a 7-day period, the formation of a compact 
aggregate model could be observed (Figure 2.6). From day 2, the cultures were 
large in diameter (> 1 mm) with obvious gaps, this showing the initial formation of 
the tissue whereby the clonal spheroids are still individual masses beginning to 
interact with each other. Throughout the culturing period, more spheroid-spheroid 
interactions were being formed, the aggregates were smaller in diameter than 






Figure 2.6 The formation of a SAOS-2 spheroid aggregate over a 7-day 
period. Fluorescent images obtained by Hoechst 33342/PI staining to identify 




Each cell line produced spheroid aggregates with large diameters of 
approximately > 700 µm displaying an outer area of viable cells and an inner 
necrotic region, likely due in part to hypoxia (Figure 2.7). A previous spheroid 
study reported that cultures over 500 µm begin to form a necrotic region (Däster 
et al., 2017). This is highly beneficial as the model provides areas of 
heterogeneity. As previously mentioned, there is correlation of hypoxia with 
chemoresistance due to depleted oxygen levels, and apoptotic and necrotic 
activity that impact the drug’s delivery and cellular uptake (Muz et al., 2015). In 
addition, the majority of chemotherapeutics are most active when cells are within 
their cell cycle, the lack of oxygen and thus the presence of non-proliferative cells 
can impact the cytotoxic activity of a drug. Therefore, the large area of hypoxia 
with necrotic activity within the spheroid aggregates is an ideal model for studying 
a drug’s behaviour and efficacy, screening drugs at the early stage of 
development.  
The morphology of the aggregates showed some irregularity across replicate 
cultures of the same cell line, possibly due to the different sizes of spheroids 
within the culture leading to randomised direction of growth. Although variance 
across cultures could be seen as a disadvantage in terms of the size of the 
phenotypic areas having an impact on drug efficacy results. Variance in 
morphology can also be seen as beneficial to study true tumour behaviour as 
cancer growth is exponential and irregular and does not lead to the formation of 
uniformed spheres (unlike the spheroid model). This variance leads to the need 
for biological repeats throughout analysis when studying drug behaviour and the 
cellular processes within the aggregate model. 
  
Figure 2.7 Spheroid aggregates of MG63, SAOS-2 and HCC827 at day 7. 
Fluorescent images obtained by Hoechst 33342/PI staining to identify viable 




During this study, the spheroid aggregate was re-termed an “aggregoid” from the 
basis of describing the model as the aggregation of spheroids, and therefore the 
3D model will be described as an aggregoid throughout the remainder of the 
thesis. 
2.4.2 Sample handling for MS analysis 
Maintaining the integrity of tissues is imperative for spatial distribution studies to 
preserve the localisation and abundance of molecules in biological samples. The 
aim is to retain the tissue as close to its native state in order to obtain a true 
representation of the chemical processes within the sample. The processes of 
the collection and handling of samples are the most important steps of the 
imaging workflow to achieve quality results during MSI analysis. Many protocols 
have been developed with the aim of being universally applicable across 
ionisation methods to allow for an in-depth evaluation of species within tissues 
(Goodwin, 2012). Components of sample collection and handling include the 
stabilisation, processing and storage of tissues.  
2.4.2.1 Sample stabilisation 
Commonly, tissues are immediately snap-frozen directly in liquid nitrogen or 
isopentane at point of collection as a method of stabilising the sample. Fresh 
frozen tissues can then be stored at - 80°C until use, for a typical period of up to 
a year before molecular degradation would impact the abundance of protein 
distribution (Schwartz et al., 2003; Lemaire et al., 2006). Alternatively, following 
suit from histological preparation, MSI analysis can also be performed on 
formalin-fixed paraffin-embedded (FFPE) samples (Djidja et al., 2017; Ly et al., 
2019). The fixation of tissues enables preservation of biological samples suitable 
for indefinite storage and aids the sectioning process by increasing the rigidity of 
tissues (Howat & Wilson, 2014). However, the analysis of FFPE tissues by MSI 
is limited to proteotypic peptides, with very little literature published on the 
detection of other species (Ly et al., 2016; Denti et al., 2020). This is due to 
additional sample preparation methods required including, deparaffinisation with 
numerous washing steps, which consequently impacts the presence of 
metabolites and lipids (Vos et al., 2019).  
For smaller, fragile tissues, such as tumour aggregoids, supportive materials 




when considering sectioning of tissues. MSI compatible materials that do not 
interfere with the analysis of compounds nor impact the morphological features 
of the tissue are essential. Optimal cutting temperature compound (OCT), 
traditionally used in histology, is universally known to cause severe polymeric 
interference which subsequently suppresses analyte detection and therefore it is 
avoided (Schwartz et al., 2003). Materials more suitable for MSI studies include 
gelatin (Gill et al., 2017), carboxymethylcellulose (CMC) (Potchoiba et al., 1995; 
Stoeckli et al., 2007) and poly[N-(2-hydroxypropyl) methacrylamide] (pHPMA) 
(Strohalm et al., 2011). With many imaging studies reporting gelatin as an 
acceptable embedding medium for 3D cell culture models (Ahlf Wheatcraft et al., 
2014; Liu & Hummon, 2015; Liu et al., 2018; Palubeckaitė et al., 2019). 
Additionally, a hydrogel composed of hydroxypropyl methylcellulose (HPMC) and 
polyvinylpyrrolidone (PVP) was recently developed. Dannhorn et al., (2020) 
demonstrated the compatibility of this new hydrogel matrix across MALDI, DESI 
and SIMS techniques.  
To determine the optimum conditions for embedding the aggregoid model, three 
embedding media: gelatin; CMC; and HPMC & PVP, were evaluated. During the 
embedding process, both gelatin and CMC required heating at 50°C for the media 
to be liquid prior to coating the moulds, whereas HPMC & PVP was pre-
conditioned on ice. The high temperature of the gelatin and CMC was of initial 
concern in terms of the effect on the cellular viability of the aggregoid, potentially 
increasing the risk of sample degradation and altering the morphology of the 
tissue. Although as previously mentioned, gelatin has been demonstrated a 
suitable embedding media in spheroid studies and may not have such an impact. 
All samples were frozen in liquid nitrogen immediately after the aggregoids were 
covered with the embedding media and stored at - 80°C to reduce the possible 
risk of sample degradation from the heated media temperatures.  
2.4.2.2 Sample processing 
In terms of sectioning the samples, gelatin provided some rigidity to the 
aggregoid, where sections appeared whole with little to no splintering or fracturing 
to the tissue. However, the ability to see the aggregoid within the gelatin was 
difficult due to their similarity in colour, which led to over sectioning some of the 
samples. The aggregoids embedded in CMC on the other hand were more easily 




the sample was sectioned, causing fracturing to the aggregoid sections and 
therefore were more fragile when handling. The HPMC & PVP media however, 
provided some qualities of both gelatin and CMC. The aggregoid samples were 
easily located within the embedded mould and the sections maintained the 
sample integrity with minimal fracturing to the tissues.  
 
The morphology of the aggregoid sections within the different media was 
observed by histological staining (Figure 2.9). Slight fissures to the sections were 
observed, which most likely occurred during sectioning. From the gelatin and 
HPMC & PVP embedded aggregoids, the tissues appeared to be more cohesive 
in structure with less dense areas typically within the core. This was as expected 
as this is a region of necrosis, where some cell interactions are lost due to cell 
death. In comparison, the HPMC & PVP embedded samples showed the best 
preservation of the aggregoid tissue. The CMC embedded samples showed a lot 
of fracturing to the sections, which could be the result of the consistency of the 
media and the impact it had on sectioning. An additional step of fixing the tissues 
with PFA at the beginning of the histology stain was included to ensure the loss 
of tissue was not due to the staining process. The fixation step, however, showed 
very little impact on improving the preservation of the CMC embedded aggregoids 
(Figure 2.9b). Interestingly, the morphology around the outer region of the 
aggregoids in some samples embedded in gelatin and CMC showed obvious 
disturbance to cells, as the HPMC & PVP embedded aggregoids showed intact 
tissue. The impact on the tissue is potentially from the temperature of the media 
Figure 2.8 SAOS-2 aggregoids embedded within a) HPMC & PVP; b) Gelatin; 
c) CMC after trimming the embedding mould to reach the tissue. Red arrows 




during the embedding process. The subsequent effects of this could therefore 
affect the cellular viability around the edge of the model and could lead to 
inconsistency across samples. This was taken into consideration for MSI analysis 
of the aggregoids, when identifying phenotypic areas such as the outer 
proliferative region and how it could distort the results.  
 
  
Figure 2.9 Histology staining of SAOS-2 aggregoid sections within 
embedding media. i) HPMC & PVP; ii) Gelatin; iii) CMC. a) Histology staining 
with Mayer’s haematoxylin (purple) to identify nuclear components and eosin 
(pink) to identify the cytoplasm. b) The same histology protocol with an initial 
fixation step by 4% PFA. Slight fissures identified in the sections due to the 
sectioning process. Gelatin surrounding aggregoids showed staining from eosin 




MALDI-MS profiling of each embedding media was performed to determine the 
molecular profile and identify any significant signals that may cause interferences 
with the sample. PEG containing media, such as OCT, typically show a series of 
signals within the range of 1100-2000 Da that can cause major ion suppression 
effects in proteomic analysis (Weston & Hummon, 2013). No polymeric-like 
signals were identified across the tested media within the targeted mass range 
for peptide species, or within the lower mass range for metabolites and lipids (m/z 
100-2000) (Figure 2.10). HPMC & PVP and CMC had similar molecular profiles, 
with no obvious peak differences. Gelatin, on the other hand, displayed a 
background of signals from approximately m/z 700 onwards. This potentially 
could have effects on detecting abundant species within the lipid and peptide 
mass range, however the relative intensity of the peaks is somewhat low. Overall, 
none of the embedding media showed significant peaks that could have impact 
on the detection of molecules with the aggregoid model. 
From the analysis of the embedding media, HPMC & PVP was found to be the 
most appropriate for use with the aggregoids. This was in terms of retaining the 
morphology of the tissue, but also the ease of handling samples. Additionally, 
with the reported compatibility of this media across different imaging technologies 
(Dannhorn et al., 2020), it was of added interest for the multimodal MSI objectives 






Figure 2.10 MALDI-MS profile of embedding media: a) HPMC & PVP, b) 
Gelatin, c) CMC. Embedding media profiled with 5 mg/mL α-CHCA (70% ACN 
0.1% TFA, 2.4 µL aniline). Mass spectra acquired in positive mode, m/z 100-
2000. Spectra was processed by mMass and normalised to the highest peak (α-




2.4.2.3 Storage of sections 
A brief investigation on the effect of storage conditions on sectioned aggregoid 
samples was also performed. It is common knowledge that storage of tissue 
sections on slides over a long period of time can have an effect on analyte stability 
and can lead to less-than-optimal results (Goodwin, 2012). Slides are typically 
stored at - 80°C to retain the life-like state of the tissue sections and have shown 
to have no significant degradation on lipids over a 7-month period (Dill et al., 
2011). However, storage of slides at this low temperature can present challenges 
for MSI as the tissue sections are vulnerable to excessive ice formation and 
condensation, leading to potential analyte delocalisation (Russo et al., 2020). 
Efforts to reduce this effect have resulted in methods of desiccation and freeze-
drying techniques to remove excessive moisture before sample preparation for 
MSI analysis (Sjövall, Johansson, & Lausmaa, 2006; Porta Siegel et al., 2018). 
The addition of these steps, however, can add time to the sample preparation 
workflow and is not completely effective. A study conducted by Swales et al., 
(2018) assessed the effects of molecular stability within tissue sections under 
different storage conditions. The study established a novel protocol of desiccating 
sections immediately after thaw mounting onto slides with a nitrogen airflow, then 
subsequently vacuum packing the slides prior to storage at - 80°C.  
A comparison of aggregoid slides stored using the conventional methodology, 
whereby slides are sealed in a slide box container at - 80°C, versus the 
methodology validated by Swales et al., (2018), was carried out. From the image 
analysis, significant delocalisation of the abundant metabolite lactate (m/z 
89.023) was observed in the conventional storage method (Figure 2.11a). High 
intensity levels of lactate were observed in the region immediately surrounding 
the aggregoid sections and with noticeable levels detected across the embedding 
media. The sections that were dried with a nitrogen airflow and vacuum packed 
before storage showed levels of lactate solely within the aggregoid sections, with 
some small artifact areas within the embedding media (Figure 2.11b). With the 
size of the aggregoid sections being considerably smaller than most tissue 
sections, such as animal organs or human biopsies, the delocalisation effects are 
amplified. Thus, after observing a significant difference in the spatial localisation 




method developed by Swales et al., (2018) was the optimum protocol to achieve 
quality aggregoid imaging analysis.  
  
Figure 2.11 DESI-MSI analysis of MG63 aggregoid sections on slides 
prepared and stored in different conditions. Lactate (m/z 89.023) distribution 
displays the delocalisation effects of each storage condition: a) Slides sealed in 
a slide box mailer at - 80°C. b) Slides desiccated with a nitrogen airflow 
immediately after thaw mounting sections, vacuum packed and stored at - 80°C. 




2.4.3 MS analysis 
2.4.3.1 Direct lipid profiling and imaging of aggregoid sections 
using MALDI-MS 
Using the optimised sample handling protocol discussed in section 2.4.2, MS 
analysis of small molecule species was performed. The purpose of this was to 
demonstrate the compatibility of the aggregoid model with MS imaging by 
employing MALDI-MSI for the detection of abundant molecules. An assessment 
of ion suppression effects arising from the HPMC & PVP embedding media was 
performed. In addition, two matrix application methods for imaging were 
investigated for optimum analyte detection.  
Initially, each aggregoid model was profiled by MALDI-MS in positive ion mode. 
Sections from three biological replicates from each aggregoid model were 
analysed and spectra were acquired within the mass range m/z 100-2000. No 
signal interferences were identified from HPMC & PVP confirming the observation 
previously made when profiling the embedding media alone. Numerous peaks, 
specifically within the lipid range m/z 700-850, were identified within the 
aggregoid tissues (Figure 2.12). The most abundant lipid signals detected within 
each aggregoid model included phospholipid species, specifically of the 
phosphatidylcholine (PC) group, PC 32:1 at m/z 732.5, PC 34:1 at m/z 760.6, and 
PC 36:4 at m/z 782.5, identified through putative assignments. PC species are 
highly abundant in cancerous tissue due to their role in energy production and 
signalling for tumour progression (Cheng, Bhujwalla, & Glunde, 2016). It is 








Figure 2.12 MALDI-MS lipid profile a) MG63 b) SAOS-2 and c) HCC827. Mass 
spectra acquired in positive mode; spectra display peaks within the mass range 
m/z 700-850. a) MG63 spectrum annotated with lipid species. Spectra was 
processed by mMass and normalised to the highest peak (α-CHCA, m/z 198.09) 
to obtain the relative intensity. b) SAOS-2 shows high α-CHCA peak at m/z 845.1 




The intensity of the lipid signals varied across the aggregoid models. SAOS-2 
aggregoids showed a slightly lower intensity of PC 32:1, PC 34:1, and PC 36:4. 
However, there was no significant difference between the aggregoid models for 








To determine the distribution of lipid species in the aggregoid models, MALDI-MS 
images were acquired. In order to obtain the images, α-CHCA was deposited 
onto the aggregoid sections using the spray-coat method by the SunCollect™ 
automated sprayer. This is a conventional method of matrix application for MSI 
studies that has been used and investigated for many tissue types (Djidja et al., 
2010; Patel et al., 2015; Huizing et al., 2019). Figure 2.14 shows MALDI-MS 
images of the distribution of lipid species within a HCC827 aggregoid section. 
Abundant lipid species previously identified by profiling were also detected within 
the aggregoid samples, MG63 and SAOS-2 (data not shown). The images were 
acquired at a spatial resolution of 40 µm to enable in-depth data processing of 
the aggregoid to determine phenotypic regions that potentially corresponded to 
the tumour microenvironment. By employing segmentation analysis using 
SCiLS™ Lab software (Bruker Daltonics), whereby similar spectral 
characteristics are grouped together into a segment and are classified into 
phenotypical regions within the tissue. From the segmentation analysis, two 
Figure 2.13 Relative intensities of lipid species PC 32:1 at m/z 732.5, PC 34:1 
at m/z 760.6 and PC 36:4 at m/z 782.5. Biological replicates of each aggregoid 
were profiled (n=3). Each relative intensity was calculated from the most 
abundant α-CHCA peak at m/z 198.09. A one-way ANOVA determined there 
were no significant differences between the aggregoid models for each m/z value 




regions were identified: an outer region and an inner core. From the data of the 
fluorescent images of the aggregoid model in section 2.4.1, it can be assumed 
that these specific areas highlight the proliferative and hypoxic regions.  
 
By identifying the two regions within the aggregoid model, the distribution of lipid 
species could be associated to the outer proliferative region or inner hypoxic core 
(Figure 2.14a). Signals at m/z 732.6 (PC 32:1) and m/z 760.6 (PC 34:1) were 
distributed within the outer region of the aggregoid and therefore are assumed to 
be associated with cellular proliferation. A study analysing human breast cancer 
tissues by MALDI-MSI reported a positive correlation of the PC 32:1 signal with 
the proliferation cellular marker Ki-67 (Hosokawa et al., 2017). This is therefore 
in agreement with the distribution of PC 32:1 in the aggregoid section. In contrast, 
a peak at m/z 826.6 (PC 36:1) was distributed throughout the aggregoid. PC 36:1 
has been recognised as a hypoxia-regulated lipid in another MALDI-MSI breast 
cancer study (Jiang et al., 2015), which would explain its presence within the 
aggregoid core but not in the periphery. This initial imaging analysis demonstrates 
Figure 2.14 MALDI-MS image of a HCC827 aggregoid section. a) spectral 
segmentation identifying two phenotypical regions: an outer and core. The areas 
were outlined on the m/z images to determine distribution of abundant lipid 
species b) m/z 732.6, c) m/z 760.6, d) m/z 782.6, e) m/z 810.6, f) m/z 826.6. 
Images were normalised using TIC. α-CHCA applied by spray-coat method. 




that there are differences in lipid distributions across the tissue and allows two 
distinct regions of the tumour microenvironment to be identified.  
Interestingly, the detection of peaks m/z 782.6 (PC 36:4) and m/z 810.6 (PC 38:4) 
displayed analyte delocalisation into the area surrounding the aggregoid (Figure 
2.14d, e). It is possible that this occurred during the application of matrix via the 
spray-coat method. As the matrix requires a solvent for wetting the tissue during 
spraying, it can influence the migration and diffusion of analytes (Schwartz et al., 
2003). Optimisation of the SunCollect™ spraying parameters such as the flow 
rate, pressure, nozzle movement and height, may help minimise the 
delocalisation effects. As the diffusion was observed in selected species, it 
suggests it is due to the solubility of the analyte with the solvent opposed to the 
spraying parameters.  
Sublimation, an alternative method of matrix application, was evaluated in 
attempt to improve the spatial resolution and minimise delocalisation effects. This 
is a solvent-free matrix application therefore the migration of highly soluble 
molecules should be reduced and has been demonstrated as an efficient method 
for lipid analysis (Hankin, Barkley, & Murphy, 2007; Angel et al., 2012; Ly et al., 
2015). It was recognised in the literature that DHB was reported as the 
conventional matrix used in sublimation for the detection of lipid species. Profiling 
and imaging using DHB on the Synapt G2 mass spectrometer resulted in no 
signal of matrix or analytes (data not shown). Therefore α-CHCA was used to 
achieve analyte signal and for a comparison with the spray-coat method.  
The aggregoid images were acquired with the same parameters of the images of 
sections exposed to the spray-coat method. Figure 2.15 shows the MALDI-MS 
images of a HCC827 aggregoid section for the two analytes that displayed large 
delocalisation effects from the spray-coat matrix application. From the analysis of 
the images there was a significant reduction in analyte diffusion by the 
sublimation technique. However, the overall sensitivity of the lipid species was 
diminished, this was observed across all m/z values and in both MG63 and 
SAOS-2 aggregoid samples (data not shown). The lack of sensitivity also 
impacted determining the true localisation of analytes as background signal had 
similar intensities for the m/z values and could be identified as false signal within 
the aggregoid. This therefore is not ideal for distribution studies. By comparing 




lower signal than the spraying method. This is most likely due to the solvent in 
the matrix required for the spray-coat method which assists the extraction of the 
analyte. It is important to note that the samples from the spray-coat method and 
sublimation cannot be directly compared as the analysis was performed on 
different sections on different days.  
 
An additional step of matrix recrystallisation after sublimation could be performed 
to increase the sensitivity of lipids. The recrystallisation step creates a solvent 
vapour that rehydrates the sublimed samples. Re-introducing a solvent, however, 
could increase analyte diffusion and the recrystallisation step may not have a 
significant effect on the analyte signal, as has been reported (O'Rourke et al., 
2015). Optimisation of this step would require an investigation of solvents and 
incubation times to achieve quality images.  
It was decided that despite the small amount of analyte delocalisation observed, 
the spray-coat method was still the most appropriate technique to detect 
Figure 2.15 MALDI-MS image of a HCC827 aggregoid section achieved 
through matrix sublimation. a) spectral segmentation identifying two regions. 
The areas were outlined on the m/z mages to determine distribution of abundant 
lipid species b) m/z 782.6, c) m/z 810.6. Images normalised using TIC. Scale bar 





abundant lipid species within the 3D cultures. In addition, the ability to 
discriminate peaks within regions of the tumour microenvironment, demonstrated 
the capabilities of MALDI imaging with the aggregoid model. 
2.5 Concluding remarks 
In this chapter, establishment of a novel 3D cell culture in three models of cancer: 
MG63, SAOS-2 and HCC827 was described. The aggregoid model 
demonstrated phenotypic regions similar to the in vivo tumour microenvironment 
through live cell imaging and initial MALDI-MSI analysis. To achieve MS analysis 
and obtain quality images, sample handling techniques were evaluated. The use 
of HPMC & PVP embedding media showed the best preservation of the 
aggregoid tissues, created ease of handling for the imaging workflow and showed 
no spectral interferences. In addition, a new method of storing sectioned samples 
through desiccation and vacuum packaging of slides proved beneficial for 
reducing delocalisation of analytes within the aggregoids. Data obtained from two 
methods of matrix application demonstrated that the spray-coat method gave 
better sensitivity and enabled the detection of abundant lipid species within the 
aggregoid when compared to sublimation. Delocalisation effects were observed 
in some lipid images however, with the spatial resolution capabilities of MALDI-
MSI, it was still possible to discriminate species within the outer region and inner 




CHAPTER 3. THE CHARACTERISATION OF AN 
AGGREGATED 3D CELL CULTURE 





The spatial localisation of a molecule can determine the interplay of biological 
functions and interactions within a tissue. This also enables a greater biological 
understanding of cellular phenotypes, their structural organisation, and 
relationship to the surrounding microenvironment. MSI has therefore had an 
influential impact on cancer research and drug development by providing 
information on the spatial localisation of biomarkers, therapeutics, their active 
metabolites, and cellular responses which have resulted in new patient 
treatments (Swales et al., 2019). 
Depending on the biological sample and the molecules of interest, different MSI 
techniques can be employed for optimum analysis. MALDI is the most widely 
used MSI technique across many applications due to its high spatial resolution 
and speed of acquisition. MALDI-MSI can detect a wide range of analytes in an 
untargeted manner including metabolites, lipids, peptides and proteins (Stoeckli 
et al., 2001; Weaver & Hummon, 2013; Buchberger et al., 2018). DESI-MSI has 
gained considerable attention in drug development studies particularly when 
used in combination with Orbitrap and QTOF type mass analysers for the 
generation of images with high mass specificity for metabolites and small 
molecule therapeutics in tissue samples (Chen et al., 2005; Guenther et al., 
2015). In addition, the minimal sample preparation requirement of this ambient 
ionisation methodology limits experimental variability and reduces the timescale 
of the project (Takats et al., 2004). The requirement for the analysis of trace 
elements or metal isotope distribution in tissues has also seen the development 
of LA-ICP-MSI (Pozebon et al., 2014; Hare et al., 2015), a technique that has 
been applied to the analysis of metal-containing therapeutics such as cisplatin 
(Theiner et al., 2016; Theiner et al., 2017). A major advancement in LA-ICP-MSI 
is the evolution of IMC, a novel multiplex method capable of tissue phenotyping, 
and imaging biological processes through the detection of proteins and protein 
modifications at a high spatial resolution (< 1 µm). IMC has demonstrated high-
dimensional single-cell analysis capabilities on numerous tissue types (Giesen et 
al., 2014; Chang et al., 2017), and directly visualised platinum-based therapeutics 
and the biological responses to treatment (Chang et al., 2016). Furthermore, 
studies have demonstrated the benefits of employing multimodal MSI for the 




Veličković et al., 2018). By using different MSI techniques, a wider detection of a 
diverse range of analytes can be obtained within corresponding samples and 
therefore yield a better understanding of the biological processes that drive 
cellular metabolism. 
As discussed in detail in Chapter 1.4.1, advancements in MSI technology, 
especially the achievable spatial resolution, have enabled analysis of the 
pathophysiology in tumour spheroids. Applications of MALDI-MSI have 
characterised colon carcinoma and breast cancer spheroid models based on their 
endogenous metabolite and protein distributions (Li & Hummon, 2011; Hiraide et 
al., 2016; Tucker et al., 2019). More recently, MALDI-MSI detected similar 
tendencies in metabolic activity between KYSE-30 oesophageal cancer MCTS 
and clinical tissue samples (Zang et al., 2021). In addition, progress in the 
development of the ambient technique, single-probe MSI, was able to spatially 
resolve endogenous metabolites within colon carcinoma MCTS (Tian et al., 
2019). However, limited literature has been reported on the use of multimodal 
MSI techniques with spheroid models. With the aim of characterising the tumour 
aggregoids for the purpose of pre-clinical biopharmaceutical testing, the idea of 
employing multiple MSI modalities was an appealing approach and a novel 
method to obtain a greater amount of detail for an in-depth understanding of the 
tumour metabolism.  
In this study, the application of multimodal MSI was used to characterise the 
HCC827 lung adenocarcinoma aggregoid model. Lung adenocarcinoma is the 
most common subtype of non-small-cell lung cancer (NSCLC) and accounts for 
40% of all lung cancers (Coroller et al., 2015). NSCLC is an epithelial lung cancer 
that effects approximately 1 in 15 people in the UK. Although there have been 
considerable efforts in the development of effective therapeutic treatments, the 
patient outcome for lung adenocarcinoma is still significantly poor with < 15% 
survival rate at 5 years (Molinier et al., 2020). The reasons for this low survival 
rate are due to the aggressiveness of the primary cancer, its heterogeneity 
between patients and the high resistance to drugs, which have hindered the 
development of effective therapies. Therefore, it is necessary to develop accurate 
in vitro models that can closely represent the metabolic behaviour of lung 
adenocarcinoma. Some tumour spheroid models derived from lung cancer cell 




through the analysis of PCR and immunostaining techniques (Endo et al., 2013; 
Ekert et al., 2014; Zhang et al., 2018). Specifically, spheroids of the EGFR mutant 
HCC827 cell line showed a promising tool for studying pharmaceutical response 
to small molecule therapeutics including gefitinib and erlotinib (Jacobi et al., 
2017). Nevertheless, there is a significant gap in the literature relating to the 
molecular profile of lung cancer spheroids by high performance MS techniques, 
let alone with MS imaging methods. Therefore, there is an opportunity to 
demonstrate the capabilities of MSI to analyse the HCC827 aggregoid model in 
an attempt to improve the understanding of lung adenocarcinoma based on the 
spatial information of a broad range of molecules.  
3.2 Aims of the chapter 
The following chapter reports the characterisation of a HCC827 lung 
adenocarcinoma aggregoid model using multiple MSI modalities: DESI, IMC and 
LA-ICP. The aim of this work was to demonstrate how the aggregoid model 
displays similar phenotypical characteristics to typical tumour spheroid cultures, 
and its potential as an in vitro research tool. The objective was to detect and 
identify specific molecular markers through the analysis of metabolites, proteins 
and protein modifications, and elemental compounds by the respective imaging 
platforms to define regions of proliferation and hypoxia, in addition to key 
biological processes that drive cancer metabolism in lung adenocarcinoma. 
Through obtaining a large amount of molecular information with a complementary 
nature, it was possible to determine an in-depth understanding of the biological 
processes within the novel tumour model.  
3.3 Materials and methods 
3.3.1 Materials 
Alginic acid, CaCl2, casein solution, DPX mountant, eosin, EDTA, EtOH, 
haematoxylin, PFA, PVP, sodium citrate, Triton™ X-100 and xylene substitute 
were purchased from Sigma-Aldrich (Gillingham, UK). HPMC was purchased 




3.3.2 3D culture growth  
Culturing of HCC827 lung adenocarcinoma aggregoids is described in Chapter 
2.3.3.  
3.3.3 Tissue preparation 
Aggregoids were prepared for imaging analysis based on the tissue embedding 
and processing protocol described in Chapter 2.3.4. Frozen aggregoids were 
sectioned at 10 μm thickness and thaw-mounted onto polylysine glass slides 
followed by immediate desiccation with N2 and subsequent vacuum packing for 
storage at - 80°C. 
3.3.4 Small molecule imaging 
3.3.4.1 DESI-MSI 
Small molecule imaging by DESI-MSI was performed on a Q-Exactive mass 
spectrometer (Thermo Fisher Inc, Germany) as described in Chapter 2.3.5.3. The 
images were collected in the mass range m/z 80-900 at a spatial resolution of 30 
µm and analysed by SCiLS Lab MVS Premium 3D Version 2020a (Bruker 
Daltonics, Germany) employing RMS normalization.  
3.3.4.2 Discriminatory analysis 
The aggregoid DESI-MSI data file was segregated into regional clusters by 
spatial segmentation processing by which the “core”, “intermediate” and “outer” 
regions were identified (SCiLS, Bruker Daltonics). Discrimination between the 
two regions was achieved by automatically finding m/z values by employing the 
ROC tool to calculate the area under the curve (AUC) value. The raw data file 
from the DESI-MSI was uploaded to METASPACE (https://metaspace2020.eu) 
for metabolite identification of the discriminated m/z values by employing the 
Human Metabolome Database (HMDB) (tolerance < 1 ppm). Metabolic pathways 
were assigned based on the KEGG database by importing identified m/z values 
into Pathos software (http://motif.gla.ac.uk/Pathos/). The ion abundances for the 
m/z values were generated into histograms for comparison between regions 




3.3.5 Single-cell imaging 
3.3.5.1 IMC staining  
Tissues were fixed with 4% PFA for 10 min at RT. Prior to staining, tissues were 
permeabilised with 1x casein solution (v/v) containing 0.1% Triton™ X-100 (5 
min) at RT. Tissues were then incubated with blocking buffer (1x casein solution) 
for 30 min at RT. An antibody cocktail was made containing the appropriate 
dilutions for the antibodies. Tissues were incubated with the antibody cocktail 
overnight at 4˚C. DNA Ir-Intercalator (Fluidigm®) was diluted 1:400 and applied 
to tissues for 30 min at RT. Washes with PBS were performed three times 
between each step, with the last step washed in deionized water for 30 s. Slides 
were left to air dry until analysis.  
3.3.5.2 IMC analysis  
Images were acquired using the Hyperion Imaging System (Fluidigm®), 
rasterizing at 200 Hz and with the laser tuned to fully ablate the tissue without 
etching the glass. TIFF files of each acquisition were then exported for analysis 
in the HALO® image analysis platform (Indica Labs). Using a random forest 
machine learning Tissue Classifier module which was the sole segmentation 
process provided by HALO®, each image was segmented into the background 
and inner, core and outer area of each aggregoid. Using the Hiplex module, the 
DNA intercalator was used to first segment the nucleus of each cell, and a proxy 
for the cytoplasm of each cell defined in a 1 µm radius from the nucleus, before 
thresholds set to define positive cell staining for each marker. Percentage 
positivity of each cell was then defined within the inner and outer region of the 
aggregoid. 
3.3.6 LA-ICP-MS analysis  
Experiments were conducted using a NexION 350X ICPMS (Perkin Elmer, USA) 
coupled to an UP-213 LA system (New Wave Research, USA) with a frequency 
quintupled 213 nm Nd: YAG laser. Laser parameters were optimised to 6 μm spot 
size with, 25 μm/s scan speed, 0.07 Jcm-2 laser fluence, and 20 Hz repetition 
rate. The sample was ablated line by line with 6 μm raster spacing at 1.31 min 
acquisition time. For the ICP-MS instrument there was a direct flow with a rate of 
1.4 L/min. The following settings were used in standard mode with an 18 L/min 




monitored included 24Mg, 66Zn and 63Cu and the instrument was controlled using 
Syngistix software. Data analysis was achieved using Iolite Software on Igor Pro 
(WaveMetrics, USA). 
3.3.7 Histological staining 
After DESI-MSI, aggregoid sections were stained using Mayer’s haematoxylin 
and eosin solutions following a different protocol reported in Chapter 2.3.6. 
Sections were fixed in 4% PFA (10 min) before staining with haematoxylin (1 
min). Tissues were rinsed in tap water before and after submerging in acid 
alcohol. Tissues were subsequently stained with eosin for 30 s prior to washing 
tap water, then subsequently washed in 3 x absolute EtOH (1 min). Finally, 
tissues were submerged in xylene substitute (1 min) twice and mounted using 
DPX mountant. Stained tissues were imaged with Aperio CS2 digital pathology 
scanner (Aperio Tech., Oxford, UK) at 40 x magnification and visualized with 
ImageScope software (Aperio Tech.). 
3.4 Results and discussion 
3.4.1 Metabolite imaging  
One major hallmark of cancer is an altered cellular metabolism to generate a 
sufficient energy source contributing to the initiation, growth, and maintenance of 
tumours (Hanahan & Weinberg, 2011). In the present study, the metabolic profile 
within the lung adenocarcinoma aggregoid model was investigated by employing 
a DESI Thermo Q-Exactive MSI to classify regions of a necrotic/hypoxic core and 
a viable outer area. Initial processing of the aggregoid images was conducted to 
spatially segment the data. These segments are then classified into regions which 
represent phenotypical features of a tissue. The aggregoid data was segmented 
into three main regions that depicted a gradient-like phenotype: a core 
(corresponding to the blue cluster), an annular zone (corresponding to the yellow 
cluster), and an outer region (corresponding to the red cluster) (Figure 3.1b, c). 
From the 2- and 3-dimensional images the clear discrimination of the regional 
clusters corresponded to the histology stain of the same section after MSI 
analysis (Figure 3.1a). From this, the spectra from each region were extracted to 
distinguish the distributions of key metabolites within the aggregoid. For the 




zones were the focus when observing the distribution of species, as the 
intermediate region was anticipated to be non-discriminatory.  
 
Figure 3.1 Spatial segmentation of HCC827 aggregoid model from 
metabolite data. a) H&E stain of central aggregoid section. Black dotted lines 
were manually included to show estimate regions of different cellular morphology 
that corresponds similar to segmentation image. Scale bar 400 µm. b) Spatial 
segmentation of central aggregoid section identified three clustering regions that 
correspond to the hypoxia gradient: Core (blue cluster), intermediate/annual 
region (yellow cluster), and the outer region (red cluster)c) Realigned 3D 




Within the aggregoid model, key metabolites involved in cancer metabolism were 
identified with a mass error of < 0.5 ppm (Table 3.1). A major metabolic substrate 
that is regulated by the tumour microenvironment is lactate. Within the aggregoid, 
a high intensity of lactate (m/z 89.02440) was distributed throughout indicating 
the presence of glycolysis rather than oxidative phosphorylation (Figure 3.3b). An 
elevated expression of lactate in the core of the aggregoid implies the presence 
of hypoxia. In anaerobic conditions, the rate of glycolysis increases due to 
insufficient oxygen levels to promote tumour survival. In cancer cells, lactate is 
generated irrespective of the hypoxic or aerobic conditions to act as a primary 
metabolic fuel. An increase in the expression of lactate converted from glucose 
via the glycolysis reaction is thought to be the predominant pathway to promote 
tumour survival and growth rather than following oxidative metabolism, this is 
otherwise known as the Warburg effect (Warburg, 1956). It has also been recently 
hypothesised that the induced glycolysis reaction by cancer cells can also 
metabolically support adjacent cancer cells to further promote ATP production, 
increase proliferation and reduced cell death, also known as the reverse Warburg 
effect (Wilde et al., 2017). Hence, the high intensity levels observed in the 
aggregoid model could be explained.  
A similar distribution of a glycolysis intermediate, pyruvate (m/z 87.00880) was 
also observed (Figure 3.3a). The localisation of pyruvate across the aggregoid, 
with elevated levels in the core validates the assumption of an increased rate of 
glycolysis in response to hypoxia. A key protein associated with increased lactate 
production in low oxygen levels is hypoxia-inducible factor alpha (HIF-1α), which 
is stabilised in a hypoxic environment due to the lack of oxygen and therefore a 
direct marker of hypoxia. HIF-1α is responsible for regulating the expression of 
numerous genes under hypoxic conditions. Specifically, HIF-1α promotes the 
transportation of glucose into the cell by increasing the expression of the glucose 
transporter 1 (Glut1) (Hayashi et al., 2004). Additionally, HIF-1α promotes a high 
glycolysis rate by inducing both pyruvate dehydrogenase kinase (PDK) and 
lactate dehydrogenase A (LDH-A), to prevent the metabolism of pyruvate into 
acetyl-CoA to feed the tricarboxylic acid (TCA) cycle, and rather by favouring the 













Pyruvate 87.00880 0.4 0.240 
Lactate 89.02440 0.2 0.138 
Succinate 117.01940 0.9 0.640 
Malate 133.01430 0.4 0.700 
Glutamine 145.06190 0.2 0.114 
Glutamate 146.04590 0.1 0.396 
Citrate 191.01980 0.4 0.903 
FA 18:2 279.23280 0.7 0.639 
FA 20:4 303.23300 0.2 0.564 
Glutathione 
(GSH) 
306.07650 0.1 0.991 
Table 3.1 Assignments and errors for [M-H]- adducts, and discriminatory 
analysis of metabolites between the core and outer from SCiLS Lab 
software. Mass accuracy of metabolites with the measured m/z values and 
calculated m/z values (< 2.5 ppm). AUC determined by ROC analysis, represents 
the discrimination power of m/z signal. A perfect discrimination would yield an 
AUC equal to 0 or 1. An AUC closer to 0.5 defines the m/z value less suitable as 
a univariate criterion. In this case an AUC equal to 0 discriminates the m/z value 







Figure 3.2 Average mean spectra of metabolites within the aggregoid regions extracted from SCiLS Lab software. a) 
Combined spectra of core, intermediate and outer region classified from bisecting k-means segmentation analysis. b) Core spectrum. 
c) Intermediate spectrum. d) Outer spectrum. Relative intensity of metabolites for each aggregoid region: e) Lactate, m/z 89.02440; 




The image analysis identified an increased distribution of glutamine (m/z 
145.06190) within the core of the aggregoid (Figure 3.3c). Glutamine is 
considered a major bioenergetic substrate that sources the TCA cycle by its 
metabolism to the intermediate α-ketoglutarate achieved by the glutaminolysis 
pathway (Fan et al., 2013). The TCA cycle is described as the epicentre of cell 
metabolism due to the extensive supply of metabolic substrates that are utilised 
for energy production (Martínez-Reyes & Chandel, 2020). The localisation of 
glutamine within the core suggests the cells within the hypoxic environment are 
substituting for the lack of pyruvate sourcing the TCA cycle. Interestingly, 
glutamate (m/z 146.04590), an intermediate of glutaminolysis, is distributed 
towards the outer region of the aggregoid (Figure 3.3d). The TCA cycle is heavily 
utilised by proliferating cells for growth, the suppression of glutamine conversion 
to glutamate in the core therefore implies the presence of necrosis. Several 
spheroid studies have reported that the increase in diameter decreases the cell 
viability due to the reduced levels of oxygen and nutrients, thus the spheroid 
eventually develops an inner necrotic core (Curcio et al., 2007; Grimes et al., 
2014). By examining the gene expression profiles, Däster et al., (2017) identified 
the development of a necrotic region in multicellular spheroids larger than 500 
µm. Since the diameter of the aggregoid model is ~ 1 mm the presence of an 
inner necrotic core is highly likely. Fluorescent staining of the aggregoid with 
propidium iodide, which only enters dead cells, confirms the presence of this 
necrotic region (Chapter 2.4.1, Figure 2.7) and additionally shows the large 
asymmetric hypoxic area opposed to the simple radial gradient in a typical 
spheroid model, which could explain the asymmetric metabolite distribution in 
Figure 3.3.  
In contrast, the distributions of the major TCA cycle intermediates citrate (m/z 
191.01980), malate (m/z 133.01430), and succinate (m/z 117.01940) were 
observed solely located with more annular features (Figure 3.3e-g), implying a 
surplus of oxygen and nutrients surrounding the aggregoid and the absence of 
cell proliferation in the core. By identifying the significant metabolites that drive 
cancer metabolism, it was possible to map the ion density images onto their 
corresponding pathways to associate the metabolic activity with specific regions 









Figure 3.3 Distribution of metabolites regulating cancer growth and survival within the HCC827 aggregoid central section. 
Ion density maps of metabolites outlining the core and the outer area on the image. Mean intensity plotted on bar graph against the 
core and outer regions (n=1). Scale bar 200 µm. Intermediates of the glycolysis reaction: a) Pyruvate, m/z 87.00880; b) Lactate, m/z 
89.02440. Glutaminolysis reaction: c) Glutamine, m/z 145.06190; d) Glutamate, m/z 146.04590. TCA cycle: e) Citrate, m/z 191.01980 








Figure 3.4 Mapping metabolites to biological pathways defined areas of tumour metabolism. The glycolysis reaction is highly 
expressed across the whole aggregoid section demonstrating the Warburg effect. Conversion of glutamine to glutamate is showing 
reduced expression in the core. The TCA intermediates present within the proliferative outer region. Intermediates acetyl-CoA, α-




Proliferating cancer cells utilise fatty acids as they have essential roles as 
structural components of the membrane matrix, secondary messengers for 
signalling pathways, and sources for energy production (Beloribi-Djefaflia, 
Vasseur, & Guillaumond, 2016). Here fatty acid distribution was imaged and 
identified within the aggregoid with a mass error ≤ 0.7 ppm (Table 3.1). The image 
analysis demonstrated the presence of two polyunsaturated fatty acids, FA 18:2 
e.g., linoleic acid at m/z 279.23280, and FA 20:4 e.g., arachidonic acid at m/z 
303.23300 within the proliferative region (Figure 3.5a, b). Linoleic acid is a 
polyunsaturated fatty acid which is converted to arachidonic acid, a major 
metabolite involved in cellular proliferation and survival in cancer cells from which 
prostaglandins are synthesised via the cyclooxygenase (COX) pathway (Ding, 
Tong, & Adrian, 2000; Borin et al., 2017). The accumulation of FA 20:4 
(arachidonic acid) within the outer region of the aggregoid coincides with the 
distribution within the proliferative region of patient cancer tissue-originated 
spheroids of colorectal cancer (Hiraide et al., 2016). It has also been reported 
that the metabolism of arachidonic acid is involved in the promotion of 
angiogenesis, cell invasion and metastasis by an alternative pathway, 
lipoxygenase (LOX) (Nie et al., 2003). However, MS/MS profiling is required to 
confirm the identity of these fatty acids.  
The metabolite glutathione (GSH) (m/z 306.07650) displayed a similar 
localisation to the fatty acids described with elevated levels surrounding the 
hotspot within the outer region (Figure 3.5c). GSH protects cells against reactive 
oxygen species (ROS), a normal product from cellular metabolism, through the 
oxidation of its sulfhydryl group to form glutathione disulphide (GSSG) 
(Armstrong et al., 2002). The co-localisation of GSH with the fatty acids suggests 
an area of high metabolic activity. Interestingly, there was a lack of GSH in the 
core of the aggregoid, which is heavily associated with oxidative stress (Figure 
3.5c). In hypoxia, the expression of antioxidant genes including genes involved 
in the glutathione biosynthesis are induced to allow cells to regulate ROS. 
However, it has been shown that in presence of excess ROS, GSH is depleted 
which leads to the activation of apoptosis and other forms of cell death such as 
necrosis and ferroptosis (Kipp et al., 2017). The presence of GSH (or the lack of) 
can therefore be a potential measure of oxidative stress within the aggregoid 




understanding of a realistic tumour microenvironment and the true metabolic 
behaviour of an in vivo cancer, which  can then be utilised in applications of drug 
development.  
  
Figure 3.5 Fatty acid detection defines proliferative activity. Ion density maps 
of metabolites outlining the core and the outer area on the image. Mean intensity 
plotted on bar graph against the core and outer regions. Scale bar 200 µm. a) FA 




3.4.2 Single cell tumour characterisation 
IMC is a novel, multiplex imaging platform capable of high-dimensional tissue 
phenotyping and the detection of signalling activities by the analysis of protein 
and protein modification markers at single-cell resolution (1 µm). The analysis of 
proteins within tissues can define essential cellular functions such as 
proliferation, metabolism, gene expression, organisation, and apoptosis 
(Downward, 2001). Modifications to such proteins can manipulate their spatial 
distribution, composition, and their function (Hoffman, Sniatynaski, & Kast, 2008), 
which can contribute to tumour progression. In the present study, IMC was 
employed for single-cell phenotyping of the HCC827 aggregoid model for an in-
depth characterisation of the tumour microenvironment. Proteomic markers 
relevant to lung adenocarcinoma were selected to identify key components of 
cellular organisations, functions, and signalling.  
Due to the complex heterogeneity of cancer tissues, morphological and structural 
components provide a navigational aid to determine the initial tissue organisation 
(Chang et al., 2017). In this study, such cellular elements included DNA and 
epithelial tumour markers. The DNA intercalator selected was a generic marker, 
selected to identify the size and shape of the nucleus in individual cells within the 
aggregoid (Figure 3.7a). This data was used to spatially segment the image to 







Tumour markers observed within the HCC827 aggregoid were epithelial cadherin 
(E-cadherin), and pan-cytokeratin (Pan-CK). The image analysis of both markers 
identified similar distributions with elevated expression levels within the outer 
region of the aggregoid (Figure 3.7b, c). In epithelial cells, E-cadherin and 
cytokeratin are responsible for mediating cell-cell adhesion and mechanical 
support via intermediate filaments, respectively. The absence of these markers 
within the core is possibly due to the breakdown of cell interactions as a result of 
necrosis. Simiantonaki et al., (2007) reported a similar correlation with cellular 
necrosis and a lack of E-cadherin distribution in the core of HT-29 colorectal 
carcinoma spheroids via immunohistochemistry. Interestingly, the expression of 
both E-cadherin and cytokeratin can determine epithelial-mesenchymal transition 
(EMT), a process which promotes tumour progression and metastasis. In EMT, 
both epithelial markers are either downregulated or lost coupled with gain of 
Figure 3.6 IMC classification and spatial bisecting k-means segmentation 
using HALO™ software. a) Regions of core, outer and background were 
classified from the IMC image analysis of aggregoid. Classification of aggregoid 
in reference to Glut1 distribution which is localised within the core. b) Spatial 
segmentation of each protein marker to determine percentage positive cells. 
From top left to bottom right: Pan-CK, E-Cadherin, Glut1, Ki-67, TNC, pS6, 




mesenchymal markers, N-cadherin and vimentin (Lamouille, Xu, & Derynck, 
2014). Studies have demonstrated that EMT signalling can be induced by HIF-
1α in tumour spheroids (Lehmann et al., 2017; Essid, Chambard, & Elgaaïed, 
2018). Unfortunately, N-cadherin was not a validated marker at the time the study 
was conducted, however, vimentin was included in the antibody panel, yet it was 
not detected within the aggregoid model. This suggests there is no mesenchymal 
phenotype present within the core and therefore the lack of E-cadherin is most 
likely due to necrosis. However, as necrosis and EMT have a crucial part in 
tumour progression, future tumour aggregoid analysis of other epithelial cancer 
types with IMC has potential for applications in drug development and resistance.  
Alternatively, Tenascin C (TNC) is an ECM marker considered an active 
component of cancer. Relatively high expression of the marker was localised 
within the necrotic core of the aggregoid (Figure 3.7d). TNC is thought to promote 
survival and invasion by regulating the expression of proangiogenic factors such 
as vascular endothelial growth factor (VEGF) modulated by HIF-1α (Wang et al., 
2018). Additionally, TNC has been associated with inducing EMT changes with 
the downregulation of E-cadherin (Takahashi et al., 2013). Thus, the TNC marker 
has an inverse correlation with the distribution of the E-cadherin marker (Figure 
3.8).  
To distinguish regions of the tumour microenvironment, and to complement the 
findings from the metabolite distributions, specific markers of proliferation and 
hypoxia were included. Ki-67 is a cellular marker, present in all stages of the cell 
cycle except for early G1 and G0 quiescent phases. The high expression of Ki-67 
present within the outer region of the aggregoid therefore implies an active 
proliferative zone (Figure 3.7e). In addition, phosphorylated Histone H3 (pHH3) 
marker was identified in only a few specific cells, yet still located primarily in the 
outer region of the aggregoid (Figure 3.7f). HH3 is a nuclear core protein, and 
when phosphorylated at serine-10, is specifically involved in mitotic chromatin 
condensation (Kim et al., 2017). Hence, the expression of pHH3 can identify cells 
undergoing mitosis. It can be concluded that the cells within the outer region of 
the aggregoid are highly proliferative implying a non-hypoxic area compared to 
the cells within the core, thus tightly corresponding to the distributions of the TCA 








Figure 3.7 Representative IMC images of biological processes at subcellular detail in the HCC827 aggregoid model. Scale 
bar 100 µm. Percentage positive cells plotted on bar graph against the core and outer regions. a) DNA intercalator identified individual 
cells within the aggregoid section. Epithelial tumour markers: b) Pan-CK, c) E-Cadherin, and d) Tenascin C (TNC). Proliferation 




On the other hand, Glut1 (glucose transporter 1) is a proxy hypoxia marker. 
Elevated levels of the marker were observed solely within the necrotic core of the 
aggregoid (Figure 3.7g). Glut1 is a hypoxia responsive gene, which is 
upregulated by HIF-1α to maintain an adequate energy supply in response to 
reduced oxidative phosphorylation (Ouiddir et al., 1999). High levels of Glut1 
complement the high lactate expression from the metabolite analysis, implying 
an increase in glucose transport into cells for lactate production via glycolysis. 
From the overlay image analysis, an inverse distribution of Ki-67 and Glut1 can 
distinguish the two major regions of the tumour microenvironment: proliferative 
outer, and hypoxic core (Figure 3.8). It is noted that some studies have 
challenged GLUT1 as a reliable marker for hypoxia (Sørensen et al., 2005) and 
therefore additional staining using pimonidazole, a routinely used hypoxia marker 
would be an appropriate validation method to confirm these findings. 
Phosphorylated S6 ribosomal protein (pS6), an active marker for mTOR 
signalling for cancer growth and metabolism associated with the PI3K/Akt/mTOR 
pathway, is also regulated by hypoxia. In contrast, the expression of pS6 was 
observed primarily within the outer region of the aggregoid, with high levels within 
specific cells (Figure 3.7h). In hypoxic conditions, the activity of the 
PI3K/Akt/mTOR pathway is reduced, negatively impacting on the pS6 expression 
(Schneider, Younis, & Gutkind, 2008). Both Glut1 and pS6 markers therefore 
identified metabolic signalling within the aggregoid that is affected by hypoxia.  
Alternatively, phosphorylated Histone H2AX (γH2AX) is a marker for DNA 
damage and stress and can be indicative of cellular apoptosis (Rogakou Emmy 
et al., 2000). This therefore explains the accumulation of γH2AX within the 
hypoxic core of the aggregoid (Figure 3.7i). From the image analysis however, 
high expression levels of γH2AX were also observed within the proliferative outer 
region (Figure 3.7i). Due to oxidative stress, induced by natural ROS from 
metabolic activity, proliferative cells are subjected to constant DNA damage 
(Tanaka et al., 2006). Therefore, the distribution of γH2AX throughout the 
aggregoid is supported. In future, γH2AX marker has potential to be used for the 
detection of cellular stress within the aggregoid, with elevated levels when subject 








Figure 3.8 Structural organisation of biological processes for in-depth phenotyping of HCC827 aggregoid model. a) Optical 
image of aggregoid prior to staining with antibodies and image analysis. Scale bar 100 µm. Overlay of IMC markers displays 
representative images of b) Epithelial tumour markers: E-cadherin, TNC; c) Proliferation and hypoxia: Ki-67 and Glut1; d) Overlay 




This is the first report on the analysis of 3D cell culture models with IMC. The 
usage of IMC to characterize the HCC827 aggregoid model based on 
morphological and structural markers specific for epithelial tumour, growth and 
proliferation, and the hypoxia gradient of the tumour microenvironment has been 
demonstrated (Figure 3.8). Furthermore, with the single-cellular resolution 
capabilities of IMC it was possible to distinguish individual cells and the matrix 
surrounding based on the cellular localisation of such protein markers.  
3.4.3 Endogenous elemental analysis 
Deficiencies, defects, and accumulation of metal compounds within cells are 
known to be a hallmark of cancer and disease. Within tissues, metals have a 
heterogeneous distribution whereby high concentrations can be associated with 
high metabolic activity (Hare et al., 2015). Therefore, visualising the metal 
composition within a tissue can provide essential information to understanding 
their key functions in different environments, such as hypoxia or nutrient rich 
areas. The composition of abundant metal isotopes 24Mg, 66Zn and 63Cu were 
selected to analyse within the HCC827 aggregoid model. To measure the 
abundance of low mass range metal ions at high sensitivity LA-ICP-MSI was 
employed.  
In the cell, Mg and Zn are essential components to drive cell growth, division, and 
proliferation (Vernon, 1988; MacDonald, 2000). Observations from the LA-ICP-
MSI analysis localised both elements of high expression solely within the outer 
proliferative region of the aggregoid (Figure 3.9). Similar to Ki-67, Mg is involved 
in the cell cycle except for early G1 and G0 quiescent phases (Walker, 1986; Wolf 
& Trapani, 2008). The presence of Mg parallels with molecular control of cell 
proliferation and differentiation thus, the absence of Mg could be indicative of a 
non-proliferative region, or necrotic core. Zn on the other hand, has been directly 
linked to the proteasomal degradation of HIF-1α under normoxic conditions 
through the addition of excess Zn (Nardinocchi et al., 2010). Whether 
endogenous Zn has the same impact on HIF-1α is unclear, however it is possible 
that the absence of Zn within the aggregoid core is associated with the activation 
of HIF-1α in hypoxia; whereby Zn is possibly exported to the proliferative zone 




In contrast, the Cu levels in the aggregoid were elevated within the necrotic core 
(Figure 3.9). Increasing evidence has linked Cu with HIF-1α via the hypoxia 
signalling pathway as a response to oxidative stress to regulate Cu-dependent 
genes (Wenke Feng et al., 2009; Wu, Zhang, & Kang, 2019). These include 
BNIP3, a cell death factor that induces necrosis (Sowter et al., 2001), and VEGF 
which stimulates angiogenesis (Büchler et al., 2003). Both of which are 
stimulating factors in hypoxia. In agreement with this, VEGF is also known to be 
regulated by TNC, which from the IMC analysis was also localised within the core 
of the aggregoid (Figure 3.9). In addition, HIF-1α accordingly promotes the 
upregulation of the Cu-efflux transporter, ATP7A (Zimnicka et al., 2014), which 
tightly regulates levels of free Cu ions to prevent the formation of ROS. Thus, 
elevated Cu concentrations could imply an active export of free Cu ions into the 
ECM, accumulating in a less dense area of the aggregoid. As necrotic cells are 













Figure 3.9 Elemental distributions within HCC827 aggregoid sections obtained using LA-ICP-MS. a) Optical image taken before 
acquisition; necrotic region outlined by red dotted line. Scale bar 50 µm. Elemental maps of b) 24Mg, c) 66Zn and d) 63Cu within the 




At present, there is only a limited amount of literature on the study of endogenous 
elemental compounds in 3D cultures by LA-ICP-MSI. Yet the analysis of tumour 
spheroids with this technique has had some interest regarding the localisation of 
platinum-based therapeutics and hypoxia-responsive drugs  (Theiner et al., 2016; 
O'Neill et al., 2017). Theiner et al., (2017) differentiated morphological 
characteristics of a necrotic core, quiescent zone, and proliferative outer region 
through the analysis of platinum accumulation within HCT116 colon cancer 
spheroids. However, the elemental compositions in this study are consistent with 
literature reported in studies employing X-ray fluorescence microscopy (XFM), an 
alternative analytical technique capable of elemental analysis at high sensitivity. 
Zhang et al., (2012) reported similar distributions of Zn and Cu within DLD-1 colon 
carcinoma spheroids implying the accumulation of such compounds highlight 
regions of a proliferative outer zone and a necrotic core, respectively. 
3.5 Concluding remarks 
Advanced molecular imaging techniques have been applied for an in-depth 
phenotyping of a novel aggregated tumour model. This is the first example of an 
IMC application with a 3D cell culture model. Combining the IMC data with 
molecular information from DESI- and LA-ICP- MSI, a detailed characterisation 
of the tumour microenvironment within the aggregoid was possible. Distinct 
regions of a necrotic core and a proliferative outer were distinguished by each 
method. The localisation of metabolites including lactate, glutamine and citrate 
within the aggregoid highlighted the metabolic activity in relation to hypoxia. 
Mapping the ion density images onto the central biological pathways enabled a 
clearer understanding of the metabolite behaviour within the tumour 
microenvironment. IMC enabled single-cell phenotyping of protein signalling 
activity. The protein expression complemented the metabolite data including the 
expression of the Glut1 with elevated lactate levels in the core. In addition, the 
endogenous elemental compositions of Mg, Zn and Cu corresponded to the 
protein information and further validated the presence of heterogenous regions 
within the aggregoid model . This study improved the understanding of the 
molecular activity within the HCC827 3D cell culture tumour microenvironment. 









CHAPTER 4. CHARACTERISATION AND 
COMPARISON OF 
OSTEOSARCOMA AGGREGATED 
TUMOUR MODELS BY 





OS is the most common primary bone malignancy and largely effects adolescents 
and young adults, with 60% of patients under the age of 25. Bone sarcomas are 
classified as a rare type of cancer with OS having an estimated incidence of 
approximately 7 in 100,000 persons, with 30,000 new cases a year (Ferguson & 
Turner, 2018). Despite improvements in treatment therapies over the recent 
years, the survival rate of bone sarcomas has remained unchanged with < 50% 
at 5 years (Stiller et al., 2018). The aggressive tumoral behaviour of OS has 
challenged the development of an effective therapeutic treatment. Even with 
complete surgical resection of the primary tumour, approximately 90% of OS 
patients develop metastasis such as of the lung or breast (Ren et al., 2015). 
Hence, there is still a great need for studying the molecular activity within the 
sarcoma in order to understand the metastatic behaviour and improve treatment 
therapies.  
There are multiple cell models of OS described in vitro that express the specific 
genetic alterations of the sarcoma. The most common OS cell lines include the 
epithelial-like cells, SAOS-2 and the fibroblastic-like cells, MG63, both with a 
deficiency mutation in the tumour suppressor p53 gene. However, significant 
differences in the phenotypes of these cell lines have contributed to inconsistent 
results across studies. The SAOS-2 cells express a mature osteoblast phenotype 
with a high level of alkaline phosphatase (ALP) activity (Murray et al., 1987); a 
gene associated with bone mineralisation. In contrast, the MG63 cell line 
represent the immature osteoblast phenotype with low ALP activity and matrix 
differentiation potential (Scheven, Marshall, & Aspden, 2002).  
With differences in phenotypes, the expression of endogenous molecules would 
also be expected to vary, and thus impact the responses to treatment. Multiple 
studies have previously characterised the OS cell lines by DNA profiling and the 
expression of proteins through conventional methods, such as PCR analysis and 
immunostaining. For example, the detection of metastatic-related OS gene 
expressions, such as PHLDA1 enabled the categorisation of 18 OS cell lines from 
high to low metastatic potential, marking SAOS-2 and MG63 as relatively low 
metastatic cell lines (Ren et al., 2015). In addition, heterogenous expressions of 
ECM proteins such as collagen I and III, and MMP-9 were used to differentiated 




approaches have also been employed in metabolomics studies of both OS cell 
lines (Ren et al., 2017; Wright Muelas et al., 2020). The limitations of these 
studies, however, is the characterisation of the OS cell lines in 2D, which is not 
representative of in vivo behaviour. For instance, a significant change in the 
metabolite levels of lactate and alanine between 2D and 3D MG63 cultures was 
detected by high resolution nuclear magnetic resonance (NMR) (Santini et al., 
2004). Additionally, alterations in the proteome between monolayer and spheroid 
cultures of canine OS cells by differential gel electrophoresis (DIGE) MALDI-MS 
has also been reported (Gebhard et al., 2018). However, the characterisation of 
OS 3D culture models has still been limited to PCR analysis or immunostaining 
techniques, which leads to loss of spatial information and/or requires target-
specific analysis (Wang, Park, & Lin, 2009; Gebhard, Gabriel, & Walter, 2015; 
Bassi et al., 2020). 
In order to understand the wide molecular activity that drives OS and captures 
the heterogeneity of the tissue, a comprehensive analysis strategy is required. 
Palubeckaitė et al., (2019) previously defined apoptotic and necrotic regions 
within the SAOS-2 spheroid aggregate model by detecting heterogeneous 
distributions of endogenous metabolites using MALD-MSI. As described in 
Chapter 3, employing multimodal MSI techniques demonstrated how obtaining a 
large amount of molecular information with a complementary nature can enhance 
the understanding of the biological processes within a tissue. The detection of 
metabolites, proteins and metals determined the interplay between molecules 
and established key pathways that defined the HCC827 lung adenocarcinoma 
aggregoid model (Flint et al., 2020). A similar approach could therefore give a 
valuable insight into 3D tumour aggregoid models of OS, providing 
comprehensive information of biochemical pathways that influence the cancer 
pathogenesis. In addition to this, a recent paper demonstrated the combination 
of oesophageal cancer MCTS and clinical tissue with MALDI-MSI as an approach 
to determine the metabolic relevance of the models to in vivo (Zang et al., 2021). 
With that in mind, detailed molecular characterisation of in vitro OS models and 
clinical tissue would improve the understanding of cancer metabolism within the 




4.2 Aims of chapter 
In this chapter, multiple MSI modalities were employed to characterise two OS 
aggregoid models, MG63 and SAOS-2, for the purposes of developing a potential 
in vitro methodology for cancer research and drug development. Firstly, the 
metabolic profiles of the models were determined by DESI-MSI and compared 
against the established tumour microenvironment of the HCC827 lung 
adenocarcinoma aggregoid. An investigation into the relevance of the OS 
aggregoid models with clinical OS patient samples was then conducted to 
determine the similarities in the metabolite levels that influenced tumour 
behaviour and potentially detect metastatic activity. In addition, IMC and LA-ICP-
MSI were utilised to further establish the phenotypical characteristics of the 
tumour microenvironments of both aggregoid models through protein markers 
and metal compositions, respectively.  
4.3 Materials and methods 
4.3.1 Materials 
Alginic acid, CaCl2, casein solution, DPX mountant, eosin, EDTA, EtOH, 
haematoxylin, NaCl, PFA, PVP, sodium citrate, Triton™ X-100 and xylene 
substitute were purchased from Sigma-Aldrich (Gillingham, UK). HPMC was 
purchased from Alfa Aesar (Thermo Fisher Scientific, Heysham, UK). 
4.3.2 3D cell culture growth 
OS cell lines MG63 and SAOS-2 were cultured into 3D aggregated tumour 
models as described in Chapter 2.3.3.  
4.3.3 Sample handling 
Samples were prepared and processed following the protocol described in 
Chapter 2.3.4.  
4.3.4 Tissue sample collection and handling 
Two samples of human bone tissue biopsies which had been previously classified 
by conventional pathology as osteoblastic osteosarcoma were obtained from the 
Children’s Cancer and Leukemia Group Tissue Bank. The samples were 
provided following ethical approval of this study (Project Reference 2017 BS 06). 




Biosystems, U.K.). Sections were cut at 10 µm thickness and n=3 sections of 
each sample from different depths of the tissues were thaw mounted onto 
positively charged X-tra® adhesive slides (Leica Biosystems, U.K.).  
4.3.5 Small molecule analysis 
Metabolite and lipid images were obtained by DESI-MSI on a Thermo Fisher Q-
Exactive mass spectrometer (Thermo Fisher Inc, Germany) at 40 µm spatial 
resolution as reported in Chapter 2.3.5.3. The DESI-MSI data was analysed by 
SCiLS™ Lab MVS Premium 3D version 2020a (Bruker Daltonics, Germany) RMS 
normalization. Data was discriminated following as described in Chapter 3.3.4.2. 
Metabolites and biological pathways were identified by METASPACE 
(https://metaspace2020.eu). The peak list from each aggregoid section was 
exported into .csv files and grouped together. The data was then imported into 
MetaboAnalyst 5.0 (Xia et al., 2009) to conduct multivariate analysis. PCA and 
PLS-DA were performed on the selected sample groups for each aggregoid 
model. The samples were normalised by the median, before applying log 
transformation and Pareto scaling on the data. The data was displayed in scores 
plots with 95% confidence regions to determine variance between groups. 
Loadings plots displayed the m/z values that profiled specific groups. The ion 
abundances for the m/z values were generated into histograms for comparison 
between regions using GraphPad™ Prism® software (La Jolla, USA). 
4.3.6 Single-cell analysis 
Proteins and protein modifications were detected by IMC analysis as performed 
and described in Chapter 3.3.5. All samples were prepared for staining and 
incubated with a cocktail of antibodies specific for markers relevant to 
osteosarcoma overnight at 4°C. Images were acquired on the Hyperion Imaging 
System (Fluidigm®) with the laser tuned to fully ablate the tissue. The imaging 
data was analysed using the MCD Viewer v1.0.560.2 software (Fluidgim®). Due 
to unavailability of the HALO® image analysis software (Indica Labs) during this 
study, the images were not spatially segmented, and therefore the percentage 
positivity of markers could not be quantified.  
4.3.7 Elemental analysis 
Metals within the aggregoid samples were detected using the method based on 




μm spot size with, 25 μm/s scan speed, 0.07 Jcm-2 laser fluence, and 20 Hz 
repetition rate. Samples were ablated line by line with 6 μm raster spacing. 
Isotopes monitored were 24Mg, 66Zn and 63Cu and the instrument was controlled 
using Syngistix software. Data analysis was achieved using Iolite Software on 
Igor Pro (WaveMetrics, USA). 
4.3.8 Histology analysis 
Aggregoid samples were stained with Haematoxylin and eosin as reported in 
Chapter 3.3.7. 
4.4 Results and discussion 
4.4.1 Metabolite imaging 
4.4.1.1 Aggregoid phenotyping 
To determine the metabolic profiles of the two OS aggregoid models, a 
comparative analysis was performed by employing DESI-MSI. In this study, the 
metabolic activity within three biological replicates of the MG63 and SAOS-2 
aggregoid models were determined. Metabolite data of the lung adenocarcinoma 
model was also included as a reference to understand the phenotypes within the 
OS models.  
Initially, the data was spatially segmented to determine phenotypical regions 
within the aggregoid sections. From the segmentation analysis, different 
phenotypical regions in each model were observed (Figure 4.1). As reported in 
Chapter 3.4.1, the segmented image of the HCC827 aggregoid model comprised 
three regions: a distinctive inner core, an annular zone and an outer region, which 
were also observable in the histological image. The segmentation of the MG63 
model showed a similar pattern, where a core, two inner annular regions and a 
periphery were observable in the segmented MSI data. From the histology 
however, the MG63 model differed from the HCC827 aggregoid in that the cells 
were tightly compact throughout the section and although some condensing of 
DNA was observed, no significant apoptotic bodies were identified. This suggests 
that the core cluster within the MG63 aggregoid does not necessarily correspond 
to an obvious region of cellular stress due to hypoxia. Yet the segmentation 
analysis was still able to identify changes in metabolite activity effected by the 




The SAOS-2 model showed significantly different features to the HCC827 and 
MG63 models in the segmentation analysis (Figure 4.1). Although a core was 
identified, the clustering pattern showed a lot of heterogeneity across the section, 
which was similar in each SAOS-2 sample (n = 3). Examination of the histological 
data indicated that a lot of fracturing was present. This has been noted across 
the SAOS-2 aggregoid samples throughout the experimental work conducted 
within this thesis and is potentially due to the nature of culturing the SAOS-2 cell 
line. A previous study reported a heterogenous capability to form 3D cultures 
between OS cell lines and noted that the SAOS-2 cells formed irregular 
spheroids, whereas the MG63 formed more spherical spheroids (Rimann et al., 
2014). Interestingly, from the histology data in the paper the SAOS-2 spheroids 
displayed a compact cellular distribution. However, the spheroids were 
significantly smaller (≤ 200 µm diameter) in comparison to the aggregoid model 
reported here (~ 1 mm diameter). The histology data in this study showed that a 
large area of apoptotic and necrotic activity within the SAOS-2 aggregoid was 
present. This is likely impacting the stability of the aggregoids. As this has been 
observed throughout the SAOS-2 samples, it is most likely due to the 
morphological nature of the cell line. Nevertheless, phenotypical regions within 







Figure 4.1 Spatial segmentation of a HCC827, MG63 and SAOS-2 aggregoid 
from metabolite data by DESI-MSI. a) Spatial segmentation identified 
heterogeneous clustering phenotypes between aggregoid models. Segmentation 
of each sample was performed independently and therefore the coloured clusters 
do not correspond between samples. b) H&E stain of same aggregoid sections 
from each model. Black dotted line were manually included to highlight different 
phenotypical regions on the H&E stain that were similar to the segmentation 




PCA was conducted to determine the differences between the three aggregoid 
models. From the analysis, an obvious separation between the cell lines was 
observed with relatively tight 95% confidence grouping (Figure 4.2). The 
distribution of the OS models both located to the right of the scores plot and away 
from the HCC827 samples suggested more similarities in the metabolites 
compared to the lung model (Figure 4.2). However, from the PLS-DA, there was 
clear variance in separation on the scores plot from the detected metabolites 
between the MG63 and SAOS-2 aggregoid models (Figure 4.3). This is as 
expected, as the fibroblastic MG63 and epithelial SAOS-2 cell types will exhibit 
different metabolic behaviour. A summary of the key metabolites identified in the 
aggregoid models is reported in Table 4.1. Unfortunately, the metabolites 
involved in glycolysis and the TCA cycle, detected in the HCC827 aggregoid 
model in Chapter 3, were not detected in this study. This is likely due to the tuning 
of the DESI Thermo Fisher Q-Exactive mass spectrometer prior to acquisition 
which was performed externally by the AstraZeneca group. Due to time 
constraints, an additional image was not acquired. Nonetheless, a significant 
number of metabolites within the higher mass range including fatty acids and 








Figure 4.2 PCA scores and loadings plot show separation of the MG63 and SAOS-2 aggregoid models from the HCC827 
aggregoid model. Principal components, PC 1 (51.8%) and PC 2 (33.6%) (% = the amount of variability) showed the best separation 
between sample groups. The discriminatory m/z values of interest were distributed separately from the cluster of peaks. Samples 








Figure 4.3 PLS-DA scores and loadings plot show variance between MG63 aggregoid model and the SAOS-2 aggregoid 
model. Component 1 (69.6%) and component 2 (13.7%) showed the best separation between samples. The discriminatory m/z values 










FA 8:1;O2 173.082 0.0 OS: SAOS-2 * 
FA 9:1;O2 187.098 0.0 All 
FA 11:1;O 199.136 0.0 All 
FA 17:1 267.232 0.0 All: HCC827 * 
FA 18:5 273.186 1.0 All 
FA 18:3 277.217 -0.4 OS 
FA 18:2 279.235 6.3 All: OS 
FA 18:1 281.248 -0.4 All: HCC827 * 
FA 18:2;O 295.229 3.4 All: HCC827 * 
FA 20:5 301.218 0.0 All: MG63 * 
FA 20:4 303.231 -0.2 All: MG63 * 
FOH 27:0 395.427 3.3 MG63 * 
FA 20:4 457.371 5.0 SAOS-2 ** 
Cer 32:1;O2 508.474 1.1 SAOS-2 *** 
FAHFA 34:2;O 535.472 -0.9 All: HCC827 * 
Cer 34:1;O2 536.506 1.9 SAOS-2 *** 
Cer 32:1;O2 [M+Cl]- 544.449 -3.2 OS: SAOS-2 *** 
FAHFA 36:2;O 563.504 -1.0 All: HCC827 *** 
Cer 34:1;O2 [M+Cl]- 572.480 -2.2 OS: SAOS-2 *** 
PI 18:0 599.320 -0.2 MG63 * 
PE O-28:1 618.450 -1.0 SAOS-2 ** 
PE O-30:1 646.482 -0.3 SAOS-2 *** 
PE O-34:2 700.527 -2.1 OS: MG63 *** 
PE 34:1 716.524 0.1 OS: MG63 * 
PE O-36:6 720.498 1.1 MG63 ** 
PE O-36:2 728.562 2.5 OS *** 
PC O-33:1 730.577 1.7 OS: SAOS-2 * 
PS O-33:0 734.533 -1.2 MG63  
PC 33:2 742.540 1.4 MG63 ** 
PG 34:1 747.516 -3.0 OS: MG63 * 
PE O-38:5 750.544 -0.3 MG63 * 
PS 34:1 760.518 7.0 OS * 
PE O-38:6;O 764.526 2.7 MG63 ** 
PS 36:1 788.544 -0.4 OS: MG63 ** 
PS 38:4 810.530 1.3 MG63 ** 
PG 40:7 819.519 0.7 MG63 ** 
PS 40:6 834.523 -6.3 OS * 
PI 38:4 885.549 -0.9 OS: MG63 * 
Table 4.1 Assignments and errors for metabolites detected in specific 
aggregoid models. Metabolites were filtered by removal of isotope peaks and 
mass accuracy (< 7 ppm). Significant metabolite detection between tumour 
models was determined by mean intensities. Data is mean (n=3), one-way 





For the observed metabolites, differences in the detection levels across the 
tumour aggregoid models were observed. In particular, ceramide species Cer 
32:1;O2, Cer 34:1;O2, and their chlorine adducts were significantly elevated in 
the SAOS-2 model (Table 4.1). From the image, the intensity of Cer 34:1;O2 
[M+Cl]- at m/z 572.480 was localised across the aggregoid with highest 
concentrations within the core (Figure 4.4a). Some detection was observed in the 
MG63 aggregoid, and even less so in the HCC827 model. Ceramides are 
primarily associated with tumour suppressor activity by triggering anti-
proliferative cellular processes such as apoptosis and autophagy (Galadari et al., 
2015). Activation of ceramides are typically induced by cellular stresses such as 
hypoxia or anti-cancer drug signalling (Haimovitz-Friedman, Kolesnick, & Fuks, 
1997; Li, Feifei & Zhang, 2016). Equally, ceramides have also been associated 
with cell differentiation and bone development. Hill & Tumber (2010) detected 
ceramides in osteoblasts and determined low levels promoted cellular 
proliferation, as high levels induced apoptosis to promote bone reformation. From 
the histology images (Figure 4.1), a large area of apoptotic bodies was identified 
in the SAOS-2 model. Thus, the heterogenous ceramide levels within the SAOS-
2 aggregoid could be an indicator of apoptotic activity within an inner hypoxic 
region and cellular differentiation in an outer proliferative zone. Though, as the 
ceramide detection within the apoptotic region of HCC827 aggregoids were 
significantly lower than the SAOS-2 model, it suggests ceramides are more 
associated with osteoblast-like cells. The discriminatory levels of ceramides 
between the OS models, however, implies these metabolites differentiate the 







Within the MG63 aggregoid models, glycerophospholipid species, including PC, 
phosphatidylethanolamine (PE), phosphatidylserine (PS) and 
phosphatidylinositol (PI) were expressed considerably higher in comparison to 
the SAOS-2 and HCC827 models (Table 4.1). In highly proliferating cancer cells, 
phospholipid metabolism is altered to promote processes involved in the 
synthesis of signalling molecules, energy production and the formation of cellular 
membranes (Beloribi-Djefaflia et al., 2016). From the histology image (Figure 
4.1), the MG63 aggregoid displayed a high density of proliferative cells across 
the tissue and therefore could be reason for the higher detection of such 
phospholipids. In addition, the specific phospholipids have also been associated 
with aggressive properties of malignant cancer types (Luo et al., 2017). 
Metabolites PS 38:4 at m/z 810.530 and PI 38:4 at m/z 885.549 were significant 
within the MG63 aggregoids, with some detection in the SAOS-2 aggregoids. PI 
38:4 in particular was localised within the periphery of the MG63 aggregoid 
(Figure 4.4b). A previous study comparing the lipidomic profiles of low and high 
Figure 4.4 Distribution of metabolites detected in OS aggregoid models. Ion 
density maps of metabolites outlining the core and outer area on the image. Mean 
intensity plotted on bar graph against the SAOS-2, MG63 and HCC827 
aggregoids. Data is mean ± SD (n=3), one-way ANOVA with Tukey post hoc test  
* p < 0.05, ** p < 0.01, *** p < 0.001. Scale bar 200 µm. Peaks identified a) m/z 




metastatic breast cancer cell lines reported both PS 38:4 and PI 38:4 were 
markedly greater in the high metastatic cell type (Kim et al., 2016). The presence 
of these lipids could suggest the MG63 aggregoid is exhibiting an aggressive 
tumoral behaviour, that is if the phospholipids have the same metastatic-
promoting effects in OS as they do in breast cancer.  
4.4.1.2 Characterisation of OS aggregoid models to OS human 
tissue 
Initially, the MSI data of the OS human tissue samples was spatially segmented 
to classify the clusters with specific phenotypic regions. The spatial segmentation 
analysis showed complex clustering patterns within all tissue sections in 
comparison to the aggregoid models. This is due to the heterogeneity of the 
tissues comprising many cell types that form the tumorous tissue in addition to 
bone and cartilage. Figure 4.5a shows the spatial segmentation of a tissue 
section from OS patient_826 imaged by DESI-MSI and the histology stain after 
analysis (whole H&E image Figure 4.5b and enlarged regions Figure 4.5c-f). It 
was stated from the external pathology report, the sample had cancerous tumour 
regions identified throughout the tissue including the osteoid bone which was 
formed by tumour cells. Therefore, detection of different tumorous phenotypes 
throughout the whole tissue section was expected. From the segmentation 
analysis, a solid tumour region (yellow cluster) with an osteoid bone island 
(purple/blue clusters) was identified on the right of the tissue (Figure 4.5c). 
Similarities to this yellow tumour cluster were also detected throughout the 
sample (Figure 4.5d). A large area of mineralised bone within tumorous tissue 
was also detected and determined by the sage green cluster (Figure 4.5d, e). In 
addition, a significant area of dense osteoid bone with a filagree pattern was 






Figure 4.6 shows the spatial segmentation analysis of a tissue section from OS 
patient_882 and the histological image. From the pathology report, typical 
osteoblastic osteosarcoma phenotypes were detected. Regions of lamellar bone 
were identified, the medullary space contained various cell types with irregular 
nuclei, and osteoid production by atypical mitotic cells was determined. From the 
DESI data, the different phenotypes could be identified by the segmentation 
analysis. A large region of solid tumour was identified on the right of the tissue 
(orange cluster) (corresponding enlarged H&E image Figure 4.6c). The medullary 
space (blue cluster) with osteoid regions (green cluster) was localised within the 
focal region of the tissue (corresponding enlarged H&E image Figure 4.6d). A 
region of lamellar bone (sage green) and a large area of osteoid formation were 
localised within the left of the tissue (corresponding enlarged H&E image Figure 
4.6e). It is noted that the segmentation analysis was performed independently for 
Figure 4.5 Spatial segmentation analysis of OS patient_826 tissue sample 
from metabolite data by DESI-MSI. a) spatial bisecting k-means segmentation 
of OS section highlighting heterogeneous clusters throughout tissue. Scale bar 
600 µm. b) H&E of same OS tissue section after image analysis. Scale bar 600 
µm. Magnification of ROIs: c) solid tumour (corresponding to the yellow cluster) 
with osteoid island (corresponding to the purple/blue clusters) at the right of the 
tissue; d) region of tumour and mineralised bone located to the left of tissue 
(corresponding to the yellow and sage green clusters); e) tumour and mineralised 
bone located at the top of the tissue (corresponding to the sage green cluster); f) 




each patient sample and therefore the colour clusters do not correspond between 
groups. 
  
Figure 4.6 Spatial segmentation analysis of OS patient_882 tissue sample 
from metabolite data by DESI-MSI. a) spatial bisecting k-means segmentation 
of OS section highlighting heterogeneous clusters throughout tissue. Scale bar 
800 µm. b) H&E of same OS tissue section after image analysis. Scale bar 800 
µm. Magnification of ROIs in H&E image: c) solid tumour (corresponding to the 
orange cluster) at the right of the tissue; d) region of medullary space with osteoid 
bone located focally (corresponding to the green and blue clusters); e) lamellar 
bone located at the left of the tissue (corresponding to the sage green cluster). 




PCA was performed to determine the similarities and variances between the two 
OS aggregoid models with the two OS human tissue samples. It is stressed that 
the aggregoid data was acquired independently from the patient samples. 
Therefore, an indirect comparison of the samples from two individual imaging 
data sets has been performed in this study and thus the results are of a 
preliminary nature only. From the PCA scores plot, a clear separation of the 
aggregoid models from the OS human tissue samples was observed (Figure 4.7). 
As the human tissue is comprised of many heterogeneous regions and contains 
different cell types it was expected to have variance from the single-cell type 
aggregoid models. In addition, slight separation of the 95% confidence grouping 
of the two patient samples is also likely due to the heterogeneity between the 
tumour tissues. The MG63 aggregoid samples were relatively widely distributed 
which suggests some variability within the group. For each remaining sample type 
however, tight clustering between the samples was observed. A summary of the 
key metabolites within the OS patient samples and the OS aggregoid models is 
reported in Table 4.2. The significant metabolites detected within the samples 
highlighted the similarities that exist between the OS aggregoid models and the 









Figure 4.7 PCA scores and loadings plot show separation of the OS aggregoid models from the OS human tissue samples. 
Principal components, PC 1 (48.6%) and PC 2 (22.4%) showed the best separation between sample groups. The discriminatory m/z 
values of interest were distributed separately from the cluster of peaks. Samples were grouped with 95% confidence, MG63 (green), 





















FA 9:1;O2 187.096 0.0 OS_882 *** 187.098 0.0 Both 
FA 11:1;O 199.135 0.0 OS_882 ** 199.136 0.0 Both 
Phenol lipid 235.171 1.0 Both 235.169 -4.7 Both 
FA 16:1 253.218 3.4 Both 253.216 -5.7 Both 
FA 17:1 267.235 0.0 Both 267.232 0.0 Both 
FA 18:3 277.216 0.0 Both 277.217 -0.4 Both 
FA 18:2 279.234 2.4 Both 279.235 6.3 Both 
FA 18:1 281.247 -0.4 Both 281.248 -0.4 Both 
FA 18:2;O 295.229 2.9 OS_882 * 295.229 3.4 MG63 * 
FA 18:1;O 297.242 -6.0 Both 297.242 -5.9 MG63 * 
FA 20:5 301.218 0.3 OS_826 * 301.218 0.0 MG63 * 
FA 20:4 303.231 0.2 OS_826 ** 303.231 -0.2 Both 
FA 18:2;O2 311.224 3.5 OS_882 * 311.223 0.7 Both 
Cer 32:1;O2 508.474 0.7 OS_826 ** 508.474 1.1 SAOS-2 *** 
LPA(24:1) 519.345 -0.6 OS_882 * 519.345 -1.1 SAOS-2 * 
FAHFA 34:2;O 535.473 1.1 Both 535.472 -0.9 Both 
Cer 34:1;O2 536.505 0.0 OS_826 *** 536.506 1.9 SAOS-2 *** 
Cer 32:1;O2 [M+Cl]- 544.451 0.6 OS_826 ** 544.448 -3.2 SAOS-2 *** 
FAHFA 36:2;O 563.505 0.1 Both 563.504 -1.0 Both 
FAHFA 36:1;O 565.522 4.2 Both 565.522 2.9 Both 
Cer 34:1;O2 [M+Cl]- 572.484 4.2 OS_826 *** 572.480 -2.2 SAOS-2 *** 
PE O-28:1 618.451 1.6 OS_826 ** 618.450 -1.0 SAOS-2 ** 
PE O-30:1 646.613 -2.1 OS_826 *** 646.615 1.0 Both 
Cer 40:1;O2 [M+Cl]- 656.578 3.5 OS_826 ** 656.576 0.2 Both 








PE 34:1 716.524 0.3 OS_826 * 716.524 0.1 MG63 * 
PE O-36:2 728.560 -0.4 OS_826 * 728.562 2.5 Both 
PC O-33:1 730.575 -0.8 Both 730.577 1.7 SAOS-2 * 
PC 33:2 742.539 0.1 OS_826 * 742.540 1.4 MG63 * 
PG 34:1 747.517 -1.1 OS_826 ** 747.516 -3.0 MG63 * 
PE O-38:5 750.542 -2.6 OS_826 * 750.544 -0.3 MG63 * 
PE O-38:6;O 764.524 0.4 OS_826 * 764.526 2.7 MG63 ** 
PS 36:1 788.544 -1.3 OS_826 ** 788.544 -0.4 MG63 ** 
PS 38:4 810.528 -1.5 OS_826 * 810.530 1.3 MG63 ** 
PS 40:4 838.559 -1.3 OS_826 ** 838.562 2.2 Both 
PI 38:4 885.550 0.5 OS_826 ** 885.549 -0.9 MG63 * 
Table 4.2 Assignments and errors for metabolites detected in both the OS human tissue samples and OS aggregoid models, 
MG63 and SAOS-2. Metabolites were filtered by removal of isotope peaks and mass accuracy (< 7 ppm). Significant metabolite 
detection between tumour models was determined by mean intensities. Data is mean (n=3), unpaired t test * p < 0.05, ** p < 0.01, *** 




The major similarities between the OS human tissue samples and the OS 
aggregoid models was the detection of fatty acid species, specifically related to 
the arachidonic metabolism pathway. Figure 4.8a-c shows FA 18:2, e.g., linoleic 
acid at m/z 279.234, FA 18:1, e.g., oleic acid at m/z 281.247 and FA 20:4, e.g., 
arachidonic acid at m/z 303.231 within the OS human tissues. Mean intensities 
for each metabolite detected in the OS patient tissues and OS aggregoid models 
are shown in Appendix Figure A.1. The localisations of the metabolites were 
concentrated within the solid tumour regions of the OS human tissues and 
distributed throughout the similar tumorous areas as identified by the clustering 
analysis. These species were also identified at high levels in SAOS-2 and MG63 
aggregoid models (Figure 4.8e-f). Within the SAOS-2 model, the metabolites 
were distributed more within the periphery, compared to the MG63 model where 
the species were heavily distributed throughout the section. As discussed in 
Chapter 3, FA 18:1 and FA 20:4 were detected within the proliferation region of 
the HCC827 aggregoid model. The arachidonic acid metabolism has been 
associated with cellular proliferation and differentiation and the promotion of 
cancer growth and survival via the COX pathway (Ding et al., 2000; Borin et al., 
2017). This correlates with the observations made in the OS aggregoid models, 
where proliferative cells were localised within the outer region of the SAOS-2 
model, whereas from the histology of the MG63 model, proliferative cells were 
localised throughout the aggregoid. Therefore, this suggests that the localisation 
of the fatty acids within the OS human tissue samples are an indication of highly 









Figure 4.8 Fatty acid detection within OS human tissue and OS aggregoid models. Ion density maps of metabolites in OS 
patient_826 and OS patient_882. Scale bar 500 µm and 800 µm, respectively. Ion density maps of aggregoid models outlining the 
core and outer area. Scale bar 200 µm. Peaks identified in human tissue a) m/z 279.234, FA 18:2; b) m/z 281.247, FA 18:1; c) m/z 




Interestingly, the two aggregoid models follow a similar detection pattern of a 
lower FA 18:2 signal and elevated levels of FA 20:4 as OS patient_826. In 
contrast, OS patient_882 had higher intensities of FA 18:2. It has been reported 
that the metabolism of arachidonic acid is involved in the promotion of 
angiogenesis, cell invasion and metastasis by the LOX pathway (Nie et al., 2003). 
From the pathology reports, a case of metastasis was reported from OS 
patient_826 and not in OS patient_882. The observation of an upregulation of FA 
20:4, e.g., arachidonic acid, suggests the detection of a possible marker for 
metastatic potential, primarily within the solid tumour regions of OS patient_826 
tissues. In contrast, a higher detection of FA 18:2 within OS patient_882 tissues 
indicates a slower metabolism to FA 20:4, and thus could identify a lower 
metastatic potential. The similar detection levels of the fatty acids within the OS 
aggregoids to the metastatic patient tissue therefore implies the tissue models 
could be exhibiting metastatic-like behaviour. In addition, the elevated levels of 
FA 20:4 within the MG63 aggregoid further suggests the cell type forms a higher 
metastatic tumour model compared to the SAOS-2 aggregoid.  
To further analyse metabolites associated with metastatic potential within the 
aggregoid models, phospholipids PS 38:4 at m/z 810.528 and PI 34:4 at m/z 
885.550, as discussed in section 4.4.1.1, were also detected significantly higher 
within the metastatic OS patient_826 tissues (Appendix Figure A.2). The 
localisations of both species were observed within the large tumorous regions 
identified by the yellow and sage green cluster of OS patient_826, as low 
amounts of m/z 810.528 and m/z 885.550 were distributed in the orange tumour 
cluster of OS patient_882 (Figure 4.9a, b). These specific metabolites could 
therefore correlate to high metastatic activity within osteosarcoma, as previously 
observed in highly metastatic breast cancer cell lines (Kim et al., 2016). This 
supports the idea of the MG63 aggregoid model displaying a metastatic 
phenotype and demonstrates similarities to the OS patient_826 human tissue. 
On the other hand, the SAOS-2 samples expressed a lower signal for both 
phospholipid species and therefore suggests comparisons to a lower metastatic 









Figure 4.9 Potential metastasis-related phospholipid species detected within OS human tissue and OS aggregoid models. 
Ion density maps of metabolites in OS patient_826 and OS patient_882. Scale bar 500 µm and 800 µm, respectively. Ion density 
maps of aggregoid models outlining the core and outer area. Scale bar 200 µm. Peaks identified in human tissue a) m/z 810.528, PS 




Conversely, the ceramide species that defined the SAOS-2 aggregoid model 
were significantly expressed within the metastatic OS patient_826 tissues. Cer 
34:1;O2 at m/z 536.505 and its chlorine adduct at m/z 572.484 [M+Cl]- were 
localised within the tumorous regions that corresponded mainly to the sage green 
cluster of OS patient_826 (Figure 4.10 and Appendix Figure A.3). As discussed, 
the segmentation analysis highlighted this ROI with tumorous tissue and 
mineralised bone. The elevated ceramide levels within this region could be 
indicative of cellular differentiation and osteoid formation within the human 
tissues (Hill & Tumber, 2010). The comparison to the SAOS-2 aggregoid thus 
suggests the model exhibits similarities to regions in the OS tissue that express 
the mature differentiating osteoblast phenotype that mediates bone 
mineralisation. This contrasts with the MG63 model, which is determined as an 
immature osteoblast phenotype which could be the reason that it the lack of 
ceramide detection. Considering the differences in metabolic activity between the 
two OS aggregoid models and the processes within OS human tissue, it 
demonstrates how the 3D models can correspond to different phenotypes within 
the same tumour. This is significant in terms of drug development, as both models 








Figure 4.10 Ceramide species detected within OS human tissue and OS aggregoid models possibly identifies bone 
mineralisation. Ion density maps of metabolites in OS patient_826 and OS patient_882. Scale bar: 500 µm and 800 µm, respectively. 
Ion density maps of aggregoid models outlining the core and outer area. Scale bar: 200 µm. Peaks identified is human tissue a) m/z 
536.505, Cer 34:1;O2; b) m/z 572.484, Cer 34:1;O2 [M+Cl]-. Peaks identified in OS models c) m/z 536.504, Cer 34:1;O2; d) m/z 




4.4.2 Protein localisations 
To define the individual cellular organisation and tumour activity within the OS 
aggregoid models, IMC analysis was employed to detect protein and protein 
modification markers at 1 µm spatial resolution. Proteomic markers relevant to 
osteosarcoma were selected to identify structural and functional components that 
influence cancer metabolism.  
A generic marker for DNA was used initially to determine the tissue organisation 
by identifying the nucleus in individual cells within the OS aggregoid models 
(Figure 4.11). From the DNA expression, differences between the MG63 and 
SAOS-2 sections can be immediately defined. Within the MG63 model, the DNA 
marker showed whole nuclei expressed homogenously throughout the section. 
When compared to the SAOS-2 model, a more heterogenous pattern was 
observed whereby the outer region of the aggregoid showed whole nuclei, as in 
the core the DNA was more condensed. This is a known indicator of nuclear 
disassembly and apoptotic bodies (Toné et al., 2007), and implies a prevalent 
necrotic region within the SAOS-2 aggregoid compared to the MG63. This 
observation was consistent across OS aggregoid samples imaged with IMC and 








Figure 4.11 Representative IMC images of protein marker distributions within the OS aggregoid models. Scale bar: 100 µm. 
DNA intercalator identified individual cells within the aggregoid sections. Protein markers vimentin and collagen expressed identified 




The differences between the two OS models are further confirmed by the 
expression of tumour markers, vimentin and collagen. Both structural 
components show similar co-localisations within the aggregoid sections (Figure 
4.11). A homogeneous distribution of vimentin and collagen was detected 
throughout the MG63 aggregoid. As within the SAOS-2 aggregoid, the protein 
markers were prominently expressed within the outer region. Vimentin is known 
as a fibroblastic intermediate filament and a mesenchymal cell marker in 
differentiated cell types (Gebhard et al., 2015). A higher expression of vimentin 
across the MG63 aggregoid compared to the lower expression in the periphery 
of the SAOS-2 aggregoid could be highlighting the differentiating mesenchymal 
cells within the models. In addition, an increase in vimentin has been associated 
with the overexpression of cyclooxygenase enzyme, COX-2 in MG63 cells 
(Zhang et al., 2019). COX-2 is involved in the metabolism of arachidonic acid and 
promotes angiogenesis and migration. Therefore, the vimentin expression 
complements the metabolite data in section 4.4.1.2, where significantly high 
levels of FA 20:4 i.e., arachidonic acid was localised across the MG63 
aggregoids, and only observed in the periphery of the SAOS-2 aggregoids.  
The localisation of collagen suggests a similar expression as vimentin. Collagen 
is an important protein in bone when it is mineralised. The more differentiated the 
OS cells, the more collagen that is produced. Therefore, the levels of collagen 
could associate with tumour invasion by the nature of the differentiation status of 
the cells. The localisation of collagen within the periphery of the SAOS-2 
aggregoid indicates an area of differentiation within the outer region, as the 
expression across the MG63 aggregoid suggests differentiated cells are present 
throughout (Figure 4.11). Without quantifying the percentage positivity of 
markers, differences in collagen expression levels between the two OS models 
cannot be determined by the images. One study reported a higher production of 
collagen type I in SAOS-2 cells in comparison to MG63 cells (Baumann & Hennet, 
2016). The expression of collagen I has also been associated with ALP activity 
during bone mineralisation (Collin et al., 1992), an activity that has been detected 
high in SAOS-2 cells (Murray et al., 1987). In contrast, MG63 cells were reported 
to express higher levels of collagen III than collagen I (Jukkola et al., 1993). 
Unfortunately, the marker used in this study detected all types of collagen, and 




determined. However, the presence of different collagen types could also 
influence the heterogeneity between the models.  
Interestingly, the markers that defined the distinctive proliferative outer region and 
hypoxic core phenotypes within the lung adenocarcinoma aggregoid (Chapter 3, 
Figure 3.8), are expressed differently between the two OS models. Similar to the 
HCC827 aggregoid, the SAOS-2 model showed the hypoxia marker, Glut1 
localised within centre of the tissue surrounded by an annular expression of the 
proliferative marker, Ki-67 (Figure 4.12). The data appears to agree with the 
presence of cellular proliferation and differentiation within the periphery of the 
SAOS-2 model and identifies the core as a region of hypoxia. In the MG63 
aggregoid however, a highly intense distribution of Glut1 with an expression of 
Ki-67 were both detected across the tissue (Figure 4.12). The purpose of Glut1 
is to provide energy through the transport of glucose into cells that is converted 
into lactate for cancer to grow and survive in a severe microenvironment, such 
as hypoxia (Schneider et al., 2008). High levels of Glut1 are therefore heavily 
associated with hypoxic tumours and has been correlated with metastatic 
outcome in some patients (Airley et al., 2001). In OS, it was reported that the 
Glut1 gene is overexpressed in correlation with HIF-1α to promote tumour 
progression and is predictive of drug resistance and poor outcome in patients 
(Yang et al., 2007). A higher Glut1 expression in MG63 cells compared to SAOS-
2 cells has been previously reported (Cifuentes et al., 2011), and a knockdown 
of the Glut1 gene showed inhibition of MG63 cell growth (Jian et al., 2015). From 
the imaging data, the expression of Glut1 across the MG63 aggregoid suggests 
the gene is constantly switched on in all cells, regardless of the 
microenvironment. This in turn implies there is a constant stability of HIF-1α, 
consistent with a hypoxic environment but irrespective of oxygen levels in the 
MG63 model. This could give an indication of an aggressive hypoxic tumour 
model. This is supported by the Ki-67 expression across the MG63 aggregoid, 
whereby the cells are able to proliferate under severe hypoxic conditions due to 








Figure 4.12 Representative IMC images of protein marker distributions highlight different tumour microenvironment 
phenotypes within the OS aggregoid models. Scale bar: 100 µm. Protein markers expressed identified the proliferative and hypoxic 
regions via Ki-67 and Glut1, respectively. Markers in response to DNA damage, pNDRG1 and γH2AX. Proliferative and differentiating 




The marker for phosphorylated N-myc downregulated gene 1 (pNDRG1) showed 
significant differences between the two OS models, with high expression in the 
MG63 aggregoid and no expression in the SAOS-2 aggregoid (Figure 4.12). 
NDRG1 is a stress responsive gene that can have both oncogenic and tumour 
suppressor roles involved in cellular differentiation, tumour progression and 
metastasis, hypoxia and DNA damage response (Taketomi et al., 2003; Sun et 
al., 2013; Wang et al., 2013). It was reported an upregulation of NDRG1 was 
linked to an increase in hypoxia and HIF-1α expression (Cangul, 2004). This 
could therefore explain the co-localisation of pNDRG1 with Glut1 in the MG63 
aggregoid, however no detection was observed in the core of the SAOS-2 
aggregoid. Interestingly, Matsugaki et al., (2010) reported the detection of 
pNDRG1 in the SAOS-2 cell line, however at significantly lower levels than in the 
MG63 cells. It was thought the decrease in pNDRG1 in the SAOS-2 cells was 
due to the differentiation state of the cells and the increased invasion potential. 
The group, however, noted the detection of pNDRG1 had no effect on the 
invasive properties of MG63 cells and therefore the role of pNDRG1 between the 
OS cell lines could be due to the differences in differentiation and cell phenotypes. 
In this study, growing the cells in 3D could have downregulated the NDRG1 gene, 
hence no detection of the protein marker, without comparing the expression to 
2D cells this cannot be confirmed.  
The expression of phosphorylated S6 ribosomal protein (pS6) and Histone H3 
(pHH3) markers further confirm differences in the proliferation and differentiation 
activity between the two OS models. In the SAOS-2 aggregoid higher expression 
of pS6 and pHH3 were localised within the outer region, yet the limited expression 
within the MG63 aggregoid was randomly distributed (Figure 4.12). As previously 
discussed in Chapter 3.4.2, pS6 is an active marker for mTOR signalling which 
induces cancer growth and is downregulated in the presence of hypoxia 
(Schneider et al., 2008). A low expression of the pS6 marker in the MG63 cells is 
therefore likely associated with the high levels of the Glut1 marker. The reverse 
expression of these markers is observed in the SAOS-2 model. This is a similar 
explanation for the pHH3 marker expression which identifies cells undergoing 




4.4.3 Elemental compositions 
The elemental analysis of the two OS aggregoid models conducted by LA-ICP-
MSI, shows the typical tumour spheroid microenvironment phenotypes of an 
outer annular rim and inner core. However, there are slight differences between 
the metal distributions within the aggregoids. Firstly, Mg was highly expressed 
over a large area within the MG63 aggregoid compared to the SAOS-2 aggregoid, 
which was localised in a thin outer rim (Figure 4.13). From the discussion in 
Chapter 3.4.3, Mg is a component utilised in the cell cycle and is an indicator of 
an active energy metabolism suggesting an area of  proliferation (Wolf & Trapani, 
2008). From the IMC data, the Ki-67 proliferation marker showed the MG63 
model expressed proliferative cells across the tissue, as the SAOS-2 model 
displayed a distinctive outer proliferative region. The elemental composition of 
Mg therefore correlates with the Ki-67 expression. In addition to this, it has been 
reported that Mg ions can promote the differentiation of mesenchymal stem cells 
to induce growth (Onder et al., 2018; Qi et al., 2021). The elevated levels within 
the aggregoids could therefore be indicative of the matrix differentiation process 








Figure 4.13 Elemental compositions within the OS aggregoid models identified the tumour microenvironment regions. H&E 
stain of serial sections of same aggregoid models imaged during LA-ICP-MSI analysis. Scale bar: 100 µm. Elemental maps of 24Mg, 




The co-localisation of Zn with Mg correlates with the areas of proliferation in the 
two OS models (Figure 4.13). From Chapter 3.4.3, it was suggested that the 
absence of Zn in the core of the HCC827 aggregoid could be associated with the 
activation of HIF-1α in hypoxia; as excess Zn was shown to induce proteasomal 
degradation of HIF-1α (Nardinocchi et al., 2010). This theory coincides with the 
proliferative and hypoxic phenotype of the SAOS-2 model. The high Glut1 
expression across the whole MG63 aggregoid would however disprove this, as 
elevated levels of Zn activity were detected. Alternatively, Zn has been linked to 
vimentin production, whereby the ions influence the assembly of vimentin in 
tissues (Monico et al., 2021). Zn could be highlighting the formation of the 
structural component within the tissues due to the similar distributions of Zn and 
vimentin in the MG63 and SAOS-2 models. This would also correlate to the 
association of Mg with matrix differentiation in the mesenchymal cells.  
In comparison, the Cu was localised more within the centre of both OS aggregoid 
models (Figure 4.13). As discussed in Chapter 3.4.3, the detection of Cu ions 
within the core of the aggregoid model could be due to an upregulation of Cu-
efflux transporter, ATP7A induced by the activation of HIF-1α (Zimnicka et al., 
2014). A large area of Cu was detected within the SAOS-2 model, this is likely 
due to the large hypoxic region as observed in the H&E stain of the serial section, 
and in the Glut1 expression in the biological replicate from the IMC data. As for 
the MG63 H&E stain, it does show a small region of cells within the core that 
could be experiencing cellular damage, however apoptotic bodies were not 
present. This would suggest the MG63 aggregoid core is a less dense area due 
to the natural gradient of nutrients and oxygen and hence this is why Cu is 
accumulating within this region.  
4.5 Concluding remarks 
In this chapter, a multimodal imaging methodology was employed to characterise 
two models of osteosarcoma. Firstly, in-depth phenotyping of the metabolite 
activity within the two OS aggregoid models was achieved. A comparison of the 
metabolite data with OS human tissue samples revealed relevant fatty acid and 
phospholipid markers. Although, annotations of these species require MS/MS 
analysis for confident identification of the metabolites. From the putative 




aggressive tumour model that exhibited metastatic-like potential. Alternatively, 
the SAOS-2 aggregoids are more mature osteoblast-like phenotype that 
expressed characteristics of cellular differentiation and bone development. It was 
determined the two OS aggregoid models shared similarities of metabolic 
behaviour with different regions of OS human tissues, specifically of the higher 
metastatic grade. This is significant in terms of therapeutic research and 
development to target against aggressive in vivo OS tumours.  
In addition, employing IMC showed significant differences in the distribution of 
protein markers within the OS aggregoid models. The SAOS-2 aggregoid 
displayed a typical tumour microenvironment with an inner hypoxic core (Glut1 
marker) and an outer proliferative region (Ki-67 marker). Interestingly, the MG63 
aggregoid protein expression distributions did not show the presence of such 
distinct regions. Furthermore, the elemental compositions within the aggregoid 
models corresponded to the protein distributions of proliferative activity and 
formation of structural components. The complementary nature of both the IMC 
and LA-ICP-MSI data validated the heterogeneity of metabolite distributions 
between the 3D models.  
Overall, multimodal MSI determined the unique characteristics of two OS 
aggregoid models and improved the understanding of complex tumour 
microenvironments. MSI analysis of aggregoid models demonstrated a potential 
methodology to facilitate applications of cancer research and drug development 




CHAPTER 5. AN MSI STRATEGY TO DETERMINE 
THE CELLULAR RESPONSE TO 
BIOPHARMACEUTICAL 





An important part of pharmaceutical research and development is the 
determination of the maximum response achieved from treatment. Evaluating the 
cellular response during early pre-clinical drug development can later benefit the 
amount of therapeutics that pass the clinical stage. By studying the changes in 
levels of endogenous molecules and relating these to biochemical pathways, the 
efficacy of a drug and therapeutic resistance can be established.  
Metabolomics is an area of increasing importance studied to determine drug 
action, variation in drug response and disease pathology (Kaddurah-Daouk, 
Kristal, & Weinshilboum, 2008). Metabolites are highly responsive molecules that 
interplay with gene and protein expression, and their surrounding environment. 
Changes to the cellular metabolism are therefore more detectable within the 
metabolome compared to the genome and proteome. Metabolites are also easier 
to detect within complex matrices due to their smaller molecular weight and size 
allowing for better ionisation. Small molecules and lipids are major components 
that drive cancer metabolism to promote tumour survival and growth (Hanahan & 
Weinberg, 2011). Alterations in metabolite compositions within tissues can 
therefore be markers of specific diseases and cancer types. In addition, 
metabolites serve as cofactors and signalling substrates for a multitude of 
proteins in numerous biological pathways that effect disease development. The 
analysis of metabolites within tissues can therefore give insight to the proteomic 
activity and highlight key biological pathways that are influenced by a therapeutic 
signal.  
The study of metabolomics utilises analytical techniques which allow the 
simultaneous detection and quantitation of thousands of molecules within 
complex biological matrices. Robust techniques employed in metabolomics 
include gas chromatography mass spectrometry (GC-MS) (Fiehn, 2016), NMR 
(Zhang, Hatzakis, & Patterson, 2016), capillary electrophoresis mass 
spectrometry (CE-MS) (García et al., 2017) and FT-ICR-MS (Brown, Kruppa, & 
Dasseux, 2005). LC-MS/MS is the primary method used in metabolic studies due 
to its capabilities to detect most compounds over a wide mass range (Li et al., 
2012; Lu et al., 2019; Wang et al., 2020). This technique allows for the separation 
of compounds with different polarities to analyse large metabolic profiles with high 




Metabolomics studies of biological tissues are conventionally conducted using 
cell lysates or plasma samples. Preparing samples in this way involves the 
breakdown of tissues through homogenisation, which inevitably results in the loss 
of spatial information. The localisation of endogenous metabolites within tissues 
is valued data as the detection of heterogeneous distributions can improve the 
understanding of specific metabolic activity within different phenotypic regions of 
an organism. In addition, the spatially resolved metabolites can highlight areas of 
therapeutic response and drug metabolism.  
MSI, with high sensitivity and wide molecular coverage, can simultaneously 
detect multiple metabolites within tissues whilst maintaining its morphology. 
MALDI-MSI is the most used technique applied to metabolomics studies of 
disease characterisation and drug effects (Irie et al., 2014; Swales et al., 2018; 
Rzagalinski et al., 2019). The study of metabolomics by MALDI-MSI has been 
extended to understand the pathophysiology of 3D cell cultures (Tucker et al., 
2019; Zang et al., 2021). Additionally, the detection of drug metabolism and drug-
induced metabolic changes within phenotypic regions of 3D models has also 
been demonstrated (Liu et al., 2013; Palubeckaitė et al., 2019). The use of 
MALDI-MSI in metabolomics studies has its limitations, however. The main 
challenge of MALDI is the addition of the required matrix, which can restrict the 
amount of lipid species detected within a single acquisition and potentially mask 
important small molecule signals by ion suppression effects (Holzlechner, 
Eugenin, & Prideaux, 2019). In addition, the application of matrix can directly 
affect the spatial resolution and sensitivity capabilities, as well as impacting the 
reproducibility of the application (Goodwin, 2012).  
Ambient MSI techniques, including DESI and LESA, have increased in popularity 
for the study of metabolomics in cancer and treatment response (Eikel et al., 
2011; Lamont et al., 2018; Dexter et al., 2019; Henderson et al., 2020). This is 
due to limited sample preparation that allows for rapid and direct analysis of 
various biological sample types. In addition, DESI-MSI, similar to LC-MS/MS, has 
a broader metabolite coverage due to the use of electrospray ionisation, and can 
also potentially generate multiply charged ions. This, therefore, provides an 
alternative imaging platform to analyse a wider range of compounds that is not 




Current literature reporting metabolomic analysis of drug treatments in 3D cell 
culture models by ambient MSI techniques is limited. One study to date employed 
single-probe MSI to determine changes in metabolite distributions within 
irinotecan treated colon carcinoma spheroids (Tian et al., 2019). In addition to 
this, there is a lack of literature reporting the metabolic responses to biologic 
treatment within tissues. This is likely due to the preference of analysing effective 
small molecule drugs that produce a rapid metabolic response; as well as the 
ability to detect the distribution of the compound and its metabolites 
simultaneously. The size and complexity of biopharmaceuticals, however, limits 
the application of ambient techniques for drug detection. Although, MALDI-MSI 
has demonstrated capabilities of detecting cetuximab in colon carcinoma MCTS 
and determined the change in ATP expression by targeted analysis (Liu et al., 
2018).  
It is therefore clear there is a gap in research for studying a wide metabolomic 
response to biopharmaceuticals in 3D cell culture models. As demonstrated in 
Chapter 3 and Chapter 4, DESI-MSI analysis of the three aggregoid models 
provided a vital insight into the metabolic activity that drives their specific tumour 
microenvironment (Flint et al., 2020). Therefore, using the same approach it could 
be possible to map changes in the metabolite distributions and identify key 
biological pathways activated in response to biopharmaceutical treatment.  
5.1.1 Biologics of interest 
5.1.1.1 Tumour necrosis factor-related apoptosis-inducing 
ligand (TRAIL)-based therapies 
TRAIL is a member of the tumour necrosis factor (TNF) family of ligands that is 
an attractive anti-tumour agent due to its capability to extrinsically induce 
apoptosis through the engagement of its death receptors. TRAIL-based therapies 
can selectively target tumour cells, rather than normal cells, and are currently in 
the clinical stages of the drug development process against many cancers. 
Apoptosis by TRAIL signalling is stimulated by the activation of the caspase 
cascade through the binding of death receptors, DR4 and DR5 (Pitti et al., 1996) 
(Figure 5.1). Once bound, the apoptosis pathway is initiated via the activation of 
the carboxyl terminal death domain (DD). The ligand binding promotes receptor 




death domain (FADD). Procaspase-8 and -10 are then recruited to form the death 
inducing signalling complex (DISC). During the formation of DISC, caspase-8 and 
-10 are cleaved and activated. From this signal, two types of cell death are 
stimulated: extrinsic and intrinsic pathways. The cell death extrinsic pathway 
follows onto the cleavage and activation of caspase-3, this in turn activates death 
inducing substrates and initiates apoptosis.  
Subsequently, caspase-8 can induce the cell death intrinsic pathway, which 
typically triggers apoptosis in response to DNA damage, cell cycle checkpoint 
defects, hypoxia or other severe cellular stresses. In the intrinsic pathway, 
caspase-8 cleaves the proapoptotic Bcl-2 family member, Bid, forming truncated 
Bid (tBid). The translocation of tBid to the mitochondria targets anti-apoptotic Bcl-
2 family members and promotes mitochondrial outer membrane permeabilization 
(MOMP) through release of Bax from anti-apoptotic Bcl-2 members and results 
in the release of cytochrome c into the cytosol. Following this, the binding of 
cytochrome c with APAF-1 adapter forms the apoptosome, which stimulates the 
apoptosis-initiating protease, capsase-9. This in turn, activates the cleavage of 
caspase-3 and other ‘executioner’ proteases such as caspases -6 and -7. In 
addition, the apoptogenic factor, DIABLO is also released during MOMP, and 
blocks protein inhibitors of apoptosis (IAP) such as cIAP1, cIAP2 and XIAP. The 
mechanistic link between extrinsic and intrinsic stimulation of cell death pathways 
is thought to amplify the apoptotic signal when TRAIL binds to its surface 





Despite the effective signalling of both extrinsic and intrinsic apoptotic pathways, 
TRAIL-based therapies have still failed in clinical trials due to resistance in 
specific cancer types (Fuchs et al., 2013; Reck et al., 2013). One possible reason 
for this is the presence of decoy receptors (DcR1 and DcR2), which can inhibit 
death inducing signalling when TRAIL binds (Pan et al., 1997). Therapeutic 
monoclonal antibodies (mAb) that are specific to DR4 and DR5 have been shown 
to bypass decoy receptors and induce apoptosis in cells insensitive to TRAIL 
(Locklin et al., 2007). Conversely, engagement of death receptors can activate 
cell survival pathways. For instance, the TRAIL-induced anti-apoptotic factor, 
nuclear factor kappa B (NF-kB) has been shown to stimulate cellular proliferation 
and tumour promoting cytokines (Khanbolooki et al., 2006). In addition, excessive 
stimulation of the PI3K/Akt/mTOR proliferation pathway by oncogenes and 
growth factors has shown to affect TRAIL sensitivity (Xu et al., 2010).  
TRAIL-based therapies as independent treatment or in combination with 
chemotherapeutics have been considered promising for OS treatment based on 
evidence from both in vitro and animal experiments (Hotta et al., 2003; Suzuki et 
al., 2003; Picarda et al., 2010). However, differences in sensitivity to TRAIL and 





agonistic mAb against the death receptors have been shown across OS cell lines 
(Locklin et al., 2007; Phillips et al., 2019). Literature reporting the effects of TRAIL 
treatment on 3D models of OS is limited. Therefore, it would be interesting to 
determine metabolite abundances in the OS aggregoids treated with TRAIL-
based therapies and associate if the models exhibit pro-apoptotic or drug 
resistant responses.  
5.1.1.2 Cetuximab  
Cetuximab, otherwise known by its trade name Erbitux®, is an antagonistic mAb 
that selectively targets the epidermal growth factor receptor (EGFR). The 
immunotherapeutic has been FDA-approved for the use in treatment for 
oncogene EGFR addicted cancers including colorectal and head and neck 
(Goldberg & Kirkpatrick, 2005; Mehra, Cohen, & Burtness, 2008). Cetuximab is 
a recombinant chimeric human/mouse IgG1 monoclonal antibody generally used 
for personalised medicine. The mechanism of action is a competitive activity 
against ligands, such as the EGF and transforming growth factor-α (TGF-α) to 
bind to the EGFR and inhibit signalling.  
The EGFR pathway (Figure 5.2) is an important process for cellular proliferation 
and growth and is overexpressed in cancers, such as NSCLC (Merrick et al., 
2006). The EGFR is a tyrosine kinase receptor that is phosphorylated when 
ligand bound. This in turn can activate multiple pathways such as the 
PI3K/Akt/mTOR pathway to promote cell cycle progression (Freudlsperger et al., 
2011). A critically important pathway activated by EGFR signalling is the 
Ras/Raf/MAPK pathway (Scaltriti & Baselga, 2006). Once the EGFR is 
phosphorylated through ligand binding, adapter proteins Grb2 and SOS bind 
directly onto the docking site of the receptor in the cytosol. This in turn leads to 
the modification of SOS to allow the binding of GTP to Ras. This process 
activates the Raf kinase that leads to the phosphorylation of mitogen-activate 
protein kinases (MAPK), MEK and ERK1/2. Consequently, MAPKs are then 
imported into the nucleus where they phosphorylate specific transcription factors 
that drive the cell cycle, such as increasing the production of cyclin D, which 



















Cancers that are resistance to cetuximab treatment are considered to have 
genetic mutations in the signalling proteins of the Ras/Raf/MAPK pathway 
(Brand, Iida, & Wheeler, 2011). This means that even with the inhibition of the 
EGFR by cetuximab, the downstream proteins continue to signal for cellular 
proliferation. Despite the amplification of the EGFR gene in lung cancers, due to 
the highly mutated oncogene, K-Ras that leads to the overexpression of Ras, 
FDA-approval for cetuximab as an independent treatment was removed 
(Massarelli et al., 2007; Sgambato et al., 2014). Nonetheless, literature have still 
reported the success of cetuximab inhibiting proliferative activity in lung cancer, 
specifically in combination with therapeutic inhibitors that target signalling 
proteins downstream the EGFR pathways (Kurai et al., 2007; Steiner et al., 2007; 
Hasegawa et al., 2019). With that in mind, by studying the metabolic changes it 
could be possible to determine a potential cellular response within the HCC827 
aggregoid model treated with cetuximab.  
Figure 5.2 The EGFR signalling pathway promoting cell proliferation and 




5.2 Aims of chapter 
In this study, an untargeted DESI-MSI approach was employed to observe the 
metabolome responses to three biologic treatments in the aggregoid models. The 
osteosarcoma aggregoids, MG63 and SAOS-2, were treated with TRAIL-based 
therapies, TRAIL and agonistic anti-Death Receptor 5 mAb (anti-DR5). The 
HCC827 lung adenocarcinoma aggregoid model was treated with antagonistic 
anti-EGFR mAb, cetuximab.  
A multivariate statistical analysis approach was used to highlight specific 
metabolites of interest. PCA was used as an unsupervised method to identify 
variables with the most data variance and find potential outliers within treatment 
groups. PLS-DA was used for a supervised approach to identify differences 
between the control and the highest concentration treated groups for each 
biologic treatment.  
5.3 Materials and methods 
5.3.1 Materials 
Recombinant Human sTRAIL/Apo2L (TRAIL) was purchased from PeproTech 
EC Ltd (London, UK). Human TRAIL R2/TNFRSF10B Antibody (anti-DR5) was 
purchased from R&D Systems (Abingdon, UK). Cetuximab (Erbitux®) was 
purchased from Merck (Darmstadt, Germany). 
5.3.2 Cell culture 
5.3.2.1 2D cell culture biologic treatment 
Initial cell culture conditions for MG63 and SAOS-2 are reported in Chapter 2.3.2.  
Once confluent, cells were prepared for 2D experiments. Both cell lines were 
trypsinised and plated into 96-well plates at 5x104 cells/mL and cultured for 24 h 
before treatment. Each cell line was treated in triplicate with either TRAIL at 
concentrations: 0 ng/mL, 50 ng/mL, 200 ng/mL; or anti-DR5 at concentrations: 0 
ng/mL, 200 ng/mL, 1 µg/mL. Drug solutions were made up with DMEM 
supplemented with 10% FBS and 1% penicillin-streptomycin (Lonza Ltd, UK). 
Cells were cultured with treatment for 24 h before analysis. Cells were visualised 
with Hoechst 33342 and PI staining (10 µg/mL) using an Olympus IX81 




5.3.2.2 3D cell culture biologic treatment 
Aggregoids were cultured following the protocol described in Chapter 2.3.3. For 
the experiment, MG63 and SAOS-2 aggregoids were treated with TRAIL at 
concentrations: 0 ng/mL, 50 ng/mL, 200 ng/mL; or anti-DR5 at concentrations: 0 
ng/mL, 200 ng/mL, 1 µg/mL. HCC827 aggregoids were treated with Cetuximab 
concentrations: 0 µg/mL, 5 µg/mL, 150 µg/mL and 1000 µg/mL. Drug solutions 
were made up with DMEM supplemented with 10% FBS and 1% penicillin-
streptomycin (Lonza Ltd, UK). Samples were incubated for 24 h before 
harvesting.  
HCC827 aggregoids were visualised in brightfield. Images were taken at 0 h and 
24 h using a Cytation™ 5 Cell Imaging Multi-Mode Reader (BioTek, UK). The four 
cetuximab concentrations were imaged (n=2), and the diameter of each 
aggregoid sample was measured in triplicate. 
5.3.3 Sample handling 
Aggregoids were processed following the optimised method reported in Chapter 
2.3.4.  
5.3.4 Metabolite imaging 
5.3.4.1 DESI-MSI analysis 
Metabolite detection was performed on a Q-Exactive mass spectrometer 
(Thermo Fisher Inc, Germany) as described in Chapter 2.3.5.3. The images were 
collected in the mass range m/z 80-900 at a spatial resolution 40 µm and 
analysed by SCiLS Lab MVS Premium 3D Version 2020a (Bruker Daltonics, 
Germany) employing RMS normalization.  
5.3.4.2 Discriminatory analysis 
Data was processed following a similar method to that described in Chapter 
3.3.4.2. ROIs containing the whole aggregoid sections were determined (SCiLS, 
Bruker Daltonics). The raw data file from the DESI-MSI were uploaded to 
METASPACE (https://metaspace2020.eu) for metabolite identification of the 
discriminated m/z values by employing HMDB and LIPIDMAPS®. The resulting 
peak list from each aggregoid section was exported into .csv files and grouped 
together by treatment conditions. The data was then imported into MetaboAnalyst 




4.3.5. PCA and PLS-DA were performed on the selected treatment groups for 
each aggregoid model. Peaks of interest from the loadings plots were 
corresponded to the m/z images. To determine discriminatory peaks, ROC 
analysis was performed to determine the AUC. Statistical analysis on the mean 
intensities of each sample group was performed using a parametric unpaired t-
test, p < 0.05.   
5.3.5 Histological analysis 
Aggregoid samples were stained with Haematoxylin and eosin solutions as 
following method described in Chapter 3.3.7. 
5.4 Results and discussion 
5.4.1 Osteosarcoma treatment response 
5.4.1.1 Sensitivity to TRAIL-based therapy  
Initial assessment to determine the sensitivity of osteosarcoma cell lines, MG63 
and SAOS-2 to TRAIL and anti-DR5 treatment was determined by Hoechst 33342 
and PI nuclear staining. The percentage of apoptosis for each cell line was 
calculated (Figure 5.3). Monolayer cultures of MG63 showed a relatively high 
sensitivity to both biologic treatments. An induction of apoptosis was observed in 
> 50% of MG63 cells with 50 ng/mL TRAIL treatment. The sensitivity was reduced 
in response to anti-DR5 treatment with ~ 30% of MG63 cells displaying apoptotic 
activity at 200 ng/mL. It was, however, still significant in terms of observing a 
cellular reaction to the biologic treatment. The sensitivity of SAOS-2 to both 
TRAIL and anti-DR5 treatment was reduced in comparison. Less than 15% of 
cells displayed an induction of apoptosis with 50 ng/mL TRAIL treatment, as < 
10% was observed in response to the highest concentration, 1000 ng/mL anti-
DR5.  
A similar pattern of sensitivity to TRAIL and anti-DR5 treatment was recently 
reported, whereby apoptotic activity was heightened in MG63 cells in comparison 
to SAOS-2 cells (Phillips et al., 2019). This is likely due to an increased resistance 
to treatment in the SAOS-2 cell line. A number of publications have reported 
possible mechanisms of resistance in OS cell lines, including the expression of 
decoy receptors (DcR1 and DcR2) and osteoprotegerin (OPG), or activation of 




al., 2014). Based on this knowledge, the metabolic profiles of the OS aggregoid 
models treated with TRAIL and anti-DR5 were investigated to determine the 





Figure 5.3 Apoptosis induction in osteosarcoma cell lines in response to 
TRAIL-based therapy. a) Percentage apoptosis after 24 h treatment with TRAIL 
or anti-DR5 in MG63 and SAOS-2 OS cell lines assessed by Hoechst 33342 and 
PI nuclear staining. Data is mean ± SD (n=3), one-way ANOVA with Tukey post 
hoc test * p < 0.05, ** p < 0.01, *** p < 0.001. b) Representative Hoechst 33342 
and PI staining optical images of MG63 and SAOS-2 cells in response to TRAIL 
0 ng/mL and 200 ng/mL, anti-DR5 0 ng/mL and 1000 ng/mL. Condensed nuclei 




5.4.1.2 Metabolic activity in response to TRAIL-based therapy  
Based on the 2D experiment and the responses of the OS cell lines (MG63 and 
SAOS-2) on TRAIL-based therapies, the same doses were used to treat the OS 
aggregoid models. The metabolic response in the 3D models to TRAIL and anti-
DR5 treatments were detected by DESI-MSI, and the H&E stains of the same 
section were used to determine the presence of apoptotic cellular morphology.  
5.4.1.2.1  MG63 in response to TRAIL treatment  
From the data of TRAIL-treated MG63 aggregoids, the PCA displayed significant 
variance of the 200 ng/mL samples from the control and 50 ng/mL treated groups, 
implying there is clear discrimination of m/z values towards the highest 
concentration of TRAIL treated aggregoids (Figure 5.4). The PLS-DA plot further 
demonstrates separation of the control samples from the 200 ng/mL treated 
samples (Figure 5.5). The 200 ng/mL samples were also closely clustered 
together within their group suggesting there is a strong similarity between the 
biological replicates. From the PLS-DA loadings plot, several m/z values 
identified in the right region of the plot correlated to specific lipid species that were 
more prevalent within the control group than the treated group. A summary of the 











Figure 5.4 PCA scores and loadings plot show clear separation of control and TRAIL treated MG63 aggregoids. Principal 
components, PC 1 (40.1%) and PC 2 (35.1%) showed the best separation between sample groups. The discriminatory m/z values of 
interest were distributed separately from the cluster of peaks. Samples were grouped with 95% confidence, control (red), 50 ng/mL 









Figure 5.5 PLS-DA scores and loadings plot show variance between control and 200 ng/mL TRAIL treated MG63 aggregoids. 
Component 1 (44.9%) and component 2 (30.4%) showed the best separation between samples. The discriminatory m/z values of 
interest were distributed separately from the cluster of peaks. Samples were grouped with 95% confidence, control (red) and 200 




A particular mass localised in the periphery of the MG63 control samples at m/z 
645.452 (AUC = 0.604) was identified as glycerol 1-(9Z-octadecenoate) 2-
tetradecanoate 3-phosphate, a glycerophospholipid (Figure 5.6b). 
Glycerophospholipids are continuously synthesised by highly proliferating cancer 
cells for membrane production, in addition to being used for energy through lipid 
modifications of proteins (Dolce et al., 2011). Hence, this could explain the 
localisation of the metabolite in the outer proliferation region of the untreated 
aggregoids. A decrease in the metabolite in the TRAIL treated samples suggests 
a change in the glycerophospholipid metabolism. This is potentially due to a 
reduction in proliferation as a result of TRAIL treatment, which is known to inhibit 
cellular proliferation and stimulate apoptosis. This metabolite is also a product of 
1,2-diacylglycerol-3-phosphate (DAG). DAG is a lipid species involved in inducing 
cellular proliferation through activation of protein kinase C (PKC) signalling (Black 
& Black, 2013). Therefore, a depletion of the DAG product could further indicate 
a reduced proliferation rate in the treated samples.  
A high expression of m/z 730.576 within the core of the MG63 TRAIL treated 
samples (AUC = 0.247) was identified as PC O-33:1 (Figure 5.6c). PC is an 
abundant phospholipid in tissues, however a number of studies have reported 
that PC can inhibit growth and induce apoptosis through the assistance of death 
ligands, such as the TNF-α (Sakakima, Hayakawa, & Nakao, 2009; Li et al., 
2011). Elevated levels of PC O-33:1 in the treated samples could therefore be 
associated with apoptotic signalling induced by TRAIL. A contradictory report 
however, observed a depletion of specific PC species within HeLa and Jurkat cell 
lines treated with TRAIL due to the activation of PC-degrading enzymes (Sandra 
et al., 2005). Comparing this finding to our results could suggest a signature of 
TRAIL resistance, and the high levels of PC might only be an indication of high 
apoptotic activity within the hypoxic region of the aggregoids. From the H&E 
stains, condensed DNA with potential apoptotic and necrotic cells were detected 
in all three 200 ng/mL treated samples. The control group consisted of cells with 
normal morphology with some cells condensed in the section displayed in Figure 
5.6a, however no apoptosis was detected. The significant increase of the PC 
metabolite across the treated group therefore could imply a signal response to 




In addition, a phosphatidic acid (PA) at m/z 673.480 (PA 34:1) was also localised 
within the outer region of the MG63 control samples (AUC = 0.645) (Figure 5.6d). 
PA lipid species are known to be responsible in the progression of cancer by 
stabilising mTOR to suppress apoptotic activity via the PI3K/Akt/mTOR pathway 
(Foster, 2009). This again explains the localisation of the PA species within the 
outer proliferative region of the aggregoids. A decrease in PA 34:1 in the treated 
samples could further indicate a signature of response in the MG63 aggregoids 






Figure 5.6 MG63 TRAIL treated aggregoid images identified from 
multivariate analysis. a) H&E images of MG63 aggregoids control and 200 
ng/mL TRAIL treated. Scale bar 200 µm. Ion density maps of metabolites outlining 
the outer (white) and core (red) regions of the aggregoid sections. Mean intensity 
plotted on bar graph against the control and 200 ng/mL treated samples (n=3), 
unpaired t-test * p < 0.05. Scale bar 200 µm. Peaks identified b) m/z 645.452, 
glycerol 1-(9Z-octadecenoate) 2-tetradecanoate 3-phosphate; c) m/z 730.576, 




5.4.1.2.2  MG63 in response to anti-DR5 treatment  
The PCA of the MG63 aggregoid samples treated with anti-DR5 showed less 
discrimination between the control and the treated groups in comparison to the 
TRAIL treated aggregoids (Figure 5.7). The 95% confidence grouping of 200 
ng/mL treated samples showed overlay between the control and the 1000 ng/mL 
treated samples. This is potentially due to the lower sensitivity of MG63 to the 
anti-DR5 treatment which only targets DR5, as TRAIL targets both DR4 and DR5  
(Locklin et al., 2007). The PLS-DA however, showed slight variance of the 95% 
grouping between the control and the 1000 ng/mL samples (Figure 5.8). Though, 
from the PLS-DA scores plot, the samples for each treatment group were fairly 
distributed from one another suggesting some variability of the aggregoids within 
the groups. By looking at the imaging data for the differing peaks from the PLS-
DA loadings plot and the ROC analysis results, little discrimination of the peaks 
of interest between groups was observed, this mainly due to variation of the 
metabolite expressions between samples. Therefore, either a limited response to 
anti-DR5 was detected or too much variation between samples has impacted the 
results. The potential metabolic markers of anti-DR5 response are discussed and 









Figure 5.7 PCA scores and loadings plot show some separation of control and anti-DR5 treated MG63 aggregoids. Principal 
components, PC 2 (16.8%) and PC 4 (3.5%) showed the best separation between sample groups. The discriminatory m/z values of 
interest were distributed separately from the cluster of peaks. Samples were grouped with 95% confidence, control (red), 200 ng/mL 









Figure 5.8 PLS-DA scores and loadings plot show variance between control and 1000 ng/mL anti-DR5 treated MG63 
aggregoids. Component 1 (17.7%) and component 2 (41.3%) showed the best separation between samples. The discriminatory m/z 
values of interest were distributed separately from the cluster of peaks. Samples were grouped with 95% confidence, control (red) 




The PC O-33:1 expression, as detected in the MG63 aggregoids treated with 
TRAIL, was observed in the data of the MG63 aggregoids treated with anti-DR5. 
The m/z value at 730.576 was separated slightly from the peak clusters on the 
PLS-DA loadings plot suggesting potential discrimination towards a specific 
sample group. From the imaging data, slightly higher levels of PC O-33:1 were 
detected in the control samples (AUC = 0.567), although was not significant 
(Figure 5.9b). This observation was contradictory to the elevated PC O-33:1 
levels in the MG63 TRAIL treated samples. As previously discussed, PC species 
have been linked with apoptotic behaviour in response to death receptor 
activation (Sakakima et al., 2009; Li et al., 2011), and thus a potential increase in 
the metabolite could be expected if the MG63 aggregoids were highly sensitive 
to anti-DR5. In contrast, the similar levels of PC O-33:1 between the control and 
treated samples would suggest a lack of apoptotic response to anti-DR5. From 
the images, the localisation of the PC species within the core of the aggregoid 
samples is therefore more likely an indicator of cellular response to hypoxia.  
On the other hand, metabolite PE P-16:0 at m/z 436.280 was localised across 
the aggregoids and expressed higher in the treated samples (AUC = 0.462) 
(Figure 5.9c). PE species, like PS species, are well-known lipids that are actively 
exposed on the outer membrane of cells during the early stages of apoptosis 
(Emoto et al., 1997). However, due to the spatial resolution of the aggregoid 
cross-section image, the presence of the PE species on the outer membranes of 
the cells cannot be determined. The presence of the PE species could therefore  
be due to the normal abundance within tissues. By observing the histology stains, 
a lack of apoptotic bodies were identified across the treated aggregoid samples, 
even if some DNA condensing was present (Figure 5.9a). As H&E stained images 
provide information on the tissue morphology, it is possible early apoptotic 
changes were detected from the metabolite data. Due to the overall limited 
response and the variability between samples however, the MG63 aggregoid 
response to anti-DR5 cannot be determined. Thus, in order to establish the effect 






Figure 5.9 MG63 anti-DR5 treated aggregoid images identified from 
multivariate analysis. a) H&E images of MG63 aggregoids control and 1000 
ng/mL TRAIL treated. Scale bar 200 µm. Ion density maps of metabolites 
outlining the outer (white) and core (red) regions of the aggregoid sections. Mean 
intensity plotted on bar graph against the control and 1000 ng/mL treated 
samples (n=3). Scale bar 200 µm. Peaks identified b) m/z 730.576, PC O-33:1; 




5.4.1.2.3  SAOS-2 in response to TRAIL treatment 
Both the PCA and PLS-DA of the SAOS-2 samples treated with TRAIL showed 
little variance between the control and the treated groups (Figure 5.10 and Figure 
5.11). This is most likely due to the limited sensitivity of SAOS-2 to TRAIL-based 
therapies as demonstrated from the 2D experiment results. However, the 
samples of each group were relatively distributed throughout the scores plots and 
the imaging data observed variability between samples for specific m/z values. It 
was considered that potential sample outliers influenced the multivariate analysis 
as slight separation was observed between the control and 200 ng/mL treated 
samples in the PLS-DA scores plot (Figure 5.11). Nonetheless, by comparing 
ROC analysis some discriminatory m/z values were identified (Table 5.1), which 









Figure 5.10 PCA scores and loadings plot of control and TRAIL treated SAOS-2 aggregoids. Principal components, PC 2 (26%) 
and PC 4 (5.5%) showed the most separation between samples. The discriminatory m/z values of interest were distributed separately 










Figure 5.11 PLS-DA scores and loadings plot show some variance between control and 200 ng/mL TRAIL treated SAOS-2 
aggregoids. Component 1 (44.7%) and component 2 (32.7%) showed the best separation between samples. The discriminatory m/z 
values of interest were distributed separately from the cluster of peaks. Samples were grouped with 95% confidence, control (red) 




Glutamate (m/z 146.046) was detected at lower levels within the SAOS-2 200 
ng/mL treated samples (AUC = 0.652) (Figure 5.12b). As previously discussed 
(Chapter 3.4.1), cancer cells are relatively dependent on glutamate for tumour 
metabolism and proliferation. Glutamate is converted from glutamine within the 
mitochondria, which is either fed into the TCA cycle for proliferation (Martínez-
Reyes & Chandel, 2020) or used as an intermediate to produce GSH for ROS 
regulation (Sappington et al., 2016). As the images showed no differences in the 
GSH levels across samples (data not shown), it suggests that the reduced 
glutamate expression within the treated group could be due to a decrease in the 
rate of proliferation. The downstream effects of apoptotic signalling that induces 
MOMP and cell death would in theory have less need for glutamate.  
Elevated levels of ceramide species at m/z 508.474 (Cer 32:1;O2) and m/z 
536.506 (Cer 34:1;O2) were detected in the treated samples (AUC = 0.314; AUC 
= 0.310, respectively) (Figure 5.12c, d). As discussed previously, ceramides are 
well known secondary messengers that activate the apoptotic cascade, 
particularly stimulated through environmental stresses such as hypoxia 
(Haimovitz-Friedman et al., 1997; Mullen & Obeid, 2012). From Chapter 4.4.1.2, 
high levels of ceramide species were detected within the SAOS-2 aggregoids, 
which correlated to the large hypoxia region within the models and also potentially 
detected metabolic activity associated with bone mineralisation in the OS clinical 
tissues. Therefore, it is interesting that the treated samples have a higher 
expression of the ceramide species compared to the control. Nevertheless, an 
accumulation of ceramides has also been linked to TNF-α induced apoptosis and 
is thought to assist cell death through the inhibition of the PI3K/Akt/mTOR 
pathway (Nam, Amoscato, & Lee, 2002; Gupta & Gollapudi, 2006). From the 
histology images (Figure 5.12a), all samples showed large regions of prevalent 
apoptotic cells in the tissue sections as was commonly observed within all SAOS-
2 samples throughout the experimental work in thesis, previously explained in 
section 4.4.1.1. Therefore, it was challenging to determine the presence of an 
apoptotic response solely in relation to TRAIL treatment from the histology 
images. In order to understand  the metabolite data, further experimental analysis 
with additional biological replicates would be required to improve the DESI data. 




pathway in an attempt to differentiate apoptotic bodies created from an external 





Figure 5.12 SAOS-2 TRAIL treated aggregoid images identified from 
multivariate analysis. a) H&E images of SAOS-2 aggregoids control and 200 
ng/mL TRAIL treated. Scale bar 200 µm. Ion density maps of metabolites 
outlining the outer (white) and core (red) regions of the aggregoid sections. Mean 
intensity plotted on bar graph against the control and 200 ng/mL treated samples 
(n=3), unpaired t-test * p < 0.05. Scale bar 200 µm. Peaks identified b) m/z 




5.4.1.2.4  SAOS-2 in response to anti-DR5 treatment 
The PCA data of the anti-DR5 treated SAOS-2 samples showed little separation 
between the control and the treated groups (Figure 5.13). The loadings plot 
shows the m/z values closely clustered together suggesting there is little 
discrimination of the peaks. Separation between the groups was not expected for 
the anti-DR5 treated samples due to the low sensitivity of SAOS-2 cells in the 2D 
experiment. The PLS-DA plot, however, did display some variance between the 
control and the 1000 ng/mL treated samples allowing the identification of some 
discriminatory m/z values (Figure 5.14). The samples within the 95% confidence, 
however, were distributed widely for both groups. From the imaging data, 
variability between samples was observed and the ROC analysis of the peaks of 
interest showed little discrimination between groups. Therefore, it suggests again 
either a lack of metabolic shift within the SAOS-2 aggregoids in response to anti-
DR5, or large variability between samples. Nevertheless, some identifications of 









Figure 5.13 PCA scores and loadings plot of control and anti-DR5 treated SAOS-2 aggregoids. Principal components, PC 1 
(43.3%) and PC 2 (19.8%) showed the best separation between samples. The discriminatory m/z values of interest were distributed 
separately from the cluster of peaks. Samples were grouped with 95% confidence, control (red), 200 ng/mL anti-DR5 (blue) and 1000 









Figure 5.14 PLS-DA scores and loadings plot show some variance between control and 1000 ng/mL anti-DR5 treated SAOS-
2 aggregoids. Component 1 (47.7%) and component 2 (16.4%) showed the best separation between samples. The discriminatory 
m/z values of interest were distributed separately from the cluster of peaks. Samples were grouped with 95% confidence, control (red) 




Among the peaks of interest, a furan fatty acid (FA 20:3;O) and a product of the 
linoleic acid metabolism was identified within the periphery of the SAOS-2 
aggregoid models at m/z 321.244 (Figure 5.15b). Although present in both 
groups, elevated levels were observed within the control samples (AUC = 0.604). 
As previously discussed (Chapter 3.4.1), fatty acids support cancer proliferation 
and confirmed the presence of cell growth within the outer region of the 
aggregoid. Linoleic acid in particular, has been associated with tumorigenesis via 
its metabolism to arachidonic acid, which is involved in the LOX pathway to 
promote angiogenesis and tumour survival (Ding et al., 2000; Hanna & Hafez, 
2018). Both fatty acids were detected a high intensity in the SAOS-2 aggregoid 
model in Chapter 4.4.1.2. From this data, slightly reduced levels of FA 18:2 
(linoleic acid, m/z 279.232) (Figure 5.15c) and FA 20:4 (arachidonic acid, m/z 
303.232) (data not shown) were observed within the treated samples (AUC = 
0.598; AUC = 0.571, respectively), although no significant changes from the 
control samples were determined. A decrease in FA 20:3;O could therefore 
suggest the active metabolism of linoleic acid has been reduced. This implies a 
lower rate in proliferation within the treated samples, potentially as a response to 
anti-DR5.  
In addition, m/z 835.534 was identified as PI 34:1 and detected higher within the 
control samples in comparison to the treated groups (AUC = 0.604) (Figure 
5.15d). PI species are involved in multiple signalling pathways, including its 
phosphorylation to form phosphatidylinositol-(4,5)-bisphosphate (PIP2). PIP2 
can be hydrolysed by phospholipase C (PLC) to form two secondary messengers, 
inositol triphosphate (IP3) and also DAG, which is used to activate PKC (Gamper 
& Shapiro, 2007). As previously mentioned, PKC signalling can promote cellular 
proliferation (Black & Black, 2013). However, PKC can also be responsible for 
promoting apoptosis through activation of an alternative isoform and thus it 
depends on the cellular signal (Zhu, Tsuji, & Chen, 2010). On the other hand, 
PIP2 can be further phosphorylated by phosphoinositide 3-kinase (PI3K) to PIP3. 
This process is heavily involved in tumour survival and growth as it initiates the 
PI3K/Akt/mTOR signalling pathway (Chalhoub & Baker, 2009). Therefore, a 
depletion of the PI molecule could imply the synthesis of PIP2. This can either 
produce a positive response to anti-DR5 through PKC-induced apoptosis or 




neither PIP2 nor PIP3 were detected within the imaging data so these findings 
cannot be further supported. Considering the role of the furan fatty acids, which 
were also depleted in the treated samples, a decrease in proliferative activity is 
implied. However, due to no significant changes in both metabolites and the high 
apoptotic activity across all samples within the histology stain analysis (Figure 






Figure 5.15 SAOS-2 anti-DR5 treated aggregoid images identified from 
multivariate analysis. a) H&E images of SAOS-2 aggregoids control and 1000 
ng/mL TRAIL treated. Scale bar 200 µm. Ion density maps of metabolites 
outlining the outer (white) and core (red) regions of the aggregoid sections. Mean 
intensity plotted on bar graph against the control and 1000 ng/mL treated 
samples (n=3). Scale bar 200 µm. Peaks identified b) m/z 321.244, FA 20:3;O; 




5.4.2 Lung adenocarcinoma treatment response 
5.4.2.1 Cetuximab sensitivity 
To determine the HCC827 response to cetuximab treatment, the growth of the 
aggregoid samples were analysed by measuring the diameter of each aggregoid 
at 0 h and 24 h. From the data, no significant changes were observed among the 
treatments between the two time points (Figure 5.16). The HCC827 cell line was 
reported to be highly sensitive to cetuximab treatment (Amann et al., 2005; 
Mukohara et al., 2005). It was suggested this was due to an amplification of the 
EGFR gene in the cell line, resulting in the receptor protein being highly 
expressed and therefore treatment with cetuximab (which targets EGFR) resulted 
in a considerable inhibition of cell growth (Amann et al., 2005). However, the 
analysis of the effects of cetuximab treatment in these reports was carried out 
after a 72 h incubation on monolayer cells and therefore the experiment in this 
study is not comparable. Unfortunately, due to experimental time constraints of a 
3-day laboratory rota as a result of covid-19, a 72 h incubation was unachievable 
in this study. Nonetheless, the metabolic profiles of the HCC827 aggregoid 
models treated with cetuximab after 24 h were investigated to determine if an 
initial treatment response could be detected.  
 
  
Figure 5.16 Growth of HCC827 aggregoids treated with cetuximab after 24 




5.4.2.2 HCC827 metabolic activity in response to cetuximab  
The PCA data from the HCC827 aggregoid samples treated with four 
concentrations of cetuximab, displayed minor separation of treatment groups 
(Figure 5.17). Overlay of the 5 µg/mL and 150 µg/mL treated samples was 
observed with 95% confidence grouping. The 1000 µg/mL samples, however, 
were closely clustered together suggesting a strong similarity between the 
aggregoid replicates. The PLS-DA scores plot of the control and the 1000 µg/mL 
treated samples showed clear variance between treatment groups (Figure 5.18). 
However, the control samples were dispersed suggesting some variance within 
the group. From the loadings plot, a few peaks of interest were identified from the 
images which are discussed and summarised in Table 5.1, however the ROC 
analysis showed low discrimination between groups. The low variance is likely 
due to the incubation period of the cetuximab treatment. With a longer treatment 









Figure 5.17 PCA scores and loadings plot of cetuximab treated HCC827 aggregoids. Principal components, PC 2 (17.9%) and 
PC 4 (5%) showed the best separation between samples. The discriminatory m/z values of interest were distributed separately from 










Figure 5.18 PLS-DA scores and loadings plot show variance between control and 1000 µg/mL cetuximab treated HCC827 
aggregoids. Components, PC 1 (31.8%) and PC 2 (48.6%) showed the best separation between samples. The discriminatory m/z 
values of interest were distributed separately from the cluster of peaks. Samples were grouped with 95% confidence, control (red) 




Two peaks identified as lysophospholipid (LPL) species, LysoPE 18:1 at m/z 
478.294 and LysoPC 15:0 at m/z 480.311, were expressed in the HCC827 
cetuximab 1000 µg/mL treated samples (AUC = 0.430; AUC = 0.480) (Figure 
5.19b, c). Interestingly, an upregulation of LPLs has been reported to stimulate 
the induction of apoptosis. It is thought that LysoPC in particular, induces 
apoptotic signalling through a p38-MAPK-dependent pathway, which inhibits 
extracellular signal-regulated kinases (ERK) in the EGFR stimulated 
Ras/Raf/MAPK pathway (Takahashi et al., 2002). Therefore, the increase of 
LysoPC and potentially LysoPE could be due to a response to cetuximab 
treatment, inhibiting EGFR signalling. On the contrary, LPL expression has also 
been associated with tumour growth through stimulation of the same 
Ras/Raf/MAPK pathway (Kamphorst et al., 2013). This would explain the 
localisation of the metabolites within the outer proliferative region of the HCC827 
aggregoids and potentially an upregulation in LPLs is a signature of drug 
resistance due to a mutation in the Ras/Raf/MAPK pathway. By observing the 
histology images, a typical necrotic centre was determined however, no apoptotic 
bodies were identified within the periphery of the three treated aggregoids, similar 
to the control samples (Figure 5.19a). Therefore, the LPL expression is more 
likely associated with cellular proliferation, though as H&E staining can only 
determine morphology it is still a possibility that the metabolite data has detected 
early stage apoptotic signalling. With that in mind, if LPLs induced apoptosis their 
detection within the clear necrotic/apoptotic core would have also been expected.  
In contrast, a sterol lipid species ST 27:3;O4 at m/z 429.302 was detected higher 
in the controls samples compared to the treated (AUC = 0.619) (Figure 5.19d). 
Cancer cells depend highly on sterols for active signalling and growth via the 
biosynthesis of cholesterol. High activity of oncogenic receptors, such as the 
EGFR, have been shown to accelerate sterol uptake as they are heavily involved 
in the EGFR pathway (Gabitova, Gorin, & Astsaturov, 2014; Gabitova et al., 
2015). More specifically, a high sterol activity has been reported in lung cancer 
cell lines (Howell et al., 2020). It has been further shown that a depletion in 
specific sterols sensitised highly resistance cancer cells to the EGFR inhibitor, 
cetuximab (Sukhanova et al., 2013). With a decrease of the sterol molecule in 
the treated samples, it suggests an associated signalling with EGFR pathway 




increased LPL expression within the treated samples as a positive response to 
treatment. However, due to the overall limited response and slight variation 
between samples it is absolute that further investigations of the HCC827 
response to cetuximab treatment are conducted. Nonetheless, identifying 
changes in specific metabolites in response to cetuximab treatment enabled the 
discovery of potential biological markers that could be used in future for a targeted 
approach either by further MSI experiments or the addition of higher accuracy 






Figure 5.19 Cetuximab treated HCC827 aggregoid images identified from 
multivariate analysis. a) H&E images of HCC827 aggregoids control and 1000 
µg/mL TRAIL treated. Scale bar 200 µm. Ion density maps of metabolites 
outlining the outer (white) and core (red) regions of the aggregoid sections. Mean 
intensity plotted on bar graph against the control and 1000 µg/mL treated 
samples (n=3), unpaired t-test ** p < 0.01. Scale bar 200 µm. Peaks identified a) 





5.4.3 Summary of metabolites detected in response to 
biological treatment 
 












645.452 3.7        ↓ * 
PC O-33:1 730.576 0.2        ↑ * 
PA 34:1 673.480 -1.8        ↓ * 
MG63 Anti-DR5 
PC O-33:1 730.576 1.1        ↓ 
PE P-16:0 436.280 -6.9        ↑ 
SAOS-2 TRAIL 
Glutamate 146.046 0.5        ↓ 
Cer 32:1;O2 508.474 1.7        ↑ 
Cer 34:1;O2 536.506 2.0        ↑ * 
SAOS-2 Anti-DR5 
FA 20:3;O 321.244 2.9        ↓ 
FA 18:2 279.233 -5.9        ↓ 
FA 20:4 303.232 -3.1        ↓ 
PI 34:1 835.534 -0.6        ↓ 
HCC827 Cetuximab 
LPE 18:1 478.294 1.1        ↑ ** 
LPC 15:0 480.311 3.3        ↑ 
ST 27:3;O4 429.302 2.1        ↓ 
Table 5.1 A summary of metabolite changes detected in aggregoid models 
in response to biologic treatments. Mass accuracy < 7 ppm. Data is mean 
(n=3), unpaired t-test * p < 0.05, ** p < 0.01. 
 
5.4.4 Possible biologic resistance in 3D cultures 
Overall, the data suggests a limited metabolic response was detected within the 
three aggregoid models of cancer treated with biologics. For the MG63 aggregoid 
cultures, the response to TRAIL in comparison to anti-DR5 was similar to the data 
from the 2D experiment. A difference between TRAIL and the DR5 specific mAb 
could be due to the targeting of both death receptors (DR4 and DR5), which is 
more likely to stimulate an apoptotic response opposed to targeting DR5 only. 
The lack of metabolic response in the SAOS-2 aggregoid cultures on the other 




data. A reason for the possible TRAIL-based therapy resistance in SAOS-2 has 
been reportedly due to the lack of TRAIL receptors on the cell surface of SAOS-
2 cells (Locklin et al., 2007), however Phillips et al., (2019) showed that they do 
respond to TRAIL and anti-DR5 if treated with a TRAIL-sensitiser. Differences of 
TRAIL response between 2D to 3D cell cultures have previously been observed 
in breast cancer cells (Chandrasekaran et al., 2014), in addition to prostate 
cancer cell lines, whereby a decrease in the expression of DR4 and DR5 was 
observed in spheroids (Grayson et al., 2021). In the case of the HCC827 
aggregoids treated with cetuximab, a limited response could simply be due to the 
incubation time of treatment. However, with the knowledge of cetuximab 
resistance in lung cancers, the efficacy of the antagonistic mAb could be affected 
by mutations downstream of the EGFR signalling pathways, such as the 
overexpression of Ras (Scaltriti & Baselga, 2006).  
A major explanation to drug resistance is the presence of cancer stem cells 
(CSCs) within 3D cultures. Numerous studies have identified CSCs influencing 
key signalling pathways via self-renewal, quiescence, EMT and genetic 
modifications contributing to resistance against therapeutics (Prieto-Villa et al., 
2017; Phi et al., 2018). It is therefore highly likely that the presence of CSCs are 
playing an important role in the lack of metabolic response to biologic treatment 
of the aggregoid models. More specifically, evidence of resistance to a specific 
programmed cell death, known as anoikis has been established when monolayer 
cells are grown in 3D cultures. Anoikis is the induction of apoptosis in cells 
through both extrinsic and intrinsic pathways upon loss of attachment to the ECM 
(Frisch & Francis, 1994). The development of resistance to anoikis is essential 
for cancer cells to metastasise as they purposely detach from their ECM 
(Simpson, Anyiwe, & Schimmer, 2008). Such resistance has been directly linked 
to the expression of the phosphorylated tyrosine kinase Src (pSrc). The 
expression of pSrc correlated with E-cadherin expression in anoikis resistant 
spheroid cultures of lung adenocarcinoma, including the HCC827 cell line, and 
shown in intralymphatic lung adenocarcinoma patient tissues (Sakuma et al., 
2010). pSrc activity has also been associated with mediating the PI3K/Akt/mTOR 
pathway to promote anoikis resistance in SAOS-2 cells (Díaz-Montero, Wygant, 
& McIntyre, 2006). It is thought that such resistance to anoikis cell death can have 




apoptotic pathways, and thus leads to a resistance to apoptotic-inducing 
therapeutics (Kim et al., 2012). Through the method of culturing the aggregoid 
models, cells are initially grown into spheroids from a single cell with no 
endogenous ECM, only alginate as a scaffold which is biologically inert. It is 
therefore possible this method has selected pSrc positive cells that have survived 
anoikis to form the aggregoid models and are thus consequently resistant to 
multiple forms of cell death, such as TRAIL signalling. A suitable method to test  
and determine anoikis resistance would be to treat the aggregoid models with Src 
inhibitors. Previous experiments have demonstrated success of reprogramming 
apoptosis with Src inhibitors, such as dasatinib (Johnson et al., 2005; Araujo & 
Logothetis, 2010), and have shown dual inhibition of cancer growth in 
combination therapy, such as with cetuximab (Parseghian et al., 2017).  
Alternatively, a lack of metabolic response to treatment could also be due to the 
inefficiency of drug delivery within the aggregoid model. If a drug cannot 
penetrate through the tissue to its target or the amount of drug present is 
insufficient to cause a cellular effect, the efficacy of the drug is diminished. 
Therefore, a direct assessment of the biologic distribution within the aggregoid 
models could complement the metabolomics data to give a better understanding 
of the efficacy of the biopharmaceuticals. The development of a robust MSI 
strategy to detect cetuximab within the HCC827 aggregoid model is discussed in 
Chapter 6.  
5.5 Concluding remarks 
In this chapter, an unsupervised MVA in combination with DESI-MSI approach 
was employed to detect changes in the metabolome of the aggregoid models in 
response to biopharmaceutical treatment. The data from the two OS aggregoid 
models, suggested possible detection of metabolite changes in response to 
TRAIL-based therapy, specifically for the MG63 aggregoids treated with TRAIL. 
This was the same from the data of the cetuximab treated HCC827 lung 
adenocarcinoma aggregoids, where some changes in metabolites suggested a 
lower rate of proliferation through inhibition of EGFR signalling. Although, the 
overall limited response across the aggregoid models suggested possible drug-




determine if there is such resistance, whether it is due to a mechanistic or delivery 
issue.  
On a technical note, no definitive conclusions on the annotations of each 
metabolite or the biological pathways discussed can be made at this point of the 
study. To support the findings, MS/MS profiling of each peak would be required 
to confirm the identities. Furthermore, employing LC-MS/MS analysis with 
additional biological replicates will allow for better sensitivity and accuracy of 
results to further support the validation of this method. It is clear that there is 
variation between aggregoid samples of the same model, therefore analysis of 
additional replicates would also be heavily suggested to decrease group 
variability and improve discrimination of metabolites. Nevertheless, significant 
changes in metabolite activity within treated aggregoids were detected and 
potential biomarkers have been identified, which could assist future aggregoid 
treatment research in a more targeted approach. Overall, the method to 
determine biologic response still requires optimisation, however, the preliminary 
work in this study demonstrates a potential strategy for analysing the efficacy of 




CHAPTER 6. OPTIMISATION OF STRATEGIES 
FOR MSI DETECTION OF A 
BIOPHARMACEUTICAL IN AN 
AGGREGATED 3D CELL CULTURE 





During the development of a pharmaceutical, it is necessary to study the delivery 
of the drug to understand its efficacy and toxicity. The quantitative measurement 
of a drug within tissue can provide essential information of its concentration and 
facilitate studies of its metabolism and the biological outcome. The direct 
assessment of drug distribution within tissues is technically challenging. Most 
methods have relied solely on the quantification of therapeutics in plasma or 
tissue homogenates by LC-MS/MS (Rönquist-Nii & Edlund, 2005; Punt et al., 
2019). As previously discussed, however, drug plasma concentrations do not 
provide an accurate representation of therapeutic levels in specific organs, and 
the homogenisation of tissues loses all spatial information.  
Alternatively, the development of imaging techniques has promoted effective 
methods in research to which a drug’s penetration and distribution can be 
assessed in vivo. Traditionally, the visualisation of compounds in tissues has 
been achieved using imaging techniques such as fluorescence microscopy 
(Hermsmeier et al., 2018), PET (Piel et al., 2014) and qWBA (Solon & Kraus, 
2001). Such methodologies, however, are time consuming and costly. In addition, 
these techniques are targeted approaches which require the addition of 
fluorescent tags or radiolabels. These changes to the starting molecule can have 
a possible effect on therapeutic pathways or alter biological compositions, which 
can misrepresent the true distribution behaviour of the drug.   
On the other hand, MSI techniques have the capabilities of detecting the 
localisation of  therapeutics within a biological sample, without the use of labels. 
For that reason, MSI has emerged within pharmaceutical research and 
development as a valuable technique for drug efficacy and toxicity studies. 
Although many MSI techniques including DESI and LESA have demonstrated 
high capacity for drug distributional studies (Swales et al., 2016; Dexter et al., 
2019), MALDI is the most predominantly used platform. The continuous 
advancements in spatial resolution, speed of acquisition and high-performance 
mass analysers with MALDI-MSI  further the capabilities in pharmaceutical 
research (Swales et al., 2019). The MALDI-MSI application has also had a 
significant impact on 3D cell culture models for assessing drug efficacy with great 




Small molecule drugs have dominated the literature for MALDI-MSI applications 
in early stage drug development (Nilsson et al., 2015; Aikawa et al., 2016; Taylor, 
Dexter, & Bunch, 2018; Russo et al., 2018; Handler et al., 2021). Small molecule 
drugs are highly effective  compounds as a treatment and have the ability to be 
administered by a variety of routes. Small molecules are also more readily 
ionisable compounds which are highly detectable during MALDI analysis. 
Although, current pharmaceutical applications are edging towards DESI due to 
the greater coverage in the detection of metabolites than MALDI, which is limited 
by matrix choice. In addition, DESI ionisation techniques are often coupled to 
mass analysers, such as orbitraps , for increased sensitivity and mass accuracy.  
Over the recent years, biopharmaceuticals have received considerable attention, 
becoming one of the fastest growing sectors within the pharmaceutical industry. 
The rapid growth of biopharmaceuticals has thus challenged MSI to progress 
their detection with the same momentum. Due to its range of mass detection and 
resolution, MALDI is the superior ionisation technique for the detection of proteins 
(Hermann et al., 2020). However, the detection of complex biologics ~ 40–150 
kDa, presents issues associated with low ionisation efficiencies leading to poor 
sensitivity.  
Attempts to detect biopharmaceuticals by MALDI-MSI have been previously 
reported, although the literature is limited. Ait-Belkacem et al., (2014) exploited 
an in-source decay (ISD) top-down fragmentation approach to detect the 
monoclonal therapeutics, bevacizumab and palivizumab within the brain. The ISD 
technique has no limitation on mass range due to its ability to rapidly fragment 
proteins, therefore proved beneficial for biologic detection. However, limitations 
of in-source fragmentation include the lack of precursor ion selection and the low 
ion yield of fragments, which consequently creates issues in the accurate 
detection of biologic-specific peaks. The study, however, reported the use of a 
second fragmentation known as T3-sequencing, similar to MS/MS analysis, to 
assist the identification of specific peaks by determining the amino acid 
sequence.   
Alternatively, Liu et al., (2018) described a novel approach of an on-tissue 
reduction and alkylation for the detection of cetuximab in tumour spheroids and 
organoids. Reduction and alkylation are used to unfold structures by breaking 




prior to an in-solution or gel protein digestion. The use as an on-tissue approach 
in imaging studies has a limited amount of literature reporting this technique 
(Green‐Mitchell et al., 2011). In the biologic study, the method was used to 
separate the heavy and light chains of the antibody for the detection of cetuximab 
at a smaller mass range (from 150 kDa to ~ 20–50 kDa) (Liu et al., 2018). 
Limitations of this practice can however result in low fragmentation efficiencies, 
which can impact the ability to accurately isolate the ion of interest from 
considerable signal of endogenous species. Initial profiling of the reduced mAb 
prior to imaging is also necessary to correctly identify the biologic.  
A significant lack of publications in biopharmaceutical detection by MALDI 
imaging demonstrates the need for further method development. An alternative 
approach that has had extensive success in the detection of endogenous proteins 
by MALDI-MSI is an on-tissue bottom-up proteomics strategy (Lemaire et al., 
2007; Djidja et al., 2009; Stauber et al., 2010; Cole et al., 2011). Bottom-up 
proteomics is a technique whereby proteins are digested in situ using specific 
enzymes, mainly trypsin, into smaller peptide fragments. These fragments are of 
a lower molecular weight and are more readily ionisable, allowing for the 
identification of proteins within a tissue. 
A bottom-up proteomics approach has been previously demonstrated to be an 
accurate method to detect biologics in complex matrices such as plasma and 
tissue by direct LC-MS/MS analysis (Osaki, Tabata, & Oe, 2017; Shibata et al., 
2017). The LC-MS/MS method allowed for the identification of peptides derived 
from the variable chains of a mAb. The detection of such peptides also identified 
complementarity-determining regions (CDRs); these are hypervariable regions 
that are unique to the immunoglobulin gene sequence. The CDRs can be used 
as surrogate peptides to validate the identification of the therapeutic. Considering 
that the detection of a biologic was achievable following this proteomics method, 
an on-tissue imaging approach seems possible.  
Currently, there is not a gold-standard on-tissue digestion protocol that has been 
established. This is in part due to the difficultly in developing one method that fits 
all sample types (Martin-Lorenzo et al., 2014). Various papers have reported an 
“optimum methodology” for the detection of proteotypic peptides in biological 




from sample preparation and instrumentation to the identification and validation 
approaches has been published (Cillero-Pastor & Heeren, 2014).  
Sample preparation is an important parameter in the proteomics workflow that 
not only influences the peptide yield, but can have a significant effect on the 
accuracy, sensitivity and reproducibility of the imaging data (Diehl et al., 2015; 
Hermann et al., 2020). In peptide MALDI-MSI experiments, sample preparation 
techniques include washing conditions, enzymatic digestion and matrix coating. 
A plethora of peptide imaging studies have followed a strategic approach to 
assess and optimise sample preparation parameters specific for their sample of 
interest (Lemaire et al., 2006; Seeley et al., 2008; Diehl et al., 2015; Patel et al., 
2015; Hermann et al., 2020). Yet, the outcome of each report differs and cannot 
be comparable due to a multitude of variables, including the analysis of different 
samples. It is therefore a necessary requirement to optimise various techniques 
for specific sample types and analytes of interest, such as in the case of detecting 
of a biopharmaceutical within the aggregoid model.  
Alternatively, considering the principles of the IMC technique and following the 
successful application to analyse the aggregoid models (Chapter 3.4.2 and 
Chapter 4.4.2), a similar experimental approach could be designed for the 
detection of a biopharmaceutical; however, this is not a label-free method. The 
concept of IMC is to detect proteins and protein modifications by target specific 
antibodies that are tagged with a rare species of lanthanide metals exogenous to 
biological tissue. With that in mind, mAbs target a specific protein of interest. If 
the antibody is tagged prior to treatment, the distribution of the biologic could in 
theory be determined by imaging analysis. Van Acker et al., (2019) reported a 
similar approach in which the group tagged cetuximab with a lanthanide (165Ho) 
to detect the EGFR in 2D breast cancer cells by LA-ICP-MSI.  
As previously reported (Chapter 3.4.3 and 4.4.3) LA-ICP-MSI is sensitive 
technique for the detection of endogenous metal isotopes at high spatial 
resolution within the aggregoid model (Flint et al., 2020). Using LA-ICP-MSI, it 
would be possible to detect a metal-conjugated biologic simultaneously with 
endogenous elements to understand the distribution of the drug and the 




6.2 Aims of chapter 
In the following chapter, the aim was to employ a systematic approach to develop 
multimodal MSI strategies in which to detect the monoclonal antibody, cetuximab 
within the HCC827 aggregoid model.  
Firstly, a bottom-up MALDI-MSI proteomics method was developed. Sample 
preparation parameters were optimised by the detection of endogenous proteins 
within the aggregoid model. The parameters evaluated included: trypsin solvent 
concentration and solvent composition, tissue washing methods, incubation 
conditions, and trypsin deposition. The optimised procedure was then employed 
to detect cetuximab based on its proteotypic peptides within the aggregoid model.  
A second method of cetuximab detection by LA-ICP-MSI was also developed. 
Here, the approach used was to tag cetuximab with a rare lanthanide metal 
exogenous to the aggregoid tissue. The validation of tagging cetuximab was 
evaluated through LA-ICP-MS profiling. Following this, treatment of the aggregoid 
model with the tagged drug at therapeutic levels was evaluated by imaging 
analysis.  
6.3 Materials and methods 
6.3.1 Materials  
α-CHCA, DHB, alginic acid, ammonium bicarbonate (NH5CO2), aniline, 
phosphorus red, potassium sulphate (K2SO4), and TFA were purchased from 
Sigma-Aldrich (Gillingham, UK). ACN, acetone (AcOH), Bond breaker neutral pH 
TCEP, chloroform (CHCl3), EtOH, MeOH and isopropanol (IPA) were purchased 
from ThermoFisher Scientific (Loughborough, UK). Sequence grade modified 
trypsin (20 µg lyophilised) was purchased from Promega (Southampton, UK). 
RapiGest™ (1 mg lyophilised) was purchased from Waters (Manchester, UK). 
151Eu MaxPar® antibody labelling kit was purchased from Fluidigm® 
(Cambourne, UK). Antibody stabiliser PBS was purchased from Bioaxxess 
(Gloucestershire, UK).  
6.3.2 151Eu antibody labelling protocol 
Cetuximab was labelled with 151Eu following the MaxPar® antibody labelling kit 
protocol (Fluidigm®, UK). Briefly, the MaxPar® X8 polymer was preloaded with 




at 37°C. The protein concentration of Cetuximab was determined using the 
Nanodrop™ (ThermoFisher Scientific, UK) prior to reducing the antibody with 
TCEP at 37°C. The lanthanide-loaded polymer and the reduced antibody were 
purified using buffers provided by the labelling kit. Following this, the antibody 
was conjugated with the lanthanide-loaded polymer incubated at 37°C. The 
metal-conjugated antibody was washed with the provided buffer x3 before 
determining the yield of protein using the Nanodrop™. The antibody stabilising 
PBS buffer was added to obtain a final concentration of 0.5 mg/mL.  
To validate the 151Eu conjugation with cetuximab, a staining protocol similar to 
the IMC staining protocol described in Chapter 3.3.5.1 was followed. Briefly, 
aggregoid sections were fixed with 4% PFA (10 min) at RT. Prior to staining, 
tissues were permeabilized with 1x casein solution containing 0.1% Triton™ X-
100 for 5 min at RT. Tissues were then incubated with blocking buffer (1x casein 
solution) for 30 min at RT. The conjugated antibody was made at different 
concentrations: 1:50, 1:100 and 1:200, with a control. Tissues were incubated 
with the conjugated antibody overnight at 4˚C. Washes with PBS were performed 
x3 between each step, with the last step washed in deionized water for 30 s. 
Slides were left to air-dry until analysis. 
6.3.3 Cell culture 
6.3.3.1 A cell plug for workflow optimisation 
A cell pellet/plug was created for the purpose of optimising different parameters 
of the bottom-up proteomics workflow. Two T-175 flasks of HCC827 cell line were 
cultured in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin 
(Lonza Ltd, UK) until 80% confluent. Cells were trypsinised, combined and 
centrifuged to create a non-homogenised cell pellet. The cell pellet was washed 
in PBS twice, centrifuging between each wash before flash freezing the pellet 
with the falcon tube in liquid nitrogen for approximately 1-2 min. Embedding 
media, 7.5% HPMC and 2.5% PVP, was coated within a mould. The cell pellet 
was slightly warmed to remove from the falcon, transferred into the mould and 
covered with additional HPMC & PVP. The cell plug was flash frozen in liquid 
nitrogen for 1-2 min and stored at - 80°C prior to sectioning. The cell plug was 




tra® adhesive slides, desiccated and vacuum packed before storing at - 80°C 
until use.  
6.3.3.2 3D culture growth and drug treatment  
HCC827 lung adenocarcinoma aggregoids were cultured following the protocol 
described in Chapter 2.3.3.  
For the bottom-up MALDI-MSI proteomics experiment, aggregoids were treated 
with Cetuximab concentrations: 0 µg/mL and 150 µg/mL. Drug solutions were 
made up with DMEM supplemented with 10% FBS and 1% penicillin-
streptomycin (Lonza Ltd, UK). Samples were incubated for 24 h before 
harvesting.  
For the LA-ICP-MSI metal detection experiment, aggregoids were treated with 0 
µg/mL and 5 µg/mL 151Eu-Cetuximab. Drug solutions were made up with DMEM 
supplemented with 10% FBS and 1% penicillin-streptomycin (Lonza Ltd, UK). 
Samples were incubated for 24 h before harvesting.  
Aggregoids were processed following the optimised method reported in Chapter 
2.3.4. Samples were sectioned at a thickness of 10 µm and thaw mounted onto 
either positively charged X-tra® adhesive slides or ITO-coated slides (Visiontek 
Systems Ltd, UK) dependant on the instrumentation used for analysis. Each 
section was desiccated, and slides were vacuum packed and stored at - 80°C 
until use.  
6.3.4 Bottom-up MALDI-MSI proteomic workflow  
6.3.4.1 In-solution digest  
Firstly, varying solutions of trypsin were investigated for optimum digestion. 
Sequence grade modified trypsin (20 µg) was made up in either 25 mM or 50 mM 
NH4HCO3 and with 0.1% added or 0.1% final concentration of RapiGest™ (RG). 
The solutions were as follows: (1) 25 mM NH4HCO3 with 0.1% RG final; (2) 50 
mM NH4HCO3 with 0.1% RG final; (3) 25 mM NH4HCO3 with 0.1% RG added; (4) 
50 mM NH4HCO3with 0.1% RG added. The combinations of trypsin solution are 
shown in Table 6.1. Cetuximab (5 mg/mL) was digested with each trypsin solution 
and incubated for 1 h at 37°C. Solutions were placed on ice to stop the reaction. 
Sample clean-up was performed using C18 Milipore® Ziptips where digests were 




solution (x2), 0.1% TFA equilibrium solution (x2), sample perfusion (x10), 0.1% 
TFA wash solution (x2), and 70% ACN:0.1% TFA elution buffer perfusion (x10). 
Digests were profiled using 5 mg/mL α-CHCA (70% ACN:0.1% TFA with 
equimolar amounts of aniline). Samples were manually spotted (0.5 µL) n=3 onto 
a MALDI target plate. Matrix (0.5 µL) was mixed with each spot on the target plate 
and allowed to dry at RT prior to analysis.  
To determine the peptide mass fingerprint of cetuximab an in-solution digest was 
performed. Limit of detection of cetuximab peptides was performed by tryptic 
digestion of solutions ranging from 1 µg/mL to 5 mg/mL. Solutions were mixed 
1:1 (v/v) with 0.2% RapiGest™ (0.1% final volume) and incubated at 37°C for 20 
min prior to digesting the samples 1:25 (trypsin:protein, v/v) with optimum trypsin. 
The solutions were incubated for 1 h at 37°C. The digest was stopped on ice, and 
solutions were cleaned up using C18 Milipore® Ziptips. Digests (n=3) were 
profiled using 5 mg/mL α-CHCA.  
6.3.4.2 Sample washing  
Prior to washing, 0.5 µL of cetuximab (5 mg/mL) was spotted in one ROI onto 
each cell plug section and left to air-dry. Three washing protocols were assessed: 
(1) EtOH; (2) IPA; (3) Carnoy’s fluid. A no wash was also included to compare 
the effects of the washes on the signal intensity of the acquired mass 
spectrometric data. Washes (1) and (2) were similar procedures whereby 
samples were washed subsequently in 70% and 95% ice-cold solvent for 45 s 
each. For the Carnoy’s fluid (3) the sample was washed in 70%, 100% EtOH for 
30 s, followed by 2 min wash in Carnoy’s fluid (EtOH: CHCl3: AcOH, 6:3:1 parts 
respectively), then 100% EtOH, H2O, and 100% EtOH for 30 s. Slides were left 
to air-dry after each wash procedure. The washing conditions are shown in Table 
6.1. Trypsin was spotted in three ROIs of each cell plug, including the cetuximab 
ROI, prior to incubation. α-CHCA was spotted on each region before to MALDI 
analysis.  
6.3.4.3 Digestion incubation 
The effect of incubation methods of the digested cell plug tissue sections on the 
signal intensity of the acquired mass spectrometric data was examined. Cell plug 
sections were spotted in one ROI with cetuximab (5 mg/mL), and then in three 




chambers were prepared as follows: (1) 50% H2O: 50% MeOH within a silicone 
sealed container to ensure an air-tight environment; (2) Saturated K2SO4 within 
a silicon sealed container; (3) Wet paper within a tip box and sealed using 
parafilm. Each chamber was incubated at 37°C for 3 h. Incubation conditions are 
displayed in Table 6.1. Afterward, samples were spotted with 5 mg/mL α-CHCA 
prior to MALDI analysis.  
6.3.4.4 Trypsin application for MSI analysis 
Trypsin deposition onto aggregoid sections for the detection and localisation of 
proteotypic peptides was assessed by two methods. To assess the efficiency of 
the tryptic digestion protocol, rat brain sections (10 µm thickness) were included 
in the analysis. The two methods evaluated were spray-coat and micro-spotting. 
The spray-coat method conducted by the automated matrix TM Sprayer™ (HTX 
Technologies, USA). Trypsin was deposited onto tissue sections in 8 passes at 
a flow rate 0.06 mL/min using a nitrogen air pressure of 10 psi. The nozzle was 
set to a height of 40 mm and a temperature at 30°C. The micro-spotting technique 
was conducted using a BioSpot® TS Microarray (BioFluidiX Technologies, 
Germany). Trypsin was spotted at a volume of 50 nL, the droplet size was 
calibrated at a 0.2% variance. Trypsin deposition methods are reviewed in Table 
6.1. Slides were digested in the optimum incubation chamber at 37°C for 3 h. 
Afterward, 37.5 mg/mL DHB matrix (50% MeOH: 0.1% TFA) was applied to the 
slides using a TM Sprayer in 8 passes. The nozzle height was 40 mm and 
temperature was set to 75°C with a backup flow of 50% MeOH: H2O. The flow 







Optimal  Analysis 
Trypsin 
solution 
(1)  25 mM NH4HCO3; 0.1% (final) 
RapiGest™ 
(2)  50 mM NH4HCO3; 0.1% (final) 
RapiGest™ 
(3)  25 mM NH4HCO3; 0.1% (added) 
RapiGest™ 







(1)  70% EtOH, 95% EtOH; 45 s 
(2)  70% IPA, 95% IPA; 45 s 
(3)  70% EtOH, 100% EtOH; 30s. Carnoy’s 
fluid (EtOH:CHCl3:AcOH, 6:3:1); 2 min. 






(1)  50% H
2
O: 50% MeOH; silicon sealed 
container; 3 h 
(2)  Saturated K2SO4; silicon sealed 
container; 3 h 







(1)  Spray-coat; HTX TM Sprayer™ 
(2)  Micro-spotting; BioSpot® TS Microarray 
MALDI MS 
Imaging; DHB 
Table 6.1 An overview of the assessed parameters and conditions for the 





6.3.5 Instrumentation  
6.3.5.1 MALDI analysis 
6.3.5.1.1  MALDI-MS profiling  
The MALDI-MS profiling spectra were acquired in positive mode using a Waters 
MALDI HDMS Synapt™ G2 mass spectrometer (Waters Corporation, UK), 
equipped with a Nd:YAG laser operated at 1 kHz. Instrument calibration was 
performed using phosphorus red. Spectra were acquired in full scan sensitivity 
mode within a m/z range 600-2500 at a resolution 10 000 FWHM. The laser 
energy was set to 350 arbitrary units. The ion mobility function was enabled to 
improve the separation of peaks.  
MALDI-MS profiling data were converted to .txt file format using MassLynx™ 
software (Waters Corporation, UK) and analysed using mMass 3 open-source 
software (Strohalm et al., 2010). Peak picking settings were set at a S/N threshold 
of 5 (unless stated in text), and the picking height was 100%. Both the absolute 
and relative intensity thresholds were set to 0 with baseline correction and 
smoothing applied. Amino acid sequences of abundant proteins were compiled 
into a library on mMass. Each sequence was in silico digested and matched 
against each mass spectra to annotate peaks. Identification of values were 
validated by using the PeptideMass tool from ExPASy:SIB bioinformatics 
resource portal (Artimo et al., 2012). An in silico digest of specific protein 
sequences were cleaved and masses of generated peptides were computed.  
6.3.5.1.2  MALDI-MSI 
Initial sample preparation methods were evaluated using a MALDI rapifleX 
Tissuetyper (Bruker Daltonics, Germany) equipped with a 10 kHz Smartbeam 3D 
Nd:YAG laser. Images were acquired in positive ion-reflectron mode over a mass 
range of m/z 600-2500. Instrument calibration was performed using phosphorus 
red. Imaging data was collected at a spatial resolution of 20 µm, and 500 laser 
shots were summed per raster position.  
MALDI-MSI data were initially processed using FlexImaging 5.0 software (Bruker 
Daltonics, Germany) to determine the quality of the data after acquisition. In-
depth data processing was achieved using the SCiLS™ Lab MVS Version 2020a 




was generated from the maximum 100 peaks per spectrum. Discrimination 
between samples was achieved by employing the ROC tool in SCiLS™ to 
calculate the AUC value.  
6.3.5.2 LA-ICP-MSI analysis  
Analysis of the metal tagged protein was performed following a similar method 
described in Chapter 3.3.6. Laser parameters were optimised to 6 μm spot size 
with laser power 46%, 25 μm/s scan speed, 0.07 Jcm-2 laser fluence, and 20 Hz 
repetition rate. Samples were ablated line by line with 6 μm raster spacing. 
Isotopes monitored included 24Mg, 66Zn, 63Cu and 151Eu. The instrument was 
controlled using Syngistix software. Data analysis was achieved using Iolite 
Software on Igor Pro (WaveMetrics, USA). 
6.4 Results and discussion 
6.4.1 A bottom-up MALDI-MSI proteomics strategy 
6.4.1.1 Tryptic digestion 
6.4.1.1.1  Optimisation of trypsin solution  
First, the effect of an in-solution trypsinisation of cetuximab was investigated. 
Four combinations of trypsin solutions including concentrations of buffer, 
NH4HCO3, and surfactant, RapiGest™, were evaluated. The absolute intensity 
was determined by the most abundant peak m/z 1677.8, and the relative intensity 















NH4HCO3 is commonly used as a trypsin buffer. The slightly alkaline pH 7.7 is 
close to the optimum pH 8 for trypsin digestion to achieve optimum reaction (Link 
& LaBaer, 2011). Various publications have reported different concentrations of 
NH4HCO3 with trypsin ranging from 20 mM – 100 mM with successful peptide 
detection in situ (Ren et al., 2009; Cole et al., 2011; Ly et al., 2019). From 
observing the absolute and relative intensity in this experiment there was no 
difference between 25 mM and 50 mM, when comparing 0.1% (added) 
RapiGest™.  
Alternatively, the addition of 0.1% (final) RapiGest™ showed an increase in 
intensity for NH4HCO3 concentrations, particularly for the 25 mM solution. The 
optimum concentration of RapiGest™ therefore had an impact on the 
performance of trypsinisation. The purpose of a surfactant, or detergent, is to 
unfold the protein for more accessible enzymatic cleavage and effective 
solubilisation to increase the number of peptides and their intensity during 
analysis. RapiGest™ was used based on comparative studies that reported 
better performance to other detergents for in-solution digestions (Chen et al., 
Figure 6.1 The absolute and relative intensity of the most abundant 
cetuximab peak m/z 1677.8 with several trypsin solvent solutions. For the 
relative intensity, m/z 1677.8 was normalised with the α-CHCA peak m/z 861.0. 
Data is mean (n=3) ± SD, statistical significance determined by one-way ANOVA 




2007; Chen et al., 2008). Other typical surfactants include Octyl ß-D-
glucopyranoside (OcGlu) and N-Octanoyl-N-methylglucamin (MEGA-8) which 
have been incorporated within in-solution and in situ digestion protocols (Djidja 
et al., 2009; Patel et al., 2015). The addition of RapiGest™ for in situ digestion, 
however, has limited literature with two studies reporting preliminary data profiling 
and imaging an ungroomed fingermark (Patel et al., 2015; Deininger et al., 2016).  
Overall, a statistically significant difference in the relative intensity was observed 
from trypsin solution containing 25 mM NH4HCO3 with a 0.1% (final) RapiGest™ 
compared to the other trypsin solutions. It was therefore decided this solvent 
combination was the optimum for effective tryptic digestions.  
6.4.1.1.2  Cetuximab peptide mass fingerprint  
The tryptic peptide profile of cetuximab was determined to analyse and select 
specific peaks for the identification of the therapeutic within the aggregoid model. 
An in silico digest of cetuximab was used to assign the peaks within the acquired 
spectra. Table 6.2 reports the cetuximab peptides detected within the spectra, 
highlighting the variable chain location and the m/z values. Variable light chain 
(VL) peptides 49-YASESISGIPSR at m/z 1266.6 and 24-ASQSIGTNIHWYQQR 
at m/z 1788.8 were identified as signature peptides containing CDRs. These 
corresponded to existing literature (Li et al., 2005; Shibata et al., 2017) and were 
confirmed following the Kabat definition of CDR identification (Wu & Kabat, 1970; 
Kabat, Wu, & Bilofsky, 1977). These are unique sequences in the variable chains 
of cetuximab and therefore can be used as surrogate peptides for identification 
in situ. The CDR variable heavy chain (VH) peptide 44-
GLEWLGVIWSGGNTDYNTPFTSR at m/z 2570.2 was also identified although at 










Peptide sequence Chain 
755.4075 -1.5 SQVFFK VH 
835.4327 -1.8 DTLMISR VH 
838.5020 -1.5 ALPAPIEK VH 
1186.6509 3.6 GPSVFPLAPSSK VH 
1266.6439 9.0 YASESISGIPSR VL 
1677.8173 9.1 FNWYVDGVEVHNAK VH 
1788.8828 2.9 ASQSIGTNIHWYQQR VL 
1808.0089 1.3 VVSVLTVLHQDWLNGK VH 
1924.0779 1.5 DILLTQSPVILSVSPGER VL 
2082.9888 -8.2 TPEVTCVVVDVSHEDPEVK VH 
2570.2251 2.3 GLEWLGVIWSGGNTDYNTPFTSR VH 
Table 6.2 List of cetuximab tryptic peptides identified after in solution 
digestion by MALDI-MS analysis. Observed m/z values in positive ion mode, 
the mass error (ppm) and the variable chain are included. Underlined sequences 
highlight the CDRs. CDRs were determined following the Kabat definition. 
 
A VH peptide 277-FNWYVDGVEVHNAK at m/z 1677.8 was observed as the 
most abundant peak present in the peptide mass fingerprint of cetuximab. The 
peak was validated by MS/MS analysis to confirm the sequence of the peak. 
Figure 6.2 displays the MS/MS spectra of m/z 1677.8 highlighting the y-ions of 
the sequence. A fragment ion calculator (Systems Biology) was used to identify 






A range of cetuximab concentrations from 1 µg/mL to 5 mg/mL were digested to 
determine the limit of detection. The lowest concentration of cetuximab peptides 
detected was 5 µg/mL with a S/N of 3. The number of peptides detected, and 
their intensities were significantly reduced in comparison to 5 mg/mL, as 
expected. The VH m/z 1788.8 was the only CDR containing peptide identified 
(S/N 3) at this low concentration. Figure 6.3 displays spectra from the highest and 
lowest detected cetuximab peptides. Some peptides including m/z 1266.6 and 
m/z 1677.8 were detected within the lowest concentration, although at a S/N < 3.  
  
Figure 6.2 MALDI-MS/MS spectrum of the 5 mg/mL cetuximab tryptic 





6.4.1.1.3  In situ peptide mass fingerprint  
Direct profiling of a HCC827 cell plug was performed to investigate the protein 
expression within the aggregoid samples. As the cell plug is created through the 
growth of HCC827 cell line, the protein profile would be similar to the aggregoid. 
This was achieved by following a standardised protocol for on-tissue tryptic 
digestion, prior to optimising a protocol for aggregoid peptide imaging analysis.  
Spectra were obtained within the peptide mass range of m/z 600-2500 and 
identification of peaks were made by putative assignments. Table 6.3 reports 
some of the detected peptides within the cell plug. Signals at m/z 944.5 (Histone 
H2A), m/z 1032.6 (Histone H3), m/z 1198.7 (actin) and m/z 1325.7 (Histone H4) 
were identified. These abundant peaks have been previously detected in tissues 
by MALDI-MSI (Djidja et al., 2009; Cole et al., 2011). It was therefore decided 
these peaks would be used for reference through the study for the evaluation of 
the bottom-up proteomics workflow conditions.  
Figure 6.3 Peptide mass fingerprint of cetuximab by MALDI-MS. a) 5 mg/mL 
b) 5 µg/mL. S/N values (red) included for each detected peak in both spectra. 








Table 6.3 List including some of the observed peptides after in situ digestion and MALDI-MS analysis. Observed m/z values 
in positive ion mode, the mass error (ppm) and the protein function are included.
Protein Peptide m/z Mass error 
(ppm) 
Peptide sequence  Protein function 
Actin 1198.7123 5.7 AVFPSIVGRPR Cell mobility 
Cathepsin D 1601.8241 -5.1 LVDQNIFSFYLSR Protease 
GRP 78  1934.0120 -0.6 DNHLLGTFDLTGIPPAPR 
Protein folding and quality control 
(HSP 70) 
Histone H1 1438.7356 7.6 YSDMIVAAIQAEK Condensation of nucleosome 
Histone H2A 944.5358 4.9 AGLQFPVGR Nuclear component 
Histone H2B 816.4573 -0.1 EIQTAVR Nuclear component 
Histone H3 1032.6000 4.9 YRPGTVALR Nuclear component 
Histone H4 1325.7540 0.3 DNIQGITKPAIR Nuclear component 
HSP 70 1020.5420 -5.2 YLEAGAAGLR Molecular chaperone 
HSP 90 1513.7789 -4.4 SLSNDWEDHLAVK Molecular chaperone 
Lactate 
dehydrogenase B 
959.5558 3.9 GLTSVINQK Synthesis of lactate from pyruvate 
Stathmin  1074.5730 4.9 DLSLEEIQK Regulation of microtubule filaments 




6.4.1.2 Optimisation of an in situ bottom-up proteomic workflow 
6.4.1.2.1  Washing protocol 
Washing samples prior to trypsin application is a technique commonly used in 
peptide imaging experiments to remove lipids and salts from the tissue. The 
washing step improves peptide coverage by increasing the ion yields and the 
number of signals within the spectra.  
Several washing procedures include combinations of organic solvents that 
extract small molecules and lipids from tissues. The most common method is 
increasing concentrations of EtOH (70%-100%) that has been demonstrated to 
significantly improve the signal intensity within the peptide mass range (Schwartz 
et al., 2003; Taban et al., 2007; Goodwin et al., 2008). EtOH wash also improves 
the preservation of tissues, as it is a conventional method for fixing samples for 
staining analysis. Solvents including IPA, MeOH, AcOH and CHCl3 have also 
been used in washing protocols. A comprehensive study conducted by Seeley et 
al., (2008) evaluated these washing solvents to reveal IPA as the most effective 
solvent in terms of the MS signal of proteins and preservation of tissues. 
Alternatively, a combination of EtOH, CHCl3 and AcOH, also known as Carnoy’s 
fluid, used extensively in histology for tissue fixation, has been introduced into 
peptide imaging experiments. A recent study by Yang & Caprioli, (2011) 
developed a new washing protocol incorporating Carnoy’s fluid that significantly 
improved the sensitivity of protein analysis in comparison to EtOH.  
In this study, three washing protocols were evaluated, EtOH, IPA and Carnoy’s 
fluid, for the peptide analysis in cell plug sections. Figure 6.4 shows the use of 
IPA as a wash was better in terms of the relative intensity of the peptide reference 
peaks m/z 944.5, m/z 1032.6 and m/z 1198.7. The use of EtOH however gave 
rise to a slightly reduced relative signal but a better absolute intensity for the 






Figure 6.5 displays the spectra observed following the three washing protocols, 
including a no wash control. By observing the spectra, peaks within the lipid mass 
range (m/z 700-850) were still present within samples washed with IPA, although 
at reduced levels when compared to the control. The EtOH wash also showed 
this effect on the mass spectra, with a further reduction in the lipid signal in 
comparison to IPA. The Carnoy’s fluid was the most successful in terms of 
diminishing the lipid intensity. This is most likely due to the addition of CHCl3, 
which was demonstrated as an efficient lipid reduction method for protein analysis 
with MALDI-MSI (Lemaire et al., 2006). In this study however, the Carnoy’s fluid 
was not the most effective method to achieve a good peptide signal. From this 
conclusion, the EtOH wash was used for further experiments based on the 
absolute and relative sensitivity to detect peptide peaks, whilst suppressing a 
considerable lipid signal in comparison to IPA.  
Figure 6.4 The absolute and relative intensities of the tryptic peptide 
reference peaks (m/z 944.5, m/z 1032.6, m/z 1198.7 and m/z 1325.7) with 
different wash protocols (EtOH, IPA and Carnoy’s fluid). For the relative 
intensity, m/z values were normalised with the α-CHCA peak m/z 861.0. Data is 
mean (n=3) ± SD, statistical significance determined by one-way ANOVA with 





6.4.1.2.2  Incubation methods 
To maintain optimum enzymatic activity over a long period of time, on-tissue 
digestion protocols incubate samples within a humidity chamber typically at 37°C. 
Achieving a stable humidity at a high percentage (90-99%) is important to 
improve the quality of the digest (Ly et al., 2019). Having an environment ≥ 100% 
humidity, otherwise known as supersaturation, can subsequently lead to 
condensation, compromising the digest and in turn increasing the risk of analyte 
delocalisation in imaging studies.  
In this study, three methods of producing a humid environment were evaluated. 
Firstly, 50% H2O: 50% MeOH (MeOH) within a sealed container is a common 
solution used previously in a range of peptide tissue imaging studies (Cole et al., 
2011; Patel et al., 2015; Deininger et al., 2016). In addition, the use of wet tissue 
paper with H2O in an empty tip rack was also included due to its success of 
peptide detection in pig lung tissues by MSI (Do et al., 2020). Alternatively, a 
Figure 6.5 The effect of washing protocols on the mass spectra by direct 
MALDI-MS analysis. Annotations of lipid species PC 34:4, m/z 760.6 and PC 
36:4, m/z 782.8; α-CHCA peak, m/z 861.1; tryptic peptide species Histone H2A, 
m/z 944.5, Histone H3, m/z 1032.6, Actin, m/z 1198.7 and Histone H4, m/z 




more recent paper stated the benefit of using saturated K2SO4 solution as a 
method for stable humidity at 96% for quality peptide analysis in clinical tissue 
microarrays (Ly et al., 2019).  
 
By observing the absolute and relative intensity of the reference peaks, MeOH 
was a superior incubation method for increasing the sensitivity for peptide 
detection (Figure 6.6). Interestingly, the Histone H4 m/z 1325.7 peak had a 
relatively low intensity and could not be detected in all three ROIs of the cell plugs 
incubated by methods of K2SO4 and wet paper. The enzymatic activity during 
these incubation conditions was therefore impacted, most likely due to an 
unstable humidity.   
6.4.1.2.3 Trypsin application  
6.4.1.2.3.1 Spray-coat 
Trypsin deposition is conventionally performed using a spray-coat technique to 
achieve a homogenous layer of enzyme over the tissue. Automated spraying 
systems are a preferred method over manual application to gain better 
reproducibility. Here, trypsin was applied using the TM-sprayer following the 
technical note #27 from HTX Technologies. In addition to the aggregoid sections, 
a section of rat brain tissue was included to determine the performance of the 
trypsin digestion. Two sets of samples were adhered onto one slide. One half of 
Figure 6.6 The absolute and relative intensities of the tryptic peptide 
reference peaks with different incubation methods: MeOH, K2SO4 and wet 
paper). For the relative intensity, m/z values (m/z 944.5, m/z 1032.6, m/z 1198.7 
and m/z 1325.7) were normalised with the α-CHCA peak m/z 861.0. Data is mean 
(n=3) ± SD, statistical significance determined by one-way ANOVA with Tukey 




the slide was prepared for digestion following the optimised washed protocol with 
EtOH, before depositing the trypsin solution.  
Figure 6.7 shows the ion density maps for three of the reference peptides, m/z 
944 (Histone H2A), m/z 1032 (Histone H3) and m/z 1198 (actin). From the data, 
the detection of peptides within the aggregoid section has poor sensitivity 
compared to the images from the rat brain section where detail of the cerebellum 
can be identified with high signal. Some peptide signal can be observed within 
the aggregoid region, although no specific detail on the localisation of these 
peaks can be determined, with potential delocalisation observed. The data 
suggests that the trypsin digestion was partly successful as these peaks were not 
detectable within the non-digested samples. The lack of sensitivity for peptides 
within the aggregoid sections implies the activity of the digestion was poor, or 
weak analyte extraction from the matrix. However, as the data from the rat brain 
displayed highly intense peptide images, it suggests specific issues with the 





By studying the data further, some residual lipid peaks could be identified in the 
digested samples. A lot of delocalisation of lipid signals was observed within the 
aggregoid sections compared to the non-digested samples (Figure 6.8), this 
could be due to lipid migration as a result of the washing procedure. Although, 
another possible reason could be the high pressure and flow rate at which the 
trypsin was deposited onto the tissues, leading to molecular migration. It has also 
been reported that the combination of DHB matrix with TFA can cause significant 
hydrolysis of phospholipids (Schiller et al., 2003), which could be a contributing 
factor. Since the non-digested samples showed no delocalisation, it suggests 
such effect is from the application of trypsin, and a could be reason for the lack 
of peptide signal.  
 
Figure 6.7 MALDI-MS images of tryptic peptides in an aggregoid section 
and rat brain section. Images of a) Histone H2A, b) Histone H3 and c) actin. 
Digestion achieved by trypsin spray-coat application. The left and middle panel 
of images have an altered intensity scale for the detection of peptide signals in 
the aggregoid section. The right panel displays the rat brain images at a normal 
intensity scale. Images were normalised using TIC. Scale bar 200 µm 




An additional note, the analyte migration was only detected within the digested 
aggregoid sections and not in the digested rat brain section. This may be due to 
a delocalisation effect within tissue sections of a smaller size being more visible 
because it is off-tissue. An aggregoid sample is ~ 1 mm in diameter compared to 
larger tissues such as a rat brain section of ~ 20 mm in length.  
 
The spray technique requires further optimisation to increase the sensitivity of 
peptide detection within the aggregoid model. Reducing the pressure and flow 
rate would be the initial parameters to test for minimised analyte diffusion. 
Experimental work with the SunCollect™ sprayer, which allows for lower flow rate 
capabilities, has been performed. The detection of peptides at an increased 
intensity has been unsuccessful (data not shown). This data, however, cannot be 
compared to the data obtained by application of trypsin using the TM-sprayer due 
to different MALDI-MSI instrumentation used for analysis.  
An alternative choice of matrix could also improve the sensitivity for peptide 
detection. The data reported was acquired with DHB as a matrix. Although DHB 
has previously demonstrated success in the detection of peptides for example in 
a mouse brain section (Schober et al., 2012); α-CHCA is a more common matrix 
for peptide detection (< 2500 Da) and has demonstrated an effective matrix to 
extract peptide peaks during the optimisation of sample preparation in this study.  
Figure 6.8 MALDI-MS images of lipid peak m/z 810 in a digested and non-
digested aggregoid section. Digestion achieved by trypsin spray-coat 





An alternative method of trypsin application is micro-spotting, this method allows 
for the deposition of trypsin within specific ROIs at nanolitre volumes. In this 
experiment, trypsin was deposited using a BioSpot® TS Microarray at 50 nL. The 
volume of the droplet was sufficient to cover a whole aggregoid section, as only 
specific spots of the rat brain were covered.  
Figure 6.9 shows the detection of reference peptide peaks m/z 944, m/z 1032, 
m/z 1198 and m/z 1325 within the aggregoid sections at a relatively high intensity 
compared to the data obtained from the spray-coat technique. However, the 
spatial information using the micro-spotting technique has been impacted. Some 
images contained “water ring” marks where the droplet was deposited and 
displayed delocalisation of peptide signals. This is a major drawback; this means 
it is not a suitable method for spatial distribution studies as the localisation of 

















Although the detection of peptides was achievable, further optimisation is 
required to retain the spatial information. Automated micro-spotting systems such 
as the Portrait™ 360 and CHIP-1000 have been reported as successful methods 
for peptide imaging studies (Djidja et al., 2009; Cole et al., 2011; Quanico et al., 
2013). These systems allow the deposition of droplets of trypsin at picolitre 
volumes within a predefined array size (~ 200 µm), which would be suitable for 
the size of the aggregoid model. Numerous concentrated areas of enzymatic 
digestion across the aggregoid tissue would allow for better detail whilst obtaining 
a relative peptide signal. Some experimental work, performed on the Portrait™ 
360, detected a small number of peptides including m/z 1032 and m/z 1198 within 
the aggregoid model acquired using a different MALDI-MSI instrumentation (data 
not shown). The reproducibility of using the Portrait™ 360 for peptide detection 
in this study however was not satisfactory, although the capabilities of achieving 
Figure 6.9 MALDI-MS images of tryptic peptides in an aggregoid section by 
micro-spotting trypsin application. Images of a) Histone H2A, b) Histone H3, 





numerous enzymatic reactions for better spatial resolution demonstrates it is a 
promising technique for this specific application.  
6.4.1.3 Preliminary detection of cetuximab within the aggregoid 
model 
The purpose of this chapter was to develop an analytical method which could be 
employed to determine the localisation of a biopharmaceutical within the tumour 
aggregoid. Following the optimisation of the bottom-up proteomics workflow 
described, the micro-spotting technique was further utilised for the detection of 
cetuximab within the aggregoid model. The objective was to initially detect signal 
of cetuximab surrogate peptides within the aggregoid at the expense of the spatial 
information. This was primarily to establish the capabilities of detecting cetuximab 
in situ by MALDI-MSI.  
In this experiment, the optimised protocol was as follows: slides were initially 
washed with increasing concentrations of EtOH. Control and treated cetuximab 
(150 µg/mL) HCC827 aggregoid sections were spotted with 50 nL trypsin (20 
µg/mL in 25 mM NH4HCO3 with a 0.1% (final) RapiGest™). The sample was 
incubated within a 50% H2O:50% MeOH humid environment at 37°C for 3 h 






Figure 6.10 shows ion images of three surrogate cetuximab peaks m/z 1266 
(CDR L1), m/z 1788 (CDR L2) and m/z 1924 within the aggregoid model. The 
detection of cetuximab peaks were confirmed with signal intensity present in the 
spotted cetuximab standard ROI. The intensities of each peak is low therefore 
optimisation is required to improve the sensitivity of detection. Further analysis 
using ROC to discriminate the m/z values between the control and treated 
samples was performed. For the three surrogate peaks, the AUC value from ROC 
Figure 6.10 MALDI-MS images of cetuximab tryptic peptides in an 
aggregoid section. Surrogate peptides a) m/z 1266 (CDR L1), b) m/z 1788 
(CDR L2) and c) m/z 1924. Images were normalised using TIC. Scale bar 200 
µm. Box plot graphs displaying the medium signal intensity of each m/z value 




analysis was > 0.9 which defined the peaks as a variate in the treated sample 
and not in the control. This is promising in terms of the detection of unique 
cetuximab peptides containing the CDR sequence within the aggregoid model. 
However, the localisation of cetuximab within the aggregoid model cannot be 
determined due to the method of trypsin application.  
An important note in this study is that the data reported are preliminary results. 
Only one set of samples was analysed due to experimental error during sample 
handling, in addition to the time constraints of instrument availability to conduct 
this experiment. Therefore, no definitive conclusions on the detection of 
cetuximab within the aggregoid model can be made. To validate the method, 
additional replicates are necessary; to determine biological variation and to define 
the expression levels of the cetuximab peaks more precisely. MS/MS profiling of 
the detected peaks could also be performed to confirm the identification of the 
surrogate peptides. Furthermore, analysis by LC-MS/MS for accurate detection 
of the reference peptides at high sensitivity should be employed to validate 
cetuximab detection within the aggregoids by MALDI-MSI, in addition to acquiring 





6.4.2 LA-ICP-MSI detection of cetuximab by metal conjugation  
6.4.2.1 Validation of metal-conjugated cetuximab 
Prior to aggregoid treatment with 151Eu-cetuximab, LA-ICP-MS profiling 
experiments were conducted to confirm the presence of the 151Eu and validate 
the metal-conjugation with cetuximab. Initially, the detection of 151Eu was 
determined by acquiring three line patterns through a 0.5 µL spot of the 
conjugated antibody solution on a glass slide. Figure 6.11 shows the 151Eu 
intensity of each line as the laser acquires through the spot, confirming the 












To determine if the metal successfully conjugated to cetuximab, a staining 
protocol was employed. Four dilutions (control, 1:200, 1:100 and 1:50) of the 
151Eu-cetuximab solution were incubated onto sections of an aggregoid. 
Following this, five line patterns were acquired across each section. Figure 6.12 
shows an increase in intensity with an increase of 151Eu-cetuximab concentration 
within the aggregoid sections. A slight detection of 151Eu within the control was 
due to signal interferences, therefore the data was normalised against the control. 
The presence of 151Eu within the tissue sections was validated with the 
simultaneous detection of endogenous metals, 24Mg, 66Zn and 63Cu (data not 
Figure 6.11 LA-ICP-MS profile of the 151Eu-cetuximab solution. Three 
acquired 151Eu intensity profiles through a spot of 151Eu-cetuximab. Line patterns 




shown). The detection of 151Eu in the stained aggregoid sections therefore 
suggests the metal has conjugated to cetuximab; the antibody has bound to its 
EGFR target within the aggregoid and has been detected by its 151Eu label. Any 
excess 151Eu in the solution was expected to have been washed off during the 
staining procedure.  
 
6.4.2.2 Localisation of 151Eu-cetuximab within the aggregoid 
model 
To determine the localisation and distribution of cetuximab within the aggregoid 
model, the main experiment was to image aggregoid samples treated with 
therapeutic levels of 151Eu-cetuximab in culture by LA-ICP-MSI. The composition 
of endogenous metals, 24Mg, 66Zn and 63Cu were selected to identify the 
phenotypical regions of the HCC827 aggregoid model, as previously 
demonstrated in Chapter 3.4.3 (Flint et al., 2020).  
Figure 6.13 demonstrates the successful detection of 151Eu signal within the 
treated aggregoid; no signal was observed in the corresponding control sample. 
The distribution of 151Eu was localised at a higher signal intensity within the core 
of the treated aggregoid, suggesting this is where cetuximab is localised. This 
was validated through the contrast in distribution of 24Mg and 66Zn, which are both 
Figure 6.12 The absolute and normalised intensity of 151Eu-cetuximab 
stained aggregoid sections. Average intensity of five acquisitions per tissue 
section. 151Eu-cetuximab dilutions: control, 1:200, 1:100 and 1:50. Data is mean 
(n=3) ± SD, statistical significance determined by one-way ANOVA with Tukey 




highly expressed within the outer proliferative region. The detection of 151Eu-
cetuximab within the core implies the drug efficiently diffused through peripheral 
regions of tissue, as lower levels of 151Eu can be observed within the surrounding 
areas.  
Conversely, another possible reason of the heterogenous distribution of 151Eu-
cetuximab is due to the expression of the EGFR within the aggregoid model. Liu 
et al., (2018) reported that the EGFR expression was distributed differently 
between two spheroid models of colon cancer (in the core of the HT 29 and in 
the periphery of DLD-1 MCTS), and therefore the localisation of cetuximab also 
differed. This suggests that the HCC827 aggregoid model highly expresses the 
EGFR within its core compared to the outer region. The EGFR has also been 
associated with hypoxia. In NSCLC, an increase in hypoxia is thought to induce 
the expression of the EGFR transmembrane protein in order to stimulate the 
expression of HIF-1α for tumour survival (Swinson & O'Byrne, 2006). 
Interestingly, a recent study reported hypoxia sensitises cancer cells to EGFR 
inhibitors (Mamo et al., 2020). Therefore, the detection of cetuximab in the core 
of the aggregoid may correlate with a positive cellular response from 
metabolomics results (Chapter 5.4.2.2). Staining for the EGFR, by 
immunofluorescence or IMC, would be carried out in further work in order to 
determine its presence and confirm the co-localisation of the 151Eu-cetuximab 









Figure 6.13 The detection of 151Eu-cetuximab within a HCC827 aggregoid by LA-ICP-MSI after 24 h. Optical images of control 
and treated aggregoid sections. Scale bar 200 µm. Elemental distributions of 24Mg, 66Zn, 63Cu and 151Eu, intensity recorded in counts 




6.5 Concluding remarks 
In this chapter, two MSI strategies were developed for the detection of a 
biopharmaceutical, cetuximab, within the HCC827 aggregoid model.  
Firstly, for a bottom-up MALDI-MSI proteomics method, a number of different 
workflow parameters were assessed. An optimised protocol was developed for 
the analysis of tryptic peptides within an aggregoid model by MALDI-MSI. 
Methods tested included buffer and surfactant concentrations for a suitable 
trypsin solution, washing solvents, incubation techniques and methods of on-
tissue trypsin application.  
From the data, a trypsin solution containing 25 mM NH4HCO3 with 0.1% (final) 
RapiGest™ showed a significantly higher intensity of peptide signals. Washing 
slides with increasing concentrations of EtOH reduced the presence of lipids 
within the spectra and subsequently amplified the peptide intensity. Furthermore, 
the use of 50% H2O: 50% MeOH created an ideal humid environment to maintain 
efficient trypsin activity.  
Both the spray-coat and micro-spotting methods of trypsin application require 
further optimisation to improve the sensitivity of the method and improve the 
detection of peptides. The use of alternative automated devices are likely more 
suitable for trypsin application in order to retain the spatial information within the 
aggregoid model (necessary for analyte localisation).  
Following the current optimised protocol, preliminary work in the detection of 
cetuximab within the aggregoid model by MALDI-MSI was achieved. Additional 
experimental work is necessary for the validation of the method to ensure the 
reproducibility of the data, as well as improving the spatial capabilities of the 
sample preparation. Nonetheless, there has been progress towards the 
development of a robust proteomic imaging strategy for applications studying 
biopharmaceutical efficacy. 
The second imaging approach by LA-ICP-MS was successful in the detection of 
cetuximab by a metal labelling technique. 151Eu-cetuximab was localised 
primarily within the core of the aggregoid which demonstrated significance for 




A comparison of the two methods developed in this study would indicate that the 
detection of a metal-labelled drug allows for a more sensitive approach to detect 
a biopharmaceutical within the 3D model. Though, this conflicts with the purpose 
of using label-free MSI techniques for drug detection in pre-clinical studies. The 
more favourable approach would be the bottom-up MALDI-MSI proteomics 
method due to the capabilities of detecting the biologic closer to its natural 
behaviour. In addition, MALDI-MSI allows for the simultaneous detection of the 
proteomic response to the treatment. The lack of a standardised protocol 
however, has hindered its ability for biopharmaceutical applications thus far.  
Overall, using multimodal MSI techniques it was possible to detect and visualise 
cetuximab within the aggregoid model. This demonstrates great potential for 
applications in early stage biopharmaceutical development and assessing drug 










The analysis of 3D cell culture models by MSI has revolutionised pre-clinical drug 
testing. In particular, tumour spheroids have been demonstrated to have value 
for studying cancer metabolism and drug pharmacology in many MSI 
applications. Tumour spheroids offer a more accurate representation of the 
tumour microenvironment compared to 2D cultures, they can be produced for 
high throughput drug analysis without ethical implications, and they represent a 
valid attempt to respond to the societal requirements to implement the 3Rs – 
reduction, replacement and refinement – for the use of animals in such research. 
Whilst extensive applications of MSI in combination with tumour spheroids 
existed when this research started, there were still significant areas yet to be 
explored. Firstly, to address the conflicting arguments of whether the tumour 
spheroid model fully replicates the complex morphological, phenotypic and 
genetic characteristics of in vivo tumours, continuous advancements in model 
development is required to ensure that pharmaceutical analyses conducted using 
them is relevant to the in vivo situation. The work presented in this thesis aimed 
to address conflicting issues of tumour spheroids through the development a 
novel aggregated tumour spheroid model, termed as an aggregoid, in order to 
create higher levels of molecular heterogeneity. Following from this, it was 
important to examine the cellular metabolism that drives cancer growth within 
these 3D cultures in order to understand and highlight additional biomarkers that 
could facilitate the prediction of drug behaviour. The use of multimodal MSI 
techniques has previously been demonstrated as a methodology for extracting 
large amounts of molecular information with a complementary nature. Multimodal 
MSI was therefore employed in this study to enable an in-depth characterisation 
of the aggregoid models. In addition, a multimodal MSI strategy in combination 
with the aggregoid model was developed for the use as a pre-clinical in vitro tool 
for biopharmaceutical testing in order to address the increasing demands for 
advancements in this field in pharmaceutical industry.  
7.2 Aggregoid optimisation for MSI analysis  
The development of three aggregoid models of cancer was achieved, two 
osteosarcoma models: one from the epithelial-like cell line SAOS-2 and one from 




The purpose of developing a novel 3D culture model was to enhance the 
molecular heterogeneity to establish a more accurate representation of in vivo. 
The method in which the aggregoid models were cultured allowed for the 
development of single-cell populations to grow into individual spheroid colonies 
of different sizes and genetic variability. Therefore, once aggregated together, 
they created a tissue comprised of clonal spheroids that exhibit different genetic 
phenotypes which are easier to detect and interpret than a heterogeneous single 
cell within an conventional MCTS model. It is suggested aggregoid model 
represents the tumour microenvironment by displaying phenotypical regions of a 
hypoxic/necrotic core and a proliferative outer region developed through the 
gradient of oxygen and nutrients. The expression of these tumour environments 
was an important attribute in order to the study a drug’s behaviour and efficacy in 
heterogenous regions of the in vitro model.   
In order to efficiently analyse the aggregoid model, it was a requirement to 
optimise sample handling methods for universal application across MSI 
techniques. The use of an embedding media, HPMC & PVP, enabled 
preservation of the aggregoid tissues and created ease of handling samples 
throughout the imaging workflow. The addition of immediate desiccation of tissue 
sections followed by vacuum packing samples prior to storage effectively 
minimised delocalisation effects of analytes within the aggregoids allowing for 
quality imaging analysis. The spray-coat application of matrix gave a better 
sensitivity for the detection of lipid species in heterogenous distributions that 
corresponded to the hypoxic core and outer proliferative zone. Further 
investigations to improve the quality of the images and reduced delocalisation of 
lipids during matrix deposition is still required, such as optimising the spraying 
parameters and solvent concentrations, or an investigation of a recrystallisation 
step following from matrix application by sublimation.  
7.3 Multimodal MSI: Characterisation of a lung adenocarcinoma 
aggregoid 
The use of different MSI techniques enabled an in-depth characterisation of the 
tumour microenvironment within the lung adenocarcinoma model, allowing 
detailed molecular phenotyping based on the endogenous metabolite, protein 




activity of central biological pathways including the TCA cycle and glycolysis in 
relation to proliferative activity and the hypoxic core. The first application of IMC 
with a 3D cell culture was reported which enabled single-cell phenotyping of 
proteins and protein modifications including the detection of Glut1 expression 
which highlighted the hypoxic core and corresponded to the lactate distribution. 
The use of LA-ICP-MSI detected endogenous metals including Mg, Zn and Cu 
and complemented the DESI and IMC data. As this was an initial study, additional 
biological replicates and technical repeats imaging different slides of the same 
samples are now required to validate this methodology of characterising the 
aggregoid model. Nevertheless, this work still improved the understanding of the 
molecular activity that influences the tumour microenvironment. Following on 
from this study, further data processing of the untargeted DESI-MSI data could 
be performed to highlight all detected metabolites within the lung model to obtain 
a larger metabolic prolife.  
7.4 Multimodal MSI: Comparison of OS aggregoid models to 
sarcoma tissue 
It is important to ensure that any 3D cell culture model aimed to be used in pre-
clinical drug analysis exhibits similar molecular characteristics to in vivo tumours. 
A comparison between the two OS models and clinical OS patient tissue was 
performed using an untargeted DESI-MSI approach. In these experiments 
metabolic similarities were observed. MG63 exhibited metastatic-like potential 
due  to the detection of fatty acid and phospholipid species that were also 
detected at high concentrations in the metastatic patient tissue. SAOS-2, on the 
other hand, showed potential characteristics of cellular differentiation and bone 
development, which were identified within specific regions of bone mineralisation 
in the OS patient tissue. To validate these findings further work involving direct 
imaging analysis of the aggregoid models and OS patient tissue within the same 
acquisition is essential. In addition, imaging MS/MS analysis and/or LC-MS/MS 
is required for confident identification of metabolite species detected in this study.  
The IMC and LA-ICP-MSI techniques were also employed to enhance the 
characterisation of the models and showed heterogeneity in the expression of 
proteins and metal compositions. The SAOS-2 model displayed the typical outer 




adenocarcinoma model, as the MG63 model did not show the presence of such 
distinct regions. The phenotypical differences demonstrated the need for 
characterising the aggregoids by multimodal imaging techniques to validate the 
unique molecular distributions across OS tumour models and to understand how 
these differences could influence drug behaviour.  
7.5 Aggregoid response to biopharmaceutical treatment  
To establish the use of the aggregoid model as a pre-clinical tool for 
biopharmaceutical testing by MSI, the metabolic response to biologic treatment 
in each model was studied using DESI-MSI. The use of multivariate statistics 
(PCA and PLS-DA) allowed for the identification of potential biomarkers that 
showed changes in detection levels in response to treatment. However, the 
overall response of the aggregoids was limited suggesting a potential drug 
resistance. As this limited response was observed across all three models it 
suggested that the potential resistance is due to the method in which the 
aggregoids are cultured. Increasing evidence has showed the development of 
spheroid cultures promoted resistance to cell death via anoikis, which leads to 
alterations in the apoptotic extrinsic and intrinsic pathways and thus subsequently 
leads to the resistance to drug-induced cell death such as treatment with TRAIL-
based therapies or Cetuximab. Future work would investigate this mechanism of 
resistance through the treatment of specific inhibitors that re-establish anoikis s 
and to use inhibitors in combination with biologic therapies to determine the 
metabolic response.  
Following the untargeted DESI-MSI approach, LC-MS/MS is a necessary 
requirement for the confident identification of metabolites detected and to validate 
the method as a suitable pre-clinical biopharmaceutical analysis tool. In addition, 
due to the variability between aggregoid samples it is essential to include more 
biological replicates to improve the discrimination of metabolites. The overall 
study however still demonstrated a potential strategy for the analysis of biologic 
treatment in the aggregoid model by MSI from the detection of significant 




7.6 Development of a multimodal MSI strategy for 
biopharmaceutical detection 
A lack of metabolic response to treatment could be due to the inefficiency of drug 
delivery within the aggregoid model. In an attempt to understand the potential 
drug resistance within the aggregoid model, a MSI strategy to detect the 
biopharmaceutical, cetuximab within the lung adenocarcinoma model was 
developed. The ability to detect a drug within tissues by imaging techniques 
allows for the direct assessment of how a therapeutic penetrates, distributes and 
metabolises and is thus essential for early stage pre-clinical drug analysis.  
In chapter 6, two MSI techniques were developed. Firstly, a bottom-up MALDI-
MSI proteomics strategy was used to detect cetuximab’s constituent proteotypic 
peptides that contained unique CDRs for valid identification. This approach 
involved the optimisation of trypsin solution, sample washing, incubation 
techniques, and methods of trypsin application. Further investigations in the 
trypsin deposition is required in order to improve the sensitivity of peptide 
detection whilst retaining the spatial information. However, by using the micro-
spotting technique preliminary data showed small amounts of cetuximab peptides 
were detected within the lung adenocarcinoma aggregoid model at the expense 
of spatially localising the therapeutic. Additional experimental work is required to 
ensure reproducibility of the method with the aim of utilising this approach for a 
quantitative application in future analysis.  
The second method of biologic detection employed a targeted approach based 
on the principles of IMC using metal-tagged antibodies for the detection of 
proteins. In this study, cetuximab was tagged with 151Eu which was then used to 
treat the aggregoids in culture. Following the standard LA-ICP-MSI workflow, the 
detection of 151Eu-cetuximab localised within the core of the HCC827 aggregoid 
model was achieved. Although this method conflicts with the purpose of using a 
label-free MSI approach for drug detection, it is an example of the use of 
multimodal imaging techniques to validate and complement data of the MALDI-
MSI method which lacks a current standardised protocol for proteotypic peptide 
detection. The detection of cetuximab within the HCC827 aggregoid model also 
suggests that the potential drug resistance observed from the metabolomics 




detection of TRAIL-based therapies within the OS aggregoid models would be 
required to confirm this.  
7.7 Final conclusions 
The aim of this thesis was to develop a multimodal MSI approach to analyse a 
novel aggregated tumour model for applications in pre-clinical biopharmaceutical 
testing. The work reported here shows the culture and development of the 
aggregoid model for the universal use across various MSI techniques. It 
demonstrated the importance of characterising the wide molecular content within 
the tissues for knowledge of the biological processes that drive their unique 
cancer metabolism. The combination of multimodal MSI with the aggregoid model 
showed capacity of spatially resolving metabolite changes in response to biologic 
treatment, in addition to the detection of a biopharmaceutical through the 







Figure A.1. Mean intensity plotted on bar graph of fatty acid detection within OS 
human tissue and OS aggregoid models. Data is mean ± SD (n=3), unpaired t-
test * p < 0.05, ** p < 0.01. Peaks identified in human tissue a) m/z 279.234, FA 
18:2; b) m/z 281.247, FA 18:1; c) m/z 303.231, FA 20:4. Peaks identified in OS 















Figure A.2. Mean intensity plotted on bar graph of metastasis-related 
phospholipid species within OS human tissue and OS aggregoid models. Data is 
mean ± SD (n=3), unpaired t-test * p < 0.05, ** p < 0.01. Peaks identified in human 
tissue a) m/z 810.528, PS 38:4; b) m/z 885.550, PI 38:4. Peaks identified in OS 











Figure A.3. Mean intensity plotted on bar graph of ceramide species detected 
within OS human tissue and OS aggregoid models. Data is mean ± SD (n=3), 
unpaired t-test * p < 0.05, ** p < 0.01, *** p < 0.001. Peaks identified is human 
tissue a) m/z 536.505, Cer 34:1;O2; b) m/z 572.484, Cer 34:1;O2 [M+Cl]-. Peaks 
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(2019). Drug penetration analysis in 3D cell cultures using fiducial-based 
semiautomatic coregistration of MALDI MSI and Immunofluorescence images. 
Analytical Chemistry, 91(21), 13475-13484. doi:10.1021/acs.analchem.9b02462 
Mallah, K., Quanico, J., Trede, D., Kobeissy, F., Zibara, K., Salzet, M., & Fournier, 
I. (2018). Lipid changes associated with traumatic brain injury revealed by 3D 
MALDI-MSI. Analytical Chemistry, 90(17), 10568-10576. 
doi:10.1021/acs.analchem.8b02682 
Mamo, M., Ye, I. C., DiGiacomo, J. W., Park, J. Y., Downs, B., & Gilkes, D. M. 
(2020). Hypoxia alters the response to anti-EGFR therapy by regulating EGFR 
expression and downstream signaling in a DNA methylation-specific and HIF-
dependent manner. Cancer Research, 80(22), 4998-5010. doi:10.1158/0008-
5472.CAN-20-1232 
Martínez-Reyes, I., & Chandel, N. S. (2020). Mitochondrial TCA cycle metabolites 
control physiology and disease. Nature Communications, 11(1), 102-11. 
doi:10.1038/s41467-019-13668-3 
Martin-Lorenzo, M., Balluff, B., Sanz-Maroto, A., van Zeijl, R. J. M., Vivanco, F., 
Alvarez-Llamas, G., & McDonnell, L. A. (2014). 30μm spatial resolution protein 
MALDI MSI: In-depth comparison of five sample preparation protocols applied to 
human healthy and atherosclerotic arteries. Journal of Proteomics, 108, 465-468. 
doi:10.1016/j.jprot.2014.06.013 
Maschmeyer, I., Lorenz, A. K., Schimek, K., Hasenberg, T., Ramme, A. P., 
Hübner, J., Lindner, M., Drewell, C., Bauer, S., Thomas, A., Sambo, N. S., 




long-term co-culture of human intestine, liver, skin and kidney equivalents. Lab 
on a Chip, 15(12), 2688-2699. doi:10.1039/c5lc00392j 
Massarelli, E., Varella-Garcia, M., Tang, X., Xavier, A. C., Ozburn, N. C., Liu, D. 
D., Bekele, B. N., Herbst, R. S., & Wistuba, I. I. (2007). KRAS mutation is an 
important predictor of resistance to therapy with epidermal growth factor receptor 
tyrosine kinase inhibitors in Non–Small-cell lung cancer. Clinical Cancer 
Research, 13(10), 2890-2896. doi:10.1158/1078-0432.CCR-06-3043 
Massonnet, P., & Heeren, R. M. A. (2019). A concise tutorial review of TOF-SIMS 
based molecular and cellular imaging. Journal of Analytical Atomic Spectrometry, 
34(11), 2217-2228. doi:10.1039/c9ja00164f 
Matsugaki, T., Zenmyo, M., Hiraoka, K., Fukushima, N., Shoda, T., Komiya, S., 
ono, M., Kuwano, M., & Nagata, K. (2010). N-myc downstream-regulated gene 
1/Cap43 expression promotes cell differentiation of human osteosarcoma cells. 
Oncology Reports, 24(3), 721-725. doi:10.3892/or_00000913 
McMahon, K. M., Volpato, M., Chi, H. Y., Musiwaro, P., Poterlowicz. K., Peng, Y., 
Scally, a. J., Patterson, L. H., Phillips, R. M., & Sutton, C. W. (2012). 
Characterisation of changes in the proteome in different regions of 3D multicell 
tumour spheroids. Journal of Proteome Research, 11(5), 2863-2875. doi: 
10.1021/pr2012472 
Mehra, R., Cohen, R. B., & Burtness, B. A. (2008). The role of cetuximab for the 
treatment of squamous cell carcinoma of the head and neck. Clinical Advances 
in Hematology & Oncology, 6(10), 742-750.  
Merrick, D. T., Kittelson, J., Winterhalder, R., Kotantoulas, G., Ingeberg, S., Keith, 
R. L., Kennedy, T. C., Miller, y. E., Franklin, W. A., & Hirsch, F. R. (2006). Analysis 
of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in 
bronchial dysplasia: Evaluation of potential targets for chemoprevention of lung 
cancer. Clinical Cancer Research, 12(7), 2281-2288. doi:10.1158/1078-
0432.CCR-05-2291 
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